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Abstract 
Monozygotic (MZ) twins were long thought to be genetically identical, however recent 
studies have demonstrated genetic differences between them. To test the hypothesis that 
early post-twinning mutational events leads to phenotypic discordance, thirteen MZ twins 
discordant for a range of complex disorders were investigated at the genomic and 
proteomic level. 
Whole-exome sequencing data was analysed using a union of VarScan2 and MuTect2 
variant calling algorithms. Copy-number variation (CNV) analysis from Illumina 
HumanCore array data was also carried out using PennCNV and cnvPartition to identify 
structural variants that would not be detected by exome sequencing. All single nucleotide 
variants (SNVs), indels and CNVs were evaluated for functional consequence, 
evolutionary conservation, population frequency and overlap with known disease-
susceptibility genes. 
Twenty-two putative discordant SNVs and indels, but no discordant structural variants, 
were identified. Parent-offspring trio analysis was implemented to assess potential 
association of germline de novo mutations with susceptibility to disease. A rare, highly 
conserved de novo mutation in RASD2 was detected in twins discordant for attention 
deficit hyperactivity disorder (ADHD). RASD2 is enriched in the striatum and involved 
in the modulation of dopaminergic transmission. In the twins discordant for Tourette’s 
syndrome, an inherited stop loss mutation was detected in AADAC, a known candidate 
gene for the disorder. Further, a de novo CNV duplication was identified in a twin pair 
discordant for ADHD overlapping CD38, a gene implicated in social amnesia and autism. 
When analysing the burden of shared CNVs among the twins, a rare hemizygous deletion 
in region 15q13.2 was detected in twins with schizophrenia, overlapping ARHGAP11B, 
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a human-specific gene involved in basal progenitor amplification and neocortex 
expansion.  
To investigate potential downstream consequences of (epi)genetic mechanisms and 
underlying biochemical pathways, proteomic profiling of serum samples obtained from 
an MZ twin pair discordant for ischaemic stroke was analysed through a label-free 
pipeline. Biological processes overrepresented in the affected twin predominantly 
corresponded to stroke-related processes, including wound healing, blood coagulation 
and haemostasis. Further, a comparison of blood chemistries showed a >10- and >18-fold 
elevation of γ-glutamyltransferase (GGT) and erythrocyte sedimentation rate (ESR) 
levels respectively in the affected twin. 
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Chapter 1. Introduction 
 Overview 
In this review, the continuing value of classical twin methods is considered from the 
modern perspective of molecular genetics before delving into a discussion on the impact 
of de novo mutations on human disease. Some of the popular myths and unquestioned 
assumptions about the twinning process are brought into focus, and a range of twin studies 
are presented. Methodological considerations and future strategies are also explored, 
while drawing from caveats of our own research. There has been a gradual shift in twin 
research, from focusing on the initial level of the DNA sequence, through to capturing 
the downstream effects of disease-causing mutations. Thus, novel strategies using omics 
technologies and their integration across multiple omics layers are briefly described in 
the context of twin research. 
 
 A thing or two about twins  
1.2.1 History of twin research 
Twins have captured the interest of researchers for centuries, and proposals to use them 
in empirical studies originate from as early as 415CE by Augustine of Hippo (Augustine, 
2013). Galton published his classic article on twins in the 19th century (Galton, 1876) 
earning him the widely-held recognition of having been the first to iterate the classical 
twin method. According to Rende, Plomin and Vandenberg (1990), however, Galton did 
not make the distinction between MZ and dizygotic (DZ) twins, an understandable 
shortcoming nonetheless due to the ignorance of heredity at the time. Rende et al. (1990) 
conclude that Siemens (1924) and Merriman (1924) together discovered the genetic 
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identity of MZ and DZ twins, but the fundamental work of Poll (1915) and Weinberg 
(1901), and their forerunners, nor Bonnevie (1924), were not considered. Some of the 
obscurities in the origin of the method may have arisen from the possible language 
barriers of English-speaking scientists. Nevertheless Siemens, a dermatologist, made 
significant contributions to the systematic analysis of similarity of MZ and DZ twins, who 
independently formulated the twin rule of pathology: identical twins are more likely to 
be concordant for a heritable disease than non-identical twins, and concordance will be 
even lower in non-siblings (Siemens, 1924).  
Siemens’ study of moles (skin demarcations, not the animal) led him to come up with an 
innovative idea of merging correlation analysis and twin data. He correlated mole counts 
between co-twins and contrasted this correlation between MZ and DZ twin pairs. MZ 
twins, who share all – or nearly all – of their genetic material had a mole count correlation 
of 0.4. Whereas DZ twins, who are on average 50% genetically identical, had a correlation 
of only 0.2. The results demonstrated the importance of genetic factors to the variation in 
mole count. More generally, the genetic similarity of MZ twins is associated with their 
larger resemblance for the phenotype under study. 
1.2.2 The classical twin design 
The classical twin study compares phenotypic resemblances of MZ and DZ twins. 
Comparing the resemblance of MZ twins for a trait or disease with resemblance of DZ 
twins offers an initial estimate of the extent to which genetic variation determines 
phenotypic variation of that trait.  
Hereditability (h2) can be defined as the proportion of variance of a phenotype that is due 
to genetic influences between individuals in a population. It can be estimated from twice 
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the difference between MZ and DZ correlations – that is, 2(rMZ - rDZ), where rMZ and rDZ 
are the estimated correlation coefficients of MZ and DZ twins, respectively. 
In a meta-analysis of twin correlations, Polderman et al. (2015) reported variance 
components of all published twin studies of complex traits. They report that the 
heritability estimate for all 17,804 non-unique traits investigated is 49%. The largest 
heritability estimates were for traits classified under the ophthalmological domain (h2 = 
70%). Traits in the reproduction, environment and social values domains had the lowest 
heritability estimates.  
In a population-based study of 1033 female-female twin pairs, the average MZ and DZ 
correlations for depression was reported to be around 0.4 and 0.2, respectively (Kendler, 
1992); thus, the estimated heritability is calculated as approximately 40%. Further, in a 
meta-analysis of published twin studies of autism spectrum disorders (Tick et al., 2015), 
the meta-analysis correlations for MZ were almost perfect at 0.98, whereas DZ correlation 
was 0.53. Thus, the meta-analytic heritability estimates are considerable, ranging up to 
90%.  
The application of this type of analysis led to substantial changes in the way we think 
about the determinants of health and disease and the causes of individual differences in 
normal and abnormal behaviour. During the last couple of decades, a shift has taken place 
from strict environmental explanations to a more balanced view that recognises the 
importance of genes, for example in autism spectrum disorders in children, or in the 
development of dependence on nicotine, alcohol and other drugs in adults (Manuck and 
McCaffery, 2014). The recent advancement in DNA sequencing techniques has led to 
significant methodological improvements, allowing the comparison of twin genomes up 
to the base pair level. This is especially true with the co-evolution of next-generation 
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sequencing (NGS) platforms and DNA microarray strategies (Schuster, 2007). This has 
ineluctably spurred greater interest in the research of de novo mutations and cases of 
mosaicism in relation to MZ twins, including the mapping of disease genes in DZ twins 
(Tan et al., 2010). 
1.2.3 The case co-twin design 
Twins are particularly useful in case-control studies, and MZ twins form the ideal case-
control study, as they are perfectly matched for genotype and family background. In an 
earlier use of this approach, the effect of vitamin C on the common cold was studied by 
administering it in one twin and a placebo in the co-twin. Contrary to popular belief, it 
was determined that vitamin C is no more effective than a placebo (Martin et al., 1982). 
In line with the Barker hypothesis (Hales and Barker, 2001), differences in birthweight 
in MZ and DZ twin pairs and at their association with differences in cardiovascular and 
metabolic parameters have been investigated. If these associations are due to shared 
genetic factors, difference scores are uncorrelated in MZ, but not in DZ twins. IJzerman, 
Stehouwer and Boomsma (2000) determined that the association between low birth 
weight and high blood pressure in later life seems to be mediated by common genes. 
In a case–control design more relevant to this study, discordant MZ twins, only one of 
whom has a disease, are used to investigate which non-shared environmental influences 
are related to the disorder (Asbury et al., 2003). Such discordant MZ pairs might also 
form the perfect case-control design for gene-expression studies to distinguish between 
genes that are related to the causes of disease and genes that are expressed as a 
consequence of disease. Alternatively, such differential expression, congruent with 
disease discordance, might indicate causal genes that are differentially activated by 
epigenetic factors (Petronis et al., 2003). 
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More recently, the classical co-twin design has received much interest for studying 
molecular biology. Identifying genomic differences between twins and appreciating the 
subtle nuances in choosing the ideal analytical approach relies on an understanding of the 
mechanism and aetiology of the twinning process – and it is to this theme we now turn. 
 
 Mechanisms of twinning 
1.3.1 Traditional models of twinning 
Conventional wisdom dictates that DZ twins are the result of fertilisation of two distinct 
ova by two different spermatozoa, while MZ twins are the product of a single ovum and 
sperm that subsequently splits and forms two embryos (Hall, 2003). 
The development of the chorion, the foetal placental membrane, begins around day three 
or four after conception, and the formation of the amnion occurs between day six and 
eight (Hall, 2003). The widely-held consensus of MZ twinning mechanisms are based on 
the yet unverified theory of postzygotic division of the conceptus. According to this 
model, the number of foetuses, chorions, and amnions depend on the time at which the 
embryo splits. In most DZ pregnancies, each embryo develops a separate chorion, amnion 
and placenta – although rare occurrences of other mechanisms have been reported 
(Hackmon, 2009).  
Twins can be distinguished into four groups based on the zygosity and number of the 
placental membranes. In general, DZ pairs, who develop from the fertilisation of two ova, 
are dichorionic diamniotic (DC DA). MZ twins, however, may have a different 
arrangement of the adnexa (foetal membranes) depending on the timing of embryo 
division. Here, there are three possibilities; namely, monochorionic monoamniotic (MC 
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MA), monochorionic diamniotic (MC DA), and dichorionic diamniotic (DC DA). The 
latter state occurs if the embryo divides at an early stage, which would resemble the 
membrane constitution of DZ twins. 
Various factors have been associated with DZ twinning, such as assisted reproductive 
technology pregnancies, genetic factors, and increased concentrations of follicle-
stimulating hormone. The aetiology of MZ twinning is less clear. It used to be assumed 
that MZ twinning is a random process (Wong, Gottesman and Petronis, 2005), but it is 
now considered to be a consequence of prior events affecting the gamete. Several studies 
have demonstrated that MZ twinning is not a random teratogenic event, but rather 
familial, aluding to the idea that twinning itself may be an inherited phenomenon. Some 
reported cases appear to show twinning to have an autosomal dominant inheritance 
pattern (Machin, 2009a). Epigenetic mechanisms or even a twinning gene are thought to 
be involved (Machin, 2009b). 
Proposed triggers for splitting include postzygotic mutations, abnormalities in cell surface 
proteins, skewed X-inactivation, and aberrations in the development of the zona pellucida 
(McNamara et al., 2016; Hall, 2003). It has even been postulated that genetic alterations 
in cells within the blastocyst could recognise each other as foreign, thereby using cell-
recognition mechanisms to set up two separate cell masses, thus leading to the twinning 
process (Hall, 2003). 
In vitro fertilisation has increased the incidence of MZ twins by two- to five-fold 
(McNamara et al., 2016), possibly owing to the handling, culture media, and/or 
microinjection procedures that damage, and thus split, the embryo. Of course, intrinsic 
irregularities associated with infertility may also be a factor, an idea that is consistent with 
the substantially increased rate of twin births reported among teenage girls and older 
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women – that is, at the beginning and end of reproductive age (Blickstein, Verhoeven and 
Keith, 1999; Alikani et al., 1994). 
It may be worth mentioning, without straying too far from our primary focus, that induced 
delay of ovulation in rats (Butcher and Fugo, 1967), rabbits (Al Mufti and Bomse-
Helmrich, 1979) and humans (Papiernik et al., 1979), as well as delayed artificial 
insemination in guinea pigs (Blandau and Young, 1939), are associated with overripeness 
ovopathy, intrauterine growth restriction and chromosomal aberrations of embryos and 
foetuses. Interestingly, in some of the experimental models, twinning was also observed. 
For instance, in the rabbit, twinning was evidenced by the observation of two early 
blastocysts inside the same intact zona pellucida (Al Mufti and Bomse-Helmrich, 1979). 
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Figure 1.1. The traditional model of twinning. DZ twins are the product of 2 distinct fertilisation events, 
resulting in DC DA twins with each conceptus developing to become a genetically distinct individual. MZ 
twins result from postzygotic splitting of the product of a single fertilisation event. Splitting on days 1–3 
(up to the morula stage) results in DC DA twins, on days 3–8 (during which blastocyst hatching occurs) in 
MC DA twins, on days 8–13 in MC MA twins, and if no split has occurred by day 13, in conjoined twins 
(not shown). In this diagram, 2 of the 3 oocyte-derived polar bodies are shown at the zygote stage. Figure 
from McNamara et al. (2016). 
 
 
1.3.2 Zygosity myth-conceptions 
In recruiting discordant MZ twins for our ongoing research in investigating postzygotic 
de novo mutations, we have come across an increasing number of participants who have 
been told they are DZ but have almost identical traits and physical features, or had been 
told they were MZ but present more like fraternal siblings (Vadgama et al, 2015). Some 
parents or twins had mistaken assumptions of zygosity diagnosis, acquired either 
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according to their own presuppositions or because they were given incorrect information 
by medical professionals. 
Current practice guidelines for classifying twins as either MZ or DZ are prone to error, 
which are still largely based on chorionicity (the notion of whether the twins shared a 
placenta) and physical similarity (Boklage, 2009). Indeed, one of the popular twin-myths 
among the public is the idea that MZ twins must look exactly alike, or that like-sexed 
twins are invariably identical. Among medical professionals, a common error in zygosity 
assignment is the presumption that like-sexed twins are DZ if they were determined to be 
DC at birth. Results of DNA-based gold standard methods have shown that up to 25% of 
all like-sexed twin pairs classified as DZ, and 7% classified as MZ by chorionicity, turn 
out to be misclassifications (Forget-Dubois et al., 2003; Bamforth and Machin, 2004).  
Moreover, as mentioned previously, rare cases of MC DZ twins have been reported, thus 
undermining the reliability of current prenatal diagnosis based on chorionicity (Hackmon 
et al., 2009). 
We propose the ethical importance and financial feasibility to carry out genetic testing 
using placental tissue or even buccal swabs in all like-sexed twins as a standard procedure 
under the National Health Service (Vadgama et al., 2015). 
1.3.3 Challenging the convention 
The traditional model of twinning is theoretical merely, not proven. It is based on our 
current understanding of embryological events, but it is widely endorsed because it seems 
plausible. Certainty and science are usually – or perhaps should always be – mutually 
exclusive. The orthodox view of twinning mechanisms is buttressed on pillars of 
‘common knowledge’, incorrectly and submissively simplified by a disregard of attention 
and curiosity. In twin research, tracing the often-cited received opinions that are purported 
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to be facts to their origin, one finds them to be supported merely by repetition, rather than 
the verifiable observations critical to scientific integrity.  
Nevertheless, the traditional models of twinning have not been unchallenged. For 
instance, the Spanish physician Gonzalo Herranz urges serious rethinking of the hitherto-
unchallenged hypothesis of postzygotic splitting (Herranz, 2013). Four interconnected 
grounds of doubt may be found through his line of reasoning; namely, splitting has never 
been observed in vitro, factors that cleave the embryo have not been clearly defined, 
distinct embryos coexisting within a single zona pellucida is improbable, and postzygotic 
splitting becomes increasingly unlikely with the passage of time. Herranz’s alternative 
theory of twinning is based on two postulates: first, MZ twinning transpires at the first 
cleavage division of the zygote; and second, the chorionicity and amnionicity status is 
determined by the degree of fusion of embryonic membranes within the zona pellucida 
(Figure 1.2). 
However, this appraisal was not received without rebuttals. Denker (2013), for example, 
questioned Herranz’s argument by noting that a lack of evidence may be the result of 
ethical limitations on research with human embryos. Denker also recapitulated the 
available data regarding twinning mechanisms in animals, the observed in vivo and in 
vitro differences in the zona pellucida, and the postzygotic developmental potential of 
cell lineages – factors which, he believed, Herranz overlooked. Denker concluded that 
both Herranz’s fusion model and the traditional fission model remain unverified. 
The mechanism of twinning remains poorly understood at the molecular level, warranting 
further research to determine what hypothesis, if either, is tenable. But it can only be done 
if our complacency with received opinion does not hinder rational inquiry. There is much 
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work to be done to address those unanswered questions buried under those unquestioned 
answers. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. An alternative model of MZ twinning. In this model, splitting occurs at the postzygotic 2 cell 
stage, with each cell forming a distinct individual. If twin blastocysts hatch from the zona pellucida 
together, DC DA twins will result. If the 2 trophectoderms fuse before hatching and the inner cells masses 
are separated within the shared trophectoderm, MC DA twins will result. If the inner cell masses are fused 
and separated later, MC MA twins will result. Figure from McNamara et al. (2016). 
 
 
 Similar but not identical 
As MZ twins frequently show discordance in some phenotypic aspects, the use of the 
term ‘identical twins’ is increasingly being relegated to the margins. Some cases of twin 
discordance might possibly be stochastic in origin. Transcriptional or translational 
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stochasticity will inevitably lead to variation, necessitated by the haphazard movements 
of molecules and the intricacy of their relations (Czyz et al., 2012). This can occur 
irrespective of identical environmental conditions (Petronis, 2006). But with a lack of 
understanding of causal mechanisms in operation, it is difficult to exclude environmental 
or genetic interactions when explaining discordance, such as for hair or eye colour, 
fingerprint profiles (suggesting twins cannot carry out the ‘perfect crime’, contrary to 
popular fiction), mirror image features (present in up to 25% of MZ twins), and major 
deformities (Czyz et al., 2012; Gringras and Chen, 2001). The most frequent are minor 
asymmetries of facial characteristics (ptosis, side of eruption of the first tooth, side of 
upsweep of the hair or eyebrow), handedness and side of wrinkles. These mirror-image 
features may be related to a disturbance of laterality. 
Many mechanisms responsible for discordance in MZ twins have been described to date. 
The most commonly reported are mosaicism for chromosomal or single gene disorders, 
skewed X-inactivation, uniparental disomy, differential repeat expansion, differential 
telomere length reduction, asymmetric transmission of mitochondria, and epigenetic 
mechanisms such as genomic imprinting and inner cell mass damage of the blastocyst 
(Zwijnenburg, Meijers-Heijboer and Boomsma, 2010). 
In the past few years, there have been comparatively more reports of epigenetic 
differences than genetic differences between MZ twins. This is perhaps owed to the 
limitations of NGS technologies in detecting genetic differences (a theme we will revisit 
later), or because studies have typically involved a search only in or around coding 
regions. Nevertheless, sequence differences between twins have been identified. In the 
following section, a review of the literature on de novo mutations is presented, with a 
particular focus on their detection, biological characterisation, and medical impact in MZ 
twins. 
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 Finding the hay in a needlestack 
1.5.1 Chromosomal aneuploidy and structural abnormalities 
A de novo mutation is one that arises in one family member for the first time due to a 
genetic alteration in a gamete (an ovum or sperm) of one of the parents, or occurs 
postzygotically, in the fertilised egg itself. Effectively, all disease-causing aneuploidies 
arise as de novo events. The most recognised example for this is trisomy 21, first 
identified in 1959 as the cause of Down’s syndrome (Lejeune, Gautier and Turpin, 1959). 
Phenotypic discordance in MZ twins can result from chromosomal mosaicism. A 
discrepant karyotype in MZ twins can arise via two different mechanisms: A mitotic error 
arising before the twinning event, resulting in a mosaic showing a discrepant distribution 
of the two different cell lines between the two foetuses; or a mitotic error occurring after 
twinning, resulting in a mosaic chromosomal alteration in one foetus only (Campbell et 
al., 2015). 
Only a select few aneuploidies are compatible with human life in the constitutional state; 
namely trisomy of chromosomes 13, 18, 21 and X, and monosomy of X. A wider range 
of aneuploidies has been observed in the mosaic state. These include monosomy 7, 18 
and 21, and trisomy 7, 8, 9, 12, 14, 15, 16, 17, 20 and 22 – each with varying percentages 
of cells affected, prevalence and clinical features. Whole chromosomal aneuploidy occurs 
via nondisjunction with meiotic risk increasing with maternal age. Mosaic aneuploidy is 
the result of a combination of meiotic nondisjunction rescued by postzygotic loss or copy 
of a whole chromosome, which can in turn lead to uniparental disomy in the euploid cell 
line (Conlin et al., 2010) or alternatively due to postzygotic nondisjunction. Two other 
large-scale abnormalities that are observed in the mosaic state are ring chromosomes and 
isochromosomes. 
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Figure 1.3. Examples of structural chromosomal abnormalities: deletion, duplication, inversion, ring 
chromosome, translocation, and insertion. Image from Abzug et al. (2014). 
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Grams, Rand and Norton (2011) report a case of iso(5p), resulting in tetrasomy (5p), 
detected prenatally in one foetus of an MC DA twin pair. The unaffected twin was found 
to be structurally and karyotypically normal. The mechanism of this rare nonmosaic 
iso(5p) event may be explained in three parts: first, the occurrence of trisomy 5 by meiosis 
II nondisjunction; second, a postzygotic rearrangement leading to the iso(5p) formation; 
third, the splitting in the twinning process leading to a loss of the isochromosome in one 
cell line – hence the discordant co-twins. 
Some isochromosomes occur frequently enough that recognisable syndromes can be 
established, the most common being Xq (Pascual and Rosenberg, 2015). Another 
example includes that of 12p, which causes Pallister-Killian syndrome. Iso(12p) is only 
seen in the mosaic state, probably because such an aberration is lethal constitutionally 
(Campbell et al., 2015), but tolerated if eradicated from tissues vital to life (Raffel et al., 
1986). 
Timing of the division of cell linages in the twinning process can determine whether the 
MZ twins are completely discordant for the aneuploidy, or possess partial discordance 
due to the degree of somatic mosaicism. For example, in a study investigating twins 
discordant for trisomy 21, blood samples from a pair of MC DA twins showed 15% 
mosaicism for this aneuploidy in both twins (Egan et al., 2014). Remarkably, cheek and 
skin biopsies from the twins confirmed two distinct karyotypes: 47,XY,+21 in the 
affected twin and 46,XY in the unaffected twin. The presence of mosaicism in the blood 
samples of both twins was the consequence of their shared MC circulation. It was 
determined that postzygotic non-dysjunction during meiosis was the likely cause for the 
discordant somatic aneuploidy, and thus phenotype. 
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1.5.2 Single nucleotide variations 
Recent studies based on observation of de novo SNV in parent-offspring trios have 
identified a low rate estimated to range between 0.82-1.70x10-8 mutations per base per 
generation (Dal et al., 2014; Kong et al., 2012; Campbell et al., 2012). Based on the 
mutation frequency of these studies, and given that there are approximately 3.0x109 base 
pairs in the human genome (Human Genome Sequencing Consortium, 2004), it can be 
inferred that the average individual acquires 37 to 51 de novo single nucleotide mutations 
during development. Furthermore, the proportion of early postzygotic mutations to the 
overall human de novo SNV rate was estimated to be 0.34x10-8 and 0.04x10-8 in each 
twin of the MZ twin pair investigated (Dal et al., 2014), which translates into 1 to 10 
single nucleotide mutations in the genome. This entails that although postzygotic SNVs 
are a relatively rare occurrence, they comprise a considerable proportion of the rate of de 
novo mutations in humans. Acuna-Hidalgo et al. (2015) have even shown that an 
important fraction of de novo mutations presumed to be germline in fact occurred either 
post-zygotically in the offspring, or were inherited because of low-level mosaicism in one 
of the parents. These mitotic events during embryogenesis resulting in somatic mosaicism 
may thus have an important and significant contribution in disease discordance observed 
in MZ twins. It is possible, however, that individual mutation rates vary considerably. 
This necessitates much larger studies if the true extent of variation in mutation rates are 
to be determined. 
The first study to implement whole-genome sequencing on discordant twins was 
unsuccessful in finding reproducible differences to explain discordance for multiple 
sclerosis (Baranzini et al., 2010). The authors also investigated epigenetic and 
transcriptomic differences between the twins, but again, no differences in T cells were 
found (Baranzini, et al, 2010). This study should be considered merely exploratory, as 
34 
 
only three discordant twin pairs were investigated. Notwithstanding, multiple sclerosis 
has a number important environmental risk factors associated with its aetiology, including 
viral infection and migration (Ascherio, 2013). 
Postzygotic de novo single nucleotide mutations have, nevertheless, been found to 
account for disease discordance in MZ twins. For instance, MZ twins discordant for 
neurofibromatosis type 1 were explained by the presence of a de novo NF1 mutation in 
all somatic cells investigated in the affected twin, whereas somatic cells analysed from 
the unaffected twin were mosaic for the mutation (Kaplan et al., 2010), suggesting the 
distribution of the mutant allele across the various cells to be inadequate in manifesting 
the disorder. Other examples of de novo SNVs were found in MZ twins discordant for 
frontometaphyseal dysplasia (Robertson et al., 2006), Dravet’s syndrome (Vadlamudi et 
al, 2010), Proteus syndrome (Lindhurst et al., 2011), schizophrenia (Tang et al., 2017), 
and neurodevelopmental disorders (Morimoto et al., 2017). 
1.5.3 Copy number variations 
Germline and somatic de novo genetic alterations have been implicated in human disease 
for decades. Over the past several years, genomic microarray technology has provided 
insight into the role of de novo CNVs in disease (Veltman and Brunner, 2012). Large 
CNVs typically occur at a low rate, arising at a frequency of only 0.01 to 0.02 events per 
generation (Veltman and Brunner, 2012; Kloosterman et al., 2015; Campbell and Eichler, 
2013), but their disruptive effect on many genes contributes considerably to severe 
congenital malformations and neurodevelopmental disorders (Weischenfeldt et al., 2013).  
Differences in large structural variants, particularly CNVs, have also been identified 
between clinically discordant MZ twins. In a MZ twin pair discordant for global 
developmental delay, non-allelic mitotic recombination at the 2p25.3 locus that occurred 
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during blastomeric divisions of a normal zygote, led to a variable copy number (CN) 
between the twins, with somatic mosaicism in the twin carrying the chromosomal 
anomaly (Rio et al., 2013). Several reports have mentioned twins discordant for the 
22q11.2 microdeletion (Halder et al, 2012; Singh, 2002). This is the most common 
microdeletion syndrome; usually spontaneous, and characterised by a wide spectrum of 
clinical manifestations, it has an estimated incidence of one in 4,000 to 6,000 live births 
(Halder et al, 2012). CNV differences have also been observed in MZ twins discordant 
for Parkinson’s disease (Bruder et al., 2008), congenital heart defects (Breckpot et al., 
2012), and schizophrenia (Castellani et al., 2014). 
1.5.4 Mitochondrial DNA 
When we talk of the human genome, we often overlook the fact that humans possess at 
least two distinct genomes: nuclear DNA, which has been the centre of discussion thus 
far, and mitochondrial DNA (mtDNA), a circular structure of double-stranded DNA 
found inside mitochondria. Mitochondria are vital to cellular energy production, and thus 
crucial to healthy human physiology (Leem and Koh, 2012; Raimundo, 2014). mtDNA 
consists of merely 37 genes, and encode for tRNAs, rRNAs and proteins involved in 
cellular respiration. 
Hence, disorders that are linked to tissues with high energy demands, such as brain or 
skeletal muscle, have been associated with defects in the mitochondria (Mattson, 
Gleichmann and Cheng, 2008; Rygiel et al., 2015). The pathogenesis of these disorders 
may involve mutations in either mtDNA or nuclear encoded mitochondrial genes (Rollins 
et al., 2009). 
In contrast to the nuclear genome, double-stranded circular mtDNA is present in multiple 
copies within the same cell, and is exclusively maternally inherited. Among the hundred 
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to several thousand copies of mtDNA in a single cell, segregation of the mitochondrial 
populations during cell division can lead to mtDNA variation as they divide. The 
coexistence of different mtDNA sequences is known as heteroplasmy (Stewart and 
Chinnery, 2015); and homoplasmy, as one might have guessed, describes a cell that has 
a uniform collection of mtDNA. 
Incomplete penetrance of several mitochondrial diseases can be attributed to 
heteroplasmy of pathogenic mtDNA mutations (Stewart and Chinnery, 2015; Taylor and 
Turnbull, 2005). Disease onset is (partly) dependent on whether the allele frequency of a 
mtDNA pathogenic variant exceeds a certain threshold (DiMauro and Schon, 2003). 
mtDNA is known to have a higher mutation rate owing to apparent decreased replication 
fidelity (Song, Wheeler and Mathews, 2003; Lee and Johnson, 2006). mtDNA is known 
for its lack of protective histones and limited repair capacity, which can render it 
susceptible to insults that can overcome its replicative machinery or stimulate 
mitochondrial fusion causing mtDNA levels to differ. Various forms of cancer, toxin 
exposures, aging, and oxidative stress can either increase or decrease mtDNA CN, 
depending upon the nature of the damaging process (Wrede et al., 2015). 
Deep sequencing is increasingly being used to detect genomic variation (Calvo et al., 
2012). However, quantifying mtDNA heteroplasmy has been shown to be challenging 
(Yao, Kajigaya and Young, 2015). Mitochondrial variation can be misinterpreted given 
the presence of nuclear mitochondrial sequences (numts), which are highly similar 
nuclear fragments of the mitochondrial genome located on different chromosomes 
(Hazkani-Covo, Zeller and Martin, 2010). Studies have reported difficulties in estimating 
variation due to co-amplification of numts with the mtDNA (Parr et al., 2006; Bouhlal et 
al., 2013). Recent studies, however, have demonstrated significant improvements in 
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increasing the sensitivity of heteroplasmy detection, and NGS has been recognised as an 
effective method for the identification of low-levels of mtDNA heteroplasmy (Li et al., 
2010; Kennedy et al., 2013; Kloss-Brandstätter et al., 2015). 
Where differences in the nuclear genomes of MZ twins cannot be identified, it is possible 
that different levels of mtDNA heteroplasmy might explain the phenotypic discordance 
between the twins. Several small studies have ventured to investigate such differences in 
twins discordant for a range of complex traits including, sleep duration (Wrede et al., 
2015), neurofibromatosis type 1 (Detjen et al., 2007) and schizophrenia (Li et al., 2017). 
On the most part, researchers concluded that the phenotypic discordance investigated was 
not attributable to the difference in mtDNA heteroplasmy. 
 
 Methodological considerations and future strategies 
1.6.1 Detecting mosaicism 
The above-mentioned findings point to the notion that somatic mosaicism may contribute 
to the clinical discordance between MZ twins. Thus, an optimal mosaicism search 
scenario might consist of investigations of cells in an early developmental stage and in 
the terminally differentiated tissues, and both nuclear DNA and mtDNA, to characterise 
entirely mosaicism phenotypic consequences in the examined individual. 
Deep sequencing can detect genomic differences even with low allele frequency in 
somatic mosaicism between MZ twins (Li et al., 2013). Morimoto et al. (2017) concur. 
They identified variants in their study with an allele frequency of ~10%, which is beyond 
the limits of detection by conventional Sanger sequencing (Rohlin et al, 2009). The 
authors note, however, that apparent low-frequency allele mutations may in fact be 
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heterozygous mutations upon validation with Sanger sequencing. Due to possible 
alignment errors or nonspecific PCR amplification, heterozygous mutations may appear 
as low allele frequency mutations on NGS data analysis (Morimoto et al., 2017). 
1.6.2 Tissue type matters 
Reliably detecting de novo somatic mutations is more complex than calling de novo 
germline mutations, because somatic mutations will vary between tissue types and appear 
in percentages that are akin to false-positive sequencing rates. High-level mosaicism can 
result from early postzygotic mutations in an organism, leading to a wide distribution of 
the variant in many different tissues. In contrast, mutations that occur late during 
embryogenesis, or postnatally, can be present in only a select few somatic cells (Acuna-
Hidalgo, Veltman and Hoischen, 2016). The difficulty in obtaining a wide variety of 
tissues in humans, due to ethical and practical reasons, makes a comprehensive study of 
somatic mosaicism difficult. Still, inter-tissue variation of somatic mutation frequencies 
has been determined by analysing routinely sampled tissues, such as blood, buccal 
epithelium, skin fibroblasts, hair follicles and urine. Lindhurst et al. (2011) were one of 
the first to detect somatic mosaicism in MZ twins using exome sequencing. The authors 
identified the cause of Proteus syndrome, in which a de novo mutation was found in AKT1 
in multiple tissues, but not in DNA from peripheral blood. 
Another frequently used DNA source in genetic studies are lymphoblastoid cell lines 
(LCLs), which are created through in vitro infection of B-lymphocytes with Epstein-Barr 
virus (EBV), although their reliability in replicating a true variant in the donor remains 
controversial.  
The co-twin study design is often used to identify de novo mutations, in which validation 
of the variant is an important step, especially when interpreting NGS data. Thus, 
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determining if the mutations identified in LCLs are real or an artefact can be challenging 
if false-positives are introduced in the study design. There is evidence to suggest that 
EBV promotes genetic instability in the host (Gruhne et al., 2009), and possibly causes 
mutations through integration and disintegration into the host’s genome (Morissette and 
Flamand, 2010). This calls into question whether LCLs are a bona fide source of genomic 
DNA. 
Large-scale studies, such as the 1000 Genomes project, have used LCL-derived DNA to 
characterise human genome variation on a population-based scale. Within this project, 
the genomes of parent–offspring trios were sequenced (Conrad et al., 2011). In one of the 
trio analyses, 35 de novo mutations were observed in both untransformed and LCL-
derived DNA; however, over 600 de novo mutations were unique to the cell line DNA, 
which was subsequently validated. This demonstrates that most of the de novo mutations 
were caused by cell line transformation and culturing. It has therefore been recommended 
that cell lines should not be used for de novo mutation studies (Veltman and Brunner, 
2012). 
Other studies have shown that no significant bias is introduced by EBV-transformed B 
cells by comparing DNA from untransformed material from the same donor. For instance, 
Nickles et al. (2012) used whole-genome sequencing to assess the genomic signature of 
a LCL and determined that it is genetically indistinguishable from its genomic 
counterpart. Similarly, Londin et al. (2011) performed exome sequencing on a family of 
four individuals using DNA from peripheral blood and LCLs from each individual. The 
authors note that, although EBV transformation can result in low-level de novo mutations, 
LCLs remain an appropriate representation of the donor’s genome. In summary, low 
passage LCLs may be a suitable choice in MZ twin research, although, considering 
caveats from our own research, high passage LCLs will likely introduce significant 
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anomalies rendering analysis difficult. It is up to the investigators’ discretion to determine 
if LCLs are fit for purpose with the chosen study design, while bearing in mind that 
independent validation on DNA from uncultured sources is ideal. 
1.6.3 Variant calling algorithms 
1.6.3.1 Methods in SNV and indel analysis. 
Although NGS has proven to be a powerful approach, there remain numerous technical 
challenges in obtaining an accurate and complete record of sequence variation from the 
copious data generated, and in converting raw sequence reads into biologically 
meaningful information (Pirooznia et al., 2014) (Figure 1.4). Granted accurately mapped 
and calibrated reads, identifying SNVs and indels, not to mention more complex variation 
such as, insertions, deletions, inversions, CNVs, and multiple base pair substitutions, 
requires complex statistical models and sophisticated bioinformatics tools (Pirooznia et 
al., 2014). 
Several methods have recently been developed to enhance somatic mutation calling 
accuracy. Generally, these can be classified into two different types: 1) independent 
analysis for affected and unaffected tissue datasets followed by SNV type classification 
using a simple subtraction or a statistical significance test; and 2) simultaneous analysis 
for matched affected and unaffected tissue datasets using joint probability-based 
statistical approaches (Xu et al., 2014).  Such variant callers belonging to the latter family 
include SomaticSniper, Strelka, VarScan2 and MuTect2. Unfortunately, agreement 
among different algorithms is rather low (O'Rawe et al., 2013), thus highlighting the 
different error models or assumptions underlying each algorithm. Taking the union of two 
or more variant callers will help reduce the probability of calling false positive SNVs and 
indels, and avoid biases from one particular caller. However, choosing the ideal tools for 
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variant calling will depend on a specific set of data type and experimental conditions (Xu 
et al., 2014). 
 
 
Figure 1.4. Whole-exome sequencing data analysis steps. Novel computational methods and tools have 
been developed to analyse the full spectrum of exome sequencing data, translating raw fastq files to 
biological insights and precision medicine. Figure from Hintzsche, Robinson and Tan (2016). 
 
1.6.3.2 Methods in CNV analysis 
Genotyping arrays have outplaced the use of comparative genomic hybridisation arrays 
in CNV detection uses. This is owed to microarray having a higher probe density and thus 
allowing better resolution of CNV breakpoints (Legault et al., 2015). In fact, there has 
been a significant upsurge over the past decade in the development of algorithms and 
technical resolution that have been applied across platforms and programs. Various 
software packages are available, including Birdsuite, dChip, cnvPartition, Genotyping 
Console and PennCNV. In a study assessing putative CNV calls made using multiple 
software, Castellani et al. (2014) suggest using a combination of three programs to 
optimally identify true CNV calls, giving a trade-off between sensitivity and specificity. 
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The authors also suggest the use of PennCNV over all other methods when the use of 
only one tool is preferable (Castellani et al., 2014). 
SNP arrays have been used in twin research to look for CNV differences between co-
twins. Several studies failed to validate discordant CNVs between the twins investigated. 
This could be due to a low sensitivity of the CN calling algorithm used. For non-mosaic 
(pre-twinning) CNV detection, these CN calling tools may be ideal. However, post-
twinning CNVs may lead to mosaicism, where further methodological developments in 
CN calling algorithms would have to be applied. 
In a longitudinal study investigating the age-related acquisition of somatic structural 
variants, four mosaic uniparental disomy events were identified in a cohort of elderly 
Danish twins, suggesting that somatic changes can result within different body tissues of 
the same individual (Koldby et al., 2016). Detection of non-mosaic somatic CNV 
differences between the MZ twins was also performed. Of these, however, only one CNV 
was eligible for experimental validation with qPCR, and it could not be validated. 
Numerous studies have searched for non-mosaic somatic CNV differences between MZ 
twins, with the overall findings being unfruitful. Although this is typically attributed to a 
small sample size, some studies have recruited a relatively large cohort of twins. For 
instance, Abdellaoui et al. (2015) searched for post-twinning de novo CNV mutations in 
1,097 co-twins, but only two CNVs were validated with qPCR, both of which were 
present in the same individual. More recently, in a cohort of 100 twin pairs enriched for 
neurodevelopmental disorders, no postzygotic de novo CNVs were identified (Stamouli 
et al., 2017). 
Another explanation for the lack of discordant CNVs between twins is that somatic CNVs 
are more likely to be mosaic, necessitating the use of apposite CN calling tools. This 
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postulate is in line with several studies, including, Magaard Koldby et al. (2016), Bruder 
et al (2008) and Forsberg et al. (2012). For microarray data, mosaic variants can be 
detected using the Mosaic Alteration tool (González et al., 2011), and estimation of the 
mosaic proportion of cells can be performed based on the study by Rodríguez-Santiago 
et al. (2010). Exome and genome sequencing can also be harnessed to detect mosaic 
structural abnormalities. A method called MrMosaic, which uses deviations in allele 
fraction and read coverage from NGS data to detect structural mosaic abnormalities, has 
proven to be successful (King et al., 2016). 
1.6.4 Candidate variant validation 
It has been suggested that without independent validation using bench confirmation 
techniques, such as real-time PCR (qPCR) or droplet digital PCR (ddPCR), CNV calls 
using computational methods should be at best considered tentative (Castellani et al., 
2014). Further, incorporation of family data has been shown to help improve the quality 
of CNV calls alongside the use of multiple CNV calling methods (Castellani et al., 2014; 
Legault et al., 2015). 
There are several reasons for why microarray CNV calling methods are prone to error, 
and thus why experimental validation is essential. Firstly, CNV calling using SNP arrays 
is a relatively new technology, and each platform has its own sensitivity and specificity; 
secondly, with SNP arrays, the sample in question is compared to reference samples or to 
a large reference cohort, so only the relative CN is determined; third, compared to whole-
genome sequencing, SNP arrays give limited information on the location or orientation 
of a given CNV; finally, SNP arrays rely on amplification of DNA and measurements 
using (fluorescence) intensity, thus technical variation can influence experimental 
outcome (Brosens et al, 2016). 
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In terms of validating mosaic somatic SNVs and indels, other methods alongside Sanger 
sequencing are commonly used, including high-resolution melting analysis, allele-
specific PCR, immunohistochemistry, pyrosequencing, and SNaPshot. These techniques 
are especially useful in candidate variant screening and result verification in the NGS era 
(Gajecka, 2015). 
1.6.5 Catching the wave downstream 
MZ twins that are interrogated at multiple omics levels or investigated under a variety of 
environmental conditions are offering remarkable insights. The following section will 
outline how the epigenome, transcriptome and proteome of MZ twins can be studied in 
an integrative manner to provide a more systematic exploration of gene-environmental 
interaction, and what current research in this area has to offer. 
1.6.5.1 Epigenetics 
Epigenesis, a term from which ‘epigenetics’ derives, is an early embryological theory 
postulating the development of an embryo from the successive differentiation and 
elaboration of an originally undifferentiated fertilised egg (as opposed to preformation, 
an outmoded developmental model that suggested complex organisms are already 
completely formed in the germ cell and develop merely by enlargement). The term 
‘epigenetics’ was initially coined by developmental biologists who sought to explain the 
mechanism by which gene-gene and gene-environment interactions fashioned the 
phenotype of an individual during development (Youngson and Whitelaw, 2008). 
However, the term has found new meaning in modern parlance, even though a consensual 
definition is still lacking. Epigenetics can be generically described as alterations in 
genomic function that are controlled by potentially reversible heritable factors, without 
altering the DNA sequence. 
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In other words, epigenetic regulation of gene expression uses reversible modifications of 
DNA and chromatin structure to mediate the interaction of the genome with a variety of 
environmental factors and to generate changes in the patterns of gene expression in 
response to these factors. Such mechanisms include, DNA methylation, histone 
modifications, ATP-based chromatin remodelling, transcription factor-binding 
mechanisms and non-coding RNA-mediated gene silencing (Ketelaar, Hofstra and 
Hayden, 2011; Bell and Spector, 2011). 
Epigenetic discordance can be observed to variable degrees in MZ twins, estimates for 
which have been shown to be affected by sample size, tissue type, age and CpG island 
selection (Czyz et al., 2012). Indeed, a major challenge in epigenetic research is that 
epigenetic differences are often tissue- and cell-specific, and sometimes it may be 
practically impossible to obtain the ideal tissue source. As previously discussed, MZ 
twins can be sub-classified depending on whether they share the same placenta or not. 
Chronicity, however, has been shown to affect epigenetic profiles between twins, where 
MC twins have been shown to have more disparate epigenetic profiles than DC twins 
(Kaminsky et al., 2009). Notwithstanding, most studies that investigate MZ twins have 
constituted them into a uniform group.  
Epigenetic and transcriptomic modifications have been reported in twins discordant for a 
range of complex traits, including cancer (Heyn et al., 2012), Alzheimer’s disease 
(Poulsen et al., 2007), autism spectrum disorders (Loke, Hannan and Craig, 2015), 
schizophrenia and bipolar disorder (Dempster et al., 2011), multiple sclerosis 
(Handunnetthi, Handel and Ramagopalan, 2010), pain sensitivity (Bell et al., 2014), 
psoriasis (Gervin et al., 2012), and type 1 diabetes (Stefan et al., 2014). 
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1.6.5.2 Proteomics 
Where whole-genome and exome sequencing has been less beneficial, attention is 
increasingly switching to RNA sequencing and epigenetics to explore potentially-missed 
disease-causing mechanisms. Proteomics, however, has the potential to capture all the 
variations arising from genomic, transcriptomic and epigenetics changes. 
Alternative splicing and post-translational protein modifications entail that the number of 
proteins can be two orders of magnitudes higher than the number of genes (Zierer et al., 
2015). Proteomic techniques in current practice, such as immunoassays, protein arrays or 
mass spectrometry, are limited in that they can measure only a small fraction of the 
proteome. The most comprehensive analysis of the human proteome to date consists of 
over 18,000 proteins composed from 10,000 mass spectrometry experiments, across 
various tissues (Wilhelm et al., 2014) 
Analysing the proteomes of human biological fluids (such as, serum, urine, saliva, 
synovial and cerebral spinal fluids) among individuals with a shared genetic background, 
but possibly different environmental and/or epigenetic influences, may cast welcoming 
new light on the identification of putative disease-associated biomarkers. Although 
comprehensive proteomics studies on discordant MZ twins are still lacking, the few 
studies that have implemented the co-twin design have provided some important insights.  
Disorders investigated include systemic autoimmune diseases (O'Hanlon et al., 2011), 
bipolar disorder (Kazuno et al., 2013), and chronic fatigue syndrome (Ciregia et al., 
2013). In this thesis, a proteomic profiling of serum samples from MZ twins discordant 
for ischaemic stroke was analysed through a label-free pipeline. The finding of a distinct 
proteomic profile associated with ischaemic stroke raises the possibility of patient-centred 
diagnostic, prognostic and therapeutic strategies in future.  
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1.6.5.3 Metabolomics 
The metabolome refers to the complete set of low molecular weight compounds in a 
sample. These compounds are the substrates and by-products of enzymatic reactions and 
have a direct effect on the phenotype of the cell. Thus, metabolomics aims at determining 
a sample’s profile of these compounds at a specified time under specific environmental 
conditions. Similar to proteomics, there are, to date, no analytical methods at our disposal 
that can determine and quantify all metabolites in a single experiment. Remarkably, 
however, the Human Metabolome Database (Wishart et al., 2013) contains more than 
40,000 distinct metabolites from different tissues. These low molecular weight 
compounds are the closest link to phenotype. Although genomics and proteomics have 
provided extensive information regarding the genotype, it may be difficult to elicit direct 
information about the clinical phenotype being investigated.  
Several new omics technologies have emerged recently, which deserve to be mentioned 
but cannot be described in depth due to their branching themes lying beyond the scope of 
this thesis. These are glycomics (post-translational modifications), microbiomics, and 
phenomics (Zierer et al., 2015). The currently employed approach to data analysis in the 
omics era is to take the reductionist stance by focusing on individual factors. However, 
these emerging technologies have the capacity to broaden investigations into complex 
traits by an unprecedented scale. The ‘holistic’ approach, or systems biology, integrates 
data from different experiments to gain an understanding of the system as a whole (Zierer 
et al., 2015). 
Large-scale multi-omics investigations into MZ twins are currently being carried out. For 
instance, the MuTher study, consisting of several hundred female twins, has been 
evaluated globally at the genome, transcriptome, metabolome, and microbiome levels 
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(Fizelova et al., 2016). The data has given valuable insights into the genetic control of 
molecular traits, biological pathways involved in metabolic syndrome, and the heritability 
of gut microbiota (Heinig et al., 2010). Another human reference population study, 
dubbed Metabolic Syndrome in Man (METSIM), consists of a cohort of about 10,000 
Finnish men. Like the MuTher population, METSIM participants have been characterised 
clinically for a variety of metabolic and cardiovascular traits at the genomic, 
transcriptomic, and metabolomics levels (Civelek et al., 2017; Laakso et al., 2017; 
Fizelova et al., 2016). 
 
 Conclusion 
The evidence presented above challenges the use of the expression ‘identical twins’, as 
MZ twins are not truly identical. Paradoxically, they can be very much alike, while being 
differentially affected by postzygotic (epi)genetic mutations and environmental 
influences, which polarise the genotype and phenotype within a given pair. 
Whole-genome, epigenetic and transcriptomic profiling across multiple tissues and cell 
types in large cohorts of discordant MZ twins will continue to shed light on gene-
environment interactions and the aetiology of complex traits. Other omics technologies, 
such as proteomics and metabolomics, can provide insights into downstream 
consequences of disease, and are increasingly being incorporated into twin research. 
Thus, future twin studies will likely be themed on ‘multi-omics’ – the integration of 
multiple types of omics data. This will require a conceptual shift in the research paradigm 
and inject new energy in the study of human genetics. 
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 Hypothesis and thesis objectives 
Discordant MZ twins provide a unique opportunity to study the genetics of complex 
disorders, where potential disease-causing variants are difficult to identify against a 
background of thousands of randomly occurring non-pathogenic polymorphisms found 
throughout the genome. The overwhelming majority of these randomly occurring 
polymorphisms, i.e. those inherited through the parental germline, will be identical 
between co-twins. Where MZ twins tend to share a similar environment, we believe a 
genetic cause is likely to explain their discordant phenotypes. Clearly, epigenetic 
mechanisms could also be responsible. 
We have obtained DNA samples from thirteen MZ twins discordant for a variety of 
clinical phenotypes. Our proposed work provides a rare opportunity to untangle the 
genetic basis for complex disorders, and to correlate genetic variation with pathway 
analyses to gain insights into their molecular mechanisms. We hypothesise that 
phenotypic discordance between identical twins may involve postzygotic de novo 
mutations. 
The aims and objectives can be outlined as follows: 
- Chapter 3: To look for C9orf72 repeat polymorphic variations between four MZ 
twin pairs discordant for ALS, using rpPCR and Southern blotting. To sequence 
25 ALS-linked genes on an NGS panel, and confirm any potential SNPs found 
with Sanger sequencing. 
- Chapter 4: To carry out whole-exome sequencing of discordant MZ twins and 
compare different bioinformatics methodologies for optimised filtering. To 
validate potential differences found with Sanger sequencing and other SNP 
genotyping assays capable of detecting low-level mosaicism. To cross-compare 
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the exome sequence data of DNA extracted from different tissue sources where 
available. To perform parent-offspring trio analysis, where parental DNA is 
available, to look for pre-twinning de novo mutations that are shared between the 
twins. 
- Chapter 5: To determine if CNV differences exist in our cohort of MZ twin pairs, 
by unifying the results of two CNV calling methods. To validate potentially 
interesting CNVs with additional computational and experimental methods.  
- Chapter 6: To perform cytogenetic, biochemical and proteomic profile 
comparisons of twins discordant for ischaemic stroke. To identify possible 
disease-associated biomarkers and provide insights into pathogenic mechanisms 
by carrying out pathway analysis on identified proteins. 
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Chapter 2. Materials and Methods 
 Description of twin pairs 
Coriell Cell Repository DNA was obtained from five pairs of MZ twins discordant for 
ALS (218 and 318; 421 and 422; 242 and 243), Tourette’s syndrome (489 and 490), and 
Parkinson’s disease (PD821 and PD161). DNA was also obtained from the parents of the 
twins discordant for Tourette’s syndrome (487 and 488). The Coriell Institute for Medical 
Research (Camden, NJ, USA) provide essential research reagents to the scientific 
community by establishing, verifying, maintaining, and distributing cell cultures and 
DNA derived from cell cultures. These collections are supported by funds from the 
National Institutes of Health (NIH) and several foundations. 
Genomic DNA samples of two twin pairs discordant for schizophrenia were obtained; 
one pair from Professor Sir Robin Murray based at King’s College London, Institute of 
Psychiatry (IP16 and IP17), and one pair from Dr Takeo Yoshikawa based at the RIKEN 
Institute, Brain Science Institute (RT1a and RT1b).  
A further six discordant MZ twins were recruited, and DNA was extracted from blood 
and/or saliva samples for molecular/genetic analysis. These twins were discordant for 
stroke (HG and KG), ALS (LAS and SUS), lactase non-persistence (KEL and KIR), 
inclusion body myositis (AFF and UNAFF), dystonia (VF and LF), and ADHD (RP and 
OH). DNA from the parents of RP and OH was also obtained (DS and DV). Further 
details of subjects can be found on Table 2.1. Written informed consent was obtained 
from all participants prior to study entry (see Appendix A for the patient information sheet 
and consent form). 
 
52 
 
 
Table 2.1 Clinical characteristics and demographic information on the MZ twin cohort. UN = unknown; 
ALS = amyotrophic lateral sclerosis; LNP = lactase non-persistence; IBM = inclusion body myositis; 
ADHD = Attention deficit hyperactivity disorder; OCD = obsessive compulsive disorder; TS = Tourette’s 
syndrome; PD = Parkinson’s disease; HSP = hereditary spastic paraplegia; SCZ = schizophrenia; SCPD = 
schizotypal personality disorder. 
 
Subject Status Diagnosis Sex Age 
Age of 
onset 
Ethnicity DNA source 
LAS Proband ALS F 71 67 Caucasian Saliva 
SUS MZ twin - F 71 - Caucasian Saliva 
        
218 Proband ALS M 54 50 Caucasian LCL 
318 MZ twin - M 54 - Caucasian LCL 
        
421 Proband ALS F 58 55 Caucasian LCL 
422 MZ twin - F 58 - Caucasian LCL 
        
242 Proband ALS M 35 34 Caucasian LCL 
243 MZ twin - M 35 - Caucasian LCL 
        
KG(s) 
Proband Stroke F 62 56 Caucasian 
Saliva 
KG(b) Blood 
        
HG(s) 
MZ twin - F 62 - Caucasian 
Saliva 
HG(b) Blood 
        
KEL Proband LNP F 23 5 Caucasian Saliva 
KIR MZ twin - F 23 - Caucasian Saliva 
        
AFF Proband IBM M 68 66 Caucasian Blood, Saliva 
UNAFF MZ twin - M 68 - Caucasian Blood, Saliva 
        
DS Father - M UN - Caucasian Saliva 
DV Mother - F UN - Afro-Caribbean Saliva 
RP Proband ADHD M 10 7 Mixed Saliva 
OH MZ twin - M 10 - Mixed Saliva 
        
487 Father TS, OCD, ADHD M 44 6 
American 
Indian 
Blood 
488 Mother - F 44 - Caucasian Blood 
489 MZ twin - M 15 - Mixed Blood 
490 Proband TS M 15 7 Mixed Blood 
        
PD821 Proband PD M 40 30 Caucasian Blood 
PD161 MZ twin - M 40 - Caucasian Blood 
        
VF Proband Dystonia/HSP F 46 34 Caucasian Blood 
LF MZ twin - F 46 - Caucasian Blood 
        
RT1a MZ twin SCPD M UN UN Asian Blood 
RT1b Proband SCZ  M UN UN Asian Blood 
        
IP16 Proband SCZ M UN UN Caucasian Saliva 
IP17 MZ twin - M UN - Caucasian Saliva 
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 Sample preparation and quantification 
2.2.1 DNA extraction from saliva 
The Oragene DNA Kit (DNA Genotek Inc., Kanata, Canada) was used to extract total 
DNA from saliva samples according to the manufacturer’s instructions. Briefly, 500μL 
of the mixed saliva and Oragene solution was placed into a 1.5mL microcentrifuge tube 
and incubated for 2hrs at 50oC. 20μL of Oragene DNA purifier was added, and the tube 
was briefly vortexed. The solution was incubated on ice for 10mins, then centrifuged at 
room temperature for 10mins at 13,000rpm. The resulting supernatant was transferred 
into a new 1.5mL microcentrifuge tube, and the remaining pellet was discarded. 95% 
ethanol was added to the supernatant and the solution was gently mixed by inverting the 
tube several times; this was left at room temperature for 10mins to allow the DNA to 
precipitate. The solution was then centrifuged for 2mins at 13,000rpm, and the 
supernatant was carefully removed and discarded. For further purification, 200μL of 70% 
ethanol was added and then removed after 1min, taking care not to disturb the pellet. 
50μL of Tris-EDTA buffer was added to the tube to dissolve the DNA pellet. The tube 
was briefly vortexed and incubated for 1hr at 50oC. 
2.2.2 DNA extraction from blood 
Blood from subjects was taken in ethylenediaminetetraacetic acid (EDTA) bottles and 
genomic DNA was extracted from whole blood using a FlexiGene kit (Quiagen) 
according to manufacturer’s instructions. For each sample, 300μL of whole blood was 
mixed with 750μL of buffer (FG1) to lyse the cells. The sample was centrifuged for 
20secs at 13,000rpm, and the supernatant was discarded leaving only the pellet. 150μL of 
protease-contain buffer (FG2) was added to the tube and then vortexed until the pellet 
became homogenised. The sample was centrifuged for 10secs and incubated at 65°C for 
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5secs in a heating block. 150μL of 100% isopropanolol was added to the tube and inverted 
several times to allow precipitation of the DNA. The sample was centrifuged for 3mins 
at 13,000rpm and the supernatant was discarded. 150μL of 70% ethanol was added to the 
sample and vortexed for 5secs before centrifuging for 3mins at 13,000rpm. The 
supernatant was discarded and the pellet air dried. 200μL of buffer (FG3) was added and 
the sample and briefly vortexed to dissolve the DNA. 
2.2.3 DNA concentration and purity 
A NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies) was used to 
measure genomic DNA concentration and purity. 1μL of DNase and RNase-free distilled 
deionised water (dH2O) was loaded onto the pedestal to obtain a blank reading. 1μL of 
DNA from all participants was individually loaded to determine the concentration.  
Absorbance measurements determine molecules absorbing at a specific wavelength. 
DNA will absorb at 260nm and will contribute to the total absorbance. For quality control, 
the 260/280nm and 260/230nm absorbance ratios are used to assess the purity of DNA. 
For DNA, a 260/280nm absorbance ratio of ~1.8 is generally accepted as adequate purity. 
The 260/230nm absorbance ratio is used as a secondary measure of nucleic acid purity, 
and a value within the range of 2.0-2.2 is considered acceptable. 1μL of all DNA samples 
were run on a 1.3% agarose gel to determine the relative concentrations and degree of 
potential degradation. 
2.2.4 Monozygosity testing 
All twin pairs were tested for their zygosity status before proceeding with the study. 
Analysis was performed using an in-house kit, consisting of eight microsatellite markers, 
an Amelogenin marker, and a SRY marker. DNA from blood was also screened using a 
commercial kit consisting of 16 markers, including fifteen STRs and Amelogenin, 
55 
 
according to the manufacturer’s recommendations. This was carried out by John Short at 
St. George’s NHS Trust. 
 
 Initial screen of known disease-associated variants 
Some samples were screened for known pathogenic variants before being put forward for 
whole-exome sequencing analysis. A pathogenic hexanucleotide repeat expansion within 
the C9orf72 gene has been identified as the major cause of ALS. Variation in the 
hexanucleotide repeat number was first assessed by repeat-primed PCR (rpPCR). A 
modified Southern blot method was used to confirm the rpPCR detected expansions 
where sufficient DNA allowed. 
2.3.1 Repeat-primed PCR 
To provide a qualitative assessment of the presence of an expanded (GGGGCC)n 
hexanucleotide repeat in C9ORF72, a rpPCR reaction was performed in four twin pairs 
discordant for ALS. Briefly, 100ng of genomic DNA were used as template in a final 
volume of 28μL containing 14μL of FastStart PCR Master Mix (Roche Applied Science, 
Indianapolis, IN, USA), and a final concentration of 0.18mM 7-deaza-dGTP (New 
England Biolabs Inc., Ipswich, MA, USA), 1x Q-Solution (Qiagen Inc., Valencia, CA, 
USA), 7% DMSO (Qiagen), 0.9mM MgCl2 (Qiagen), 0.7μM reverse primer consisting 
of ~four GGGGCC repeats with an anchor tail, 1.4μM 6FAM-fluorescent labelled 
forward primer located 280bp telomeric to the repeat sequence, and 1.4μM anchor primer 
corresponding to the anchor tail of the reverse primer. Primers used for rpPCR are shown 
in Table 2.2 (Kobayashi et al., 2011; Warner et al., 1996). A touchdown PCR cycling 
program was used where the annealing temperature was gradually lowered from 70°C to 
56°C in 2°C increments with a 3min extension time for each cycle. 
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The rpPCR is designed so that the reverse primer binds at different points within the 
repeat expansion to produce multiple amplicons of incrementally larger size. The lower 
concentration of this primer in the reaction means that it is exhausted during the initial 
PCR cycles, after which the anchor primer is preferentially used as the reverse primer. 
Fragment length analysis was performed on an ABI 3730xl genetic analyser (Applied 
Biosystems Inc., Foster City, CA, USA), and data analysed using GeneScan software 
(version 4, ABI). Repeat expansions produce a characteristic saw-tooth pattern with a 6-
bp periodicity. 
This protocol was carried out under the supervision of Gary Adamson at UCL, Institute 
of Neurology. 
Primer name Primer sequence Concentration Modification 
ALSFTDf_(6FAM) 6-FAM-AGT CGC TAG AGG CGA AAG C 0.05 µmol Modified DNA 
Oligos 
ALSFTDr TAC GCA TCC CAG TTT GAG ACG GGG 
GCC GGG GCC GGG GCC GGG G 
0.05 µmol Unmodified DNA 
Oligos 
ALSFTDanchor TAC GCA TCC CAG TTT GAG ACG 0.05 µmol Unmodified DNA 
Oligos 
 
Table 2.2. Primers used for rpPCR 
 
2.3.2 Southern blotting 
10μg DNA was digested with HindIII and XbaI overnight. DNA fragments were 
separated on a 0.9% TRIS-Borat-EDTA (TBE) agarose gel, transferred by alkali blotting 
onto an Amersham Hybond NTM-XL membrane (GE Healthcare, Fisher Scientific, 
Germany) and hybridised to a 32P-labelled probe overnight. After washing, X-ray films 
were exposed for 4–6 days at −80°C. BstEII digested lambda DNA was used as a size 
marker for estimating repeat lengths. Minimal repeat sizes were used for calculation. This 
protocol was carried out by John Polke at UCL, Institute of Neurology.  
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2.3.3 Next-generation sequencing panels 
2.3.3.1 Amyotrophic lateral sclerosis 
Genomic DNA from one twin pair discordant for ALS (LAS and SUS) was processed on 
a gene panel designed by Morgan et al., 2015, which uses the Illumina TruSeq Custom 
Amplicon implemented on an Illumina MiSeq platform. This panel utilises PCR 
amplicon-based target enrichment and screens for variants in 25 ALS disease genes. 
Sequence analysis involved the full exomes of 10 genes strongly implicated in ALS, and 
specific genomic areas where disease-causing mutations cluster in 15 other minor or 
unproven ALS-linked genes. Probes were created using Illumina TruSeq custom 
amplicon assay DesignStudio v1.6 
(http://www.illumina.com/applications/designstudio.ilmn). 
2.3.3.2 Hereditary spastic paraplegia 
LF presented with sudden onset for HSP at 34 years with apparent recurrent 20min 
dystonic cramps in her right leg. This was triggered by exercise, driving, caffeine and 
alcohol. Her identical twin sister (VF) and 16-year-old son may have similar features of 
spasticity. A diagnosis of complicated hereditary spastic paraparesis superimposed with 
dystonia was made. The patient did not respond well to L-Dopa, and there was no diurnal 
variation in presenting symptoms. Sequencing and analysis of genomic DNA from the 
twin affected with HSP (LF) was carried out on a multi-gene panel at Sheffield Children's 
NHS Foundation Trust, using the Agilent SureSelect Neurogenetic panel Version 1 with 
Illumina MiSeq Analysis pipeline: Version 2. LF was also screened for GLUT1 
deficiency syndrome and DYT1 early-onset primary dystonia. 
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2.3.3.3 Lactase non-persistence 
Additionally, Sanger sequencing was used to detect known SNPs in twins discordant for 
lactase non-persistence (KIR and KEL) (methods described below). 
 
 Next-generation sequencing 
2.4.1 Whole-exome sequencing 
Each exome captured sequencing library was produced from either one of two exome 
capture kits and sequencing systems. For the first set of samples (n=16), genomic DNA 
(3μg) from each sample was sheared to a mean fragment size of 150bp, with the use of 
focused acoustic technology (Covaris). These fragments were end repaired, 3’ 
adenylated, and ligated with Illumina paired-end sequencing adapters according to the 
SureSelect Human All Exon V4 (Agilent Technologies) exome enrichment kit protocol. 
Between each of these steps, samples were purified using Agencourt AMPure XP beads 
to remove non-specific DNA. The sequence library was hybridised with biotinylated 
120bp RNA library baits in PCR plates on a thermocycler at 65oC for 24hrs. Streptavidin-
coated superparamagnetic beads were used to preserve DNA bound to the RNA probes, 
and the unbound fraction was discarded using SureSelect wash buffers. After eluting the 
exome-enriched pool of DNA, a low-cycle PCR was used to amplify the specific region 
of DNA. This was followed by sequencing on a HiSeq2000 (Illumina) with 100bp paired-
end reads. 
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Figure 2.1. Overall target-enriched sequencing sample preparation workflow. Briefly, genomic DNA is 
fragmented, denatured, and hybridised with capture oligos during library preparation for high-throughput 
sequencing. The captured sequences are then enriched with streptavidin-conjugated paramagnetic beads 
and further amplified before being subjected to Illumina sequencing (figure from Agilent’s protocol). 
 
2.4.2 Pipeline 1 
Sequence reads were aligned to the reference human genome (UCSC Genome Browser 
hg19, GRCh37) using Novoalign (Novocraft Technologies). Over 7.0Gb of sequences 
were uniquely aligned for each subject, where >85% of the coding bases of the 
GENCODE-defined exome were represented by at least 20 reads. Duplicate reads, 
resulting from PCR clonality or optical duplicates, and reads mapping to multiple 
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locations, were excluded from downstream analysis. Depth and breadth of sequence 
coverage was calculated using custom scripts and the BedTools package (Quinlan and 
Hall, 2010). Single-nucleotide substitutions and small insertions or deletions (indels) 
were identified with SAMtools (Li et al., 2009) and were annotated with the ANNOVAR 
software package. 
Pairwise comparisons were carried out for all the twin pairs. Sites with alleleic 
representation of >15% in one twin, that have no representation in the corresponding twin, 
were identified using the VarScan v2.2.3 package. After exclusion of repetitive regions 
of the genome by retrieving repetitive DNA tracks from the UCSC genome browser 
(Karolchik et al., 2013), candidate discrepant sites were manually reviewed in both twins 
through inspection of the alignments using the Integrative Genomics Viewer (IGV) 
software v2.1 (Robinson et al., 2011). The variants that passed this stringent multistep 
filtering criteria would be validated by Sanger sequencing, and SNP assays capable of 
detecting low-level mosaicism (see below). For the first set of DNA samples, sequence 
capture, sequencing, alignment and variant calling was performed by Michael Simpson 
at King’s College London, Division of Genetics and Molecular Medicine. 
2.4.3 Pipeline 2 
Other filtering approaches applicable to finding genetic differences between MZ twins 
were explored. Peter De Rijk (University of Antwerp, Department of Molecular Genetics) 
was recruited into the study on a collaborative basis to analyse the data using a software 
pipeline developed in-house called GenomeComb (http://genomecomb.sourceforge.net/). 
By using the query language provided, it can be used to compare, annotate and filter the 
results of NGS data, and SNVs can be ranked based on their probability of being an error 
(Reumers et al., 2012). The pipeline used fastq-mcf v1.1.2 (https://code.google.com/p/ea-
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utils/) for adapter clipping. Reads were then aligned to the reference human genome 
(hg19) using the Burrows-Wheeler algorithm, version 0.7.5a (Li and Durbin, 2009), and 
the resulting sequence alignment map (SAM) files were converted to Binary Alignment 
and Mapping (BAM) files using SAMtools (Li et al., 2009). The resulting BAM files 
were sorted, and duplicates were removed using Picard, version 1.87 
(http://broadinstitute.github.io/picard/). Realignment in the neighbouring regions of 
indels was performed with GenomeAnalysisToolKit (GATK), version 2.4–9 (McKenna 
et al., 2010). Variants with a coverage ≥5 were called using both GATK and SAMtools, 
version 0.1.19-44428cd (Li et al., 2009). At this initial stage, positions with a coverage 
<5 or a score <30 were considered unsequenced. The resulting variant sets of different 
individuals were combined and annotated using GenomeComb. The GenomeComb query 
tool was then used to select variants that differed between the twins, but complied to strict 
quality filtering rules: 
Variants in regions with a clustering of many variants were removed, as well as in regions 
of known microsatellites, simple tandem repeats and segmental duplications. Variants 
were also removed if the coverage at the variant site was <15 or the quality score <70 in 
either sample. Furthermore, variants were retained only if the genotype call by GATK 
and SAMtools was the same, and were consequently combined and annotated with a 
variety of different databases (in-house exomes, dbSNP, 1000 Genomes Project). 
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Figure 2.2. All discordant and shared SNVs between co-twins were calculated. As most discordant SNVs 
are assumed to be false positive errors, each filter was systematically tested to reduce as many discordances, 
while retaining as many shared variants as possible. Three types of filters were applied: 1) Quality filters, 
to remove regions of inferior sequencing quality, 2) repetitive DNA filters, to eliminate errors due to 
incorrect mapping to the reference genome, and 3) consensus filters, to retain SNVs identified with different 
sequence mapping and variation calling algorithms. Individual filters were combined to remove a maximum 
number of discordant variants between the twin exomes (adapted from Reumers et al., 2012). 
 
2.4.4 Pipeline 3 
As we recruited more discordant twins in our study, updated bioinformatic approaches 
were made available, with higher specificity in detecting mosaic variants. Thus, a novel 
pipeline developed by Alan Pittman at UCL Institute of Neurology was used as our main 
in-silico prioritisation tool. Previously-generated and new FASTQ files underwent 
streamlined analysis. 
2.4.4.1 DNA library construction of remaining samples 
Whole-exome sequencing libraries for the next set of samples (n=16) were prepared with 
Agilent SureSelect V6 and sequenced on an Illumina HiSeq3000 using a 75-bp paired-
end reads protocol. This was carried out by Deborah Hughes at UCL, Institute of 
Neurology. 
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2.4.4.2 Whole-exome capture 
Alignment of the previous and newly-sequenced exomes to the human reference genome 
(UCSC hg19), and variant calling and annotation was performed with an in-house 
pipeline developed by Alan Pittman. Briefly, this involves alignment with NovoAlign, 
removal of PCR-duplicates with Picard Tools followed by (sample-paired) local 
realignment around indels and germline variant calling with HaplotypeCaller according 
to the GATK best practices. 
Potentially mosaic variants were identified with GATK MuTect2 (version 2.0) and 
VarScan2 (version 2.4.3), using each pair as reference to one-another (described below). 
The raw list of SNVs and indels were then filtered using ANNOVAR. Variants in splicing 
regions, 5’UTR, 3’UTR and protein-coding regions, such as missense, frameshift, stop-
loss and stop gain mutations, were considered. Priority was given to rare variants (<1% 
in public databases, including 1000 Genomes project, NHLBI Exome Variant Server, 
Complete Genomics 69, and Exome Aggregation Consortium). Furthermore, we have an 
in-house set of approximately six thousand exomes encompassing controls, rare diseases 
for cross-checking any shortlisted candidate variants, and for sequencing artefact 
removal. 
2.4.4.3 Comparison of two somatic variant calling methods 
VarScan2 and MuTect2 algorithm tools were used to identify de novo variants using the 
somatic mutation calling method. The union of SNVs called by both variant callers was 
taken forward for tiering, filtering and manual review. This method was used on 
discordant MZ twins by treating the affected twin as the ‘tumour’ sample and the 
unaffected twin as the ‘normal’ sample (and viscera to detect somatic mutations present 
in the unaffected twin but not in the affected twin). MuTect2 uses a Bayesian classifier 
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approach to detect somatic mutations with very low allele fractions, requiring only few 
supporting reads, followed by carefully tuned filters that ensure high specificity. In this 
study, MuTect2 was run under the High-Confidence mode with its default parameter 
settings. Low quality sequenced data was first removed, followed by variant detection in 
the ‘tumour’ sample using a Bayesian classifier. A filtering step was then applied, which 
removes false positive variants caused by sequencing artefacts. Finally, variants are 
classified as somatic or germline by a second Bayesian classifier (Cibulskis et al, 2013). 
VarScan2 reads BAM files from ‘tumour’ and ‘normal’ samples simultaneously to 
heuristically call a genotype at positions achieving certain thresholds of coverage and 
quality. It uses a one-tailed Fisher’s exact test to calculate the significance of the 
difference in allele frequencies of the normal and tumour sample based on the number of 
reads supporting each allele. We used a cut-off value of Fisher’s P-value <0.05. If the 
resulting p-value meets this significance threshold, variants are classified as somatic (if 
the tumour call was different from the normal and the normal call was the same as the 
reference), loss of heterozygosity (if the tumour variant call was not heterozygous but the 
normal variant call was heterozygous), or unknown (if the tumour call was different from 
the normal call and both calls were different from the reference). The variant is classified 
as germline if the difference does not meet the significance threshold. 
In summary, VarScan2 provides sensitive detection of high-quality somatic SNVs, 
whereas MuTect2 provides sensitive detection of low allelic-fraction. The compatibility 
of the output VCF files between different methods was examined using Microsoft Excel. 
Somatic variants which were common to both algorithms were retained for downstream 
analysis. 
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Tools Version URL Remark Release date 
VarScan 2.4.3 http://dkoboldt.github.io/v 
arscan 
Sensitive 
detection of high-
quality somatic SNVs 
Dec. 2016 
MuTect2 2.0 https://software.broadinstit 
ute.org/gatk/guide/tooldoc 
s/org_broadinstitute_gatk_t 
ools_walkers_cancer_m2_Mu 
Tect2.php 
Sensitive 
detection of low 
allelic-fraction 
Nov. 2015 
 
Table 2.3. Details of algorithm tools for somatic SNV detection within NGS data 
 
2.4.5 DNA variant and gene prioritisation 
Putative discordant variants called by both MuTect2 and VarScan2 were further filtered 
according to low variant quality (VQS<90), common variants (MAF>0.01) as reported in 
public databases (1000g, ExAC, cg69), and variants in regions containing segmental 
duplications. This stringent filtering criteria provided a manageable list for evaluation of 
candidate variant sites; thus, variants with genomic locations in exonic, 5'UTR, 3'UTR, 
splice site and promoter regions were retained. 
For the detection of concordant variants, in addition to the filtering criteria above, variants 
were analysed for their potential deleterious effects using the polymorphism phenotyping 
v2 (PolyPhen2) and Sorting Tolerant from Intolerant (SIFT) algorithms (Kumar et al., 
2009; Adzhubei et al., 2010). Within the prioritised variants, those harbouring truncating 
mutations or mutations predicted to be damaging were considered the most promising 
candidates. The priority order of variants, from most to least damaging, were as follows: 
frameshift, nonsense, splice site, missense and non-stop. All missense variants predicted 
to be benign were removed. 
Where parental DNA was available, provisional postzygotic de novo mutations identified 
in the twins were excluded if they were detected in either parents. To identify germline 
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de novo mutations shared between the twins, parent-offspring trio analysis was 
performed. Contrary to single sample calling, where samples are analysed individually, 
joint genotyping was performed on all samples according to GATK best practices. 
Analysing variants simultaneously across all samples has several advantages, including 
1) Being able to better distinguish between homozygous reference sites and sites with 
missing data; 2) Having higher sensitivity for low-frequency variants. Joint calling 
enables the ‘rescuing’ of genotype calls at sites where there’s low coverage but other 
samples within the call set have a confident variant at that location; 3) Being able to more 
efficiently filter out false positives. Studies have shown that GATK's Variant Quality 
Score Recalibration (VQSR) provides better calling accuracy than simply using hard 
filtering (Pirooznia et al., 2014). VQSR builds a Gaussian mixture model by looking at 
the annotation values over a subset of the input call set, then by using machine learning 
algorithms, determines the annotation profile of good and bad calls, and evaluates all 
input variants. Joint calling provides a large enough dataset for accurate error modelling 
and ensures that filtering is applied uniformly across all samples. 
The data were filtered in Excel to identify concordant mutations in co-twins, but absent 
in the parents and other samples in the dataset. In the twins discordant for Tourette’s 
syndrome (489 and 490), because the father (487) was also affected, inherited pathogenic 
mutations from the father were also investigated. 
PubMed, Online Mendelian Inheritance in Man (OMIM), NIH Genetic Testing Registry 
(GTR) and DisGeNET were reviewed for previous publications regarding candidate 
genes. In addition, gene databases for the disorders investigated in this study were also 
searched, including Amyotrophic Lateral Sclerosis Online Genetics Database (ALSoD), 
ALSGene, PDGene, Schizophrenia Database (SZDB), Schizophrenia Gene (SZGene). 
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All identified genes for each disorder were pooled together to form a comprehensive list, 
and was cross-checked with germline variants in each twin pair (Figure 2.3). 
With the possibility of finding potentially-damaging rare variants in novel genes, after 
prediction of functional effects of the selected variants, all non-exonic variants and 
variants indicated as synonymous were removed (Figure 2.3). Genomic evolutionary rate 
profiling (GERP++) scores, a measure of evolutionary constraint at each base derived by 
aligning 29 mammalian genomes, were also used to estimate the conservation of each 
variant. Negative scores indicate a lack of conservation and high positive scores indicate 
the most conserved nucleotide positions among multiple species (Davydov et al., 2010).  
All concordant and discordant variants between twin siblings were manually reviewed in 
IGV prior to validation (see below). 
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Figure 2.3. General overview of the methods used to detect discordant and concordant variants in MZ 
twins. The MAF filter was not applicable for twins discordant for lactase non-persistence, as common 
polymorphisms are associated with the condition, and Tourette’s syndrome, where modifier variants were 
more likely to play a role. 
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2.4.6 Genome-wide SNP genotyping 
2.4.6.1 Wet lab processing 
300ng of high-quality genomic DNA from each subject was whole-genome amplified 
overnight at 37oC for 20-24hrs in a deep well plate, then fragmented at 37oC for 
1hr15mins in a hybridisation oven, precipitated and resuspended in hybridisation buffer. 
Samples were denatured then taken from the plate and loaded onto the chips using a liquid 
handling robot (Freedom Evo, Tecan Ltd, Switzerland). Hybridisation took place 
overnight for 16-20hrs at 48°C. 
The process of single base extension and staining was carried out by the liquid handling 
robot. The probes on the chip were extended by a single hapten-labelled 
dideoxynucleotide (ddNTP) base complementary to the hybridised DNA. ddATP and 
ddTTP bases were labelled with DNP (2,4- Dinitrophenol), whereas ddCTP and ddGTP 
were labelled with Biotin. The DNA samples were then stripped off the chip using 
formamide. The staining procedure involves signal amplification by multi-layer 
immunohistochemical staining. The haptens were detected simultaneously by 
Streptavidin and an anti-DNP primary antibody conjugated to green and red fluorophores 
respectively (STM reagent, Illumina). They were then counterstained with biotinylated 
anti-steptavidin and a DNP-labelled secondary antibody to the anti-DNP primary 
antibody (ATM reagent, Illumina) to amplify the fluorescent signals. The last layer of 
stain was the STM, containing the fluorophores to allow signal detection. Finally, the 
stained chips were coated in nail varnish to protect the dyes, and scanned using the iScan 
scanner with autoloader (Illumina Inc, San Diego, USA). 
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2.4.6.2 Initial data analysis and quality control 
The data were initially analysed using the Illumina Genomestudio software. This 
generates genotypes, and CN and loss of heterozygosity data (cnvPartition v3.1.6, 
Illumina). Quality control checks were performed to assess the data quality. Samples were 
assessed for their call rate, which should be >98% and >99% average across the batch. 
Specially designed control probes were also checked.  Every array contained both sample 
dependent and sample independent control probes. Sample independent probes assess the 
quality of the processing, and sample dependent probes also assess the quality of the 
DNA. The B-allele frequency (BAF) plots and CN analysis results were checked to 
identify potentially contaminated samples. The BAF plot would show more than three 
modes if the sample had been contaminated.  A noisy BAF plot may also suggest 
degradation of the DNA sample. CN data that looks to be duplicated for the whole 
genome also suggests contamination with at least one other DNA sample. The wet lab 
processing and initial data analysis was run under the supervision by Kerra Pearce at UCL 
Genomics, Institute of Child Health. 
2.4.7 Copy number variant detection 
Further analysis was carried out by Elliot Rees at Cardiff University, Institute of 
Psychological Medicine and Clinical Neurosciences. For all samples, Log R Ratios 
(LRR) and BAFs were generated using Illumina Genome Studio software (v2011.1) and 
used to call CNVs with PennCNV (Wang et al., 2007). CNV calling was performed 
following the standard protocol and adjusting for GC content. Samples were excluded if 
they were found to be an outlier for any one of the following QC metrics: LRR standard 
deviation, BAF drift, wave factor and total number of CNVs called per person. The LRR 
represents a measure of magnitude of combined fluorescence-intensity signals, and the 
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BAF denotes the relative ratio of fluorescence signals from one allelic probe compared 
with another. Duplications can be identified by an increase of LRR and the occurrence of 
four clusters in BAF. Consequently, a deletion is characterised by a decrease of LRR and 
lack of heterozygosity (at 0.5) in BAF. CNVs from samples that passed QC were joined 
together if the distance separating them was <50% of their combined length using an in-
house developed open source program 
(http://x004.psycm.uwcm.ac.uk/~dobril/combine_CNVs/). CNVs were then excluded if 
they were covered by <3 probes. After CNV merging, the remaining CNVs were visually 
re-evaluated using the GenomeStudio genotyping module. All CNV coordinates are 
according to UCSC build 37/hg19. 
I used cnvPartition as the secondary CNV detection algorithm using the following default 
parameters:  
Confidence Threshold   |35 
Detect extended homozygosity |True 
Exclude intensity only  |False 
GC wave adjust   |False 
Include sex chromosomes  |True 
Minimum homozygous region size |1000000 
Minimum probe count  |3 
 
The CNVs detected by PennCNV and cnvPartition were detected on autosomes only and 
were based on at least three consecutive probes. Here, these CNVs are referred to as non-
mosaic somatic CNVs; that is, acquired somatic CNVs that are present in a sufficiently 
high proportion of cells to be detected by the applied algorithms. 
The evaluation of the non-mosaic structural variants was based on predefined and 
structured criteria and consisted of the steps shown below. The unique CNVs remaining 
after each step are listed in Table 5.2. 
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1. After CNV detection by PennCNV, CNVs of the same type (CN = 0, 1, 2, 3 or 4) 
were merged if they overlapped with at least 50% of the length of the smaller 
CNV. 
2. Samples from MZ twins, and parents where applicable, were compared. Only 
CNVs found to be discordant between paired samples, or concordant but 
overlapping known disease-susceptibility genes, were of main interest. 
3. Discordant CNVs were evaluated by visual inspection of LRR and BAF plots in 
GenomeStudio. If both twins had the same signal intensities, the CNV was 
classified as concordant. If there was insufficient evidence, the CN call was 
disregarded. 
4. CNVs were independently detected again by cnvPartition in GenomeStudio. 
CNVs of the same type (deletion or duplication) were merged if they overlapped 
with at least 50% of the length of the smaller CNV. 
5. Only CNVs detected by both algorithms were retained for further analysis. CNVs 
called by PennCNV were disposed of if the CNV calls made by cnvPartition did 
not confirm the finding. 
6. The LRR and BAF plots of remaining CNVs were visually inspected to select the 
best candidates for ddPCR validation. 
2.4.7.1 Comparison of CNV/LOH differences between twins. 
The output files from cnvPartition and PennCNV were converted into BED format files 
using a Perl script (see http://genome.ucsc.edu/FAQ/FAQformat.html#format1 for 
details). The files contain no headers but all take the same format: ‘chr|startPosition 
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(bp)|endPosition(bp)’. BED files are useful as they can be imported as a custom track into 
the UCSC Genome Browser, allowing one to see all the genes and other features that 
coincide with the features detailed in the BED file (in this instance, the features in the 
BED files are the CNV and LOH regions). They can also be viewed and manipulated in 
Notepad or Excel. The BED files for each pair of twins were compared using BEDTools 
v2.17, an open source suite of command line operated tools for comparison of BED files 
(http://bedtools.readthedocs.org/en/latest/content/overview.html). Three comparisons 
were carried out using the ‘intersect’ tool: 
1. Find features present in twin1 but not in twin2 (filename: 
{twin1}_not_{twin2}.bed) 
2. Find features present in twin2 but not in twin1 (filename: 
{twin2}_not_{twin1}.bed) 
3. Find features that overlap between the two twins (filename: 
{twin1}_overlap_{twin2}.bed”). This file reports the original feature in twin1 
(chr|startPosition(bp)|endPosition(bp)), then the original feature in twin2 
(chr|startPosition(bp)|endPosition(bp)), and the final column contains the size of 
the overlap in bp. 
The first two files contain regions of CNV and LOH, which are different between the two 
twins. The third ‘overlap’ file was run through a Perl script to remove the overlapping 
regions to leave just the regions specific to one twin or the other (filename: 
{twin1}_{twin2}_unique_regions_from_overlaps.bed). These three files, taken together, 
contained the CN and LOH differences between each pair of twins. CNVs were then 
annotated with gene information and compared to previously reported losses, gains, 
inversions or segmental duplications, and thus categorised as novel or benign 
polymorphism, using the Database of Genomic Variants 
(http://dgv.tcag.ca/dgv/app/home). Genes contained within CNVs were then searched on 
various databases, such as PubMed, OMIM and DisGeNET, to determine pathogenic 
relevance. 
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2.4.8 CNV analysis with ExomeDepth 
ExomeDepth is an algorithm designed to use read depth data from exome sequencing 
analysis to call CNVs (Plagnol et al., 2012). It controls technical variability between 
samples, a feature which ordinarily complicates the analysis and creates spurious CNV 
calls.  
The read count information was extracted from the individual BAM files using the R 
package Rsamtools. All reads were paired-end. Only reads with a Phred scaled mapping 
quality ≥20, distance of <1000bp from each other and in the correct orientation, were 
included. The location was defined by the middle location between the extreme ends of 
both paired reads. Exons closer than 50bp were merged into a single location owing to 
the inability to properly separate reads mapping to either of them. 
Parameters for ExomeDepth were applied according to the instructions provided by the 
user guide. To set the threshold for sensitivity and specificity, the correlation between 
reference and tests count was set to 0.9898. It is advised that this correlation should be 
>0.97 to avoid a high false positive rate. There is an option, as used in the cancer field, of 
combining sequence data for healthy and tumour tissue. It is possible to utilise this 
function by pairing the affected and unaffected twin as ‘tumour’ and ‘normal’, 
respectively – thus replacing the test sample with the affected twin sample, and the 
reference sample with the unaffected twin sample. However, it would be statistically more 
viable to compare each sample independently against an aggregate reference of all exome 
samples. This would render shared CN calls between twin pairs, that are not present in 
other samples, as more likely to be real. This data was used to confirm CNVs detected by 
the SNP genotyping method. CN calls that were shared by all three calling algorithms 
(PennCNV, cnvPartition, and ExomeDepth) were considered high confidence CNVs. 
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 Biochemical and label-free quantitative proteomics analysis 
2.5.1 Cytogenetics 
Before carrying out biochemical and proteomic analysis on the MZ twins discordant for 
ischaemic stroke (HG and KG), cytogenetic analysis of peripheral lymphocytes was 
performed according to standard protocols to rule out karyotypic abnormalities. 
Chromosomes from cultured peripheral blood lymphocytes were analysed on G-bands by 
trypsin using Giemsa (GTG)-banded metaphase spreads. A total of 20 metaphases were 
analysed for each twin, including karyotyping of 10 metaphases using light microscopy. 
The banding resolution was 450 bands for each sample. The constitutional karyotypes 
were described in accordance with the International System for Human Cytogenetic 
Nomenclature (Simons et al., 2013). 
2.5.2 Blood chemistry 
Blood samples were drawn from the twins by standard venesection into plain tubes and 
fluoride and EDTA anticoagulated tubes, just prior to lunch, and processed in parallel. A 
total of 59 individual markers were measured to check for renal, liver, glucose, 
cardiovascular, blood, immunological, and hormonal function. The data were compared 
with the corresponding reference intervals for the age group. 
2.5.3 Blood collection for proteomic analysis 
From each plasma sample, 2ml blood was allowed to clot at 4°C for at least 2hrs and then 
centrifuged at 1500g for 10mins to reach sediment the clotted cells. Plasma was then 
collected, divided into aliquots, and stored frozen at −80°C until the analysis was carried 
out. The control sample was created by taking 5l of sample from each twin’s serum after 
processing to generate peptides and pooling these together. As the control serum contains 
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all the features of both twin samples, it was used to align the data effectively – that is, to 
correct for any drift in the retention time of the peptides analysed. 
2.5.4 Gel electrophoresis and in-gel digestion 
1l of a 1:4 dilution of each serum sample was run on SDS-PAGE using a 4-12% bis-tris 
gel and MOPS buffer system. Briefly 10ul of sample buffer and 4l of reducing agent 
were added to each sample prior to addition of 25l of milliQ water. The gel lanes from 
each serum sample were processed as follows. Samples were processed by in-gel 
reduction with 10mM dithiothreitol and alkylation with 50mM iodoacetamide prior to 
overnight (16hrs) trypsin digestion (Modified Sequencing Grade, Roche) at 30oC. 
Peptides were extracted from the gel by 1% formic acid, then 100% acetonitrile, and dried 
in a SpeedVac concentrator (Thermo Scientific). The resulting peptides were then 
resuspended in 50µl 1% formic acid, centrifuged and transferred to the high-performance 
liquid chromatography (HPLC) vial. 7.5l of each sample and pooled was used for 
analysis. 
2.5.5 Sample separation 
Technical replicates (3 x 7.5l) of trypsin-digested peptides were separated using an 
UltiMate 3000 RSLCnano UHPLC System (Thermo Scientific) coupled to a LTQ 
Orbitrap Velos Pro (Thermo Scientific). The nLC buffers used were buffer A (0.1% 
formic acid), and buffer B (80% acetonitrile in 0.08% formic acid). Technical replicates 
(3 x 2.5μg) of each sample were initially trapped on an Acclaim PepMap100 C18, 5µM 
(100µM x 2cm nanoViper). After trap enrichment, peptides were separated on an Easy-
Spray PepMap RSLC C18, 2µM column (75µM x 50cm nanoViper) (Thermo Scientific) 
with a linear gradient of 2-40% buffer B over 120mins with a constant flow of 0.3μL/min. 
77 
 
The UHPLC system was coupled to a LTQ Orbitrap Velos Pro (Thermo Scientific), via 
a nano electrospray ion source (Proxeon Biosystems). A Top 15 method was used to 
acquire Data Dependant Acquisition data. Briefly, a 60,000-resolution full-scan mass 
spectrometry (MS) survey spectra (m/z 335-1800) were attained in the Orbitrap with an 
automatic gain control target of 1,000,000 ions. Lock mass was set at 445.120024 and the 
spray voltage set to 1.8kV. This was followed by ion-trap MS/MS scans for the 15 most 
intense peptide ions.  
Maximal filling times were 500ms for the full scans and 100ms for the MS/MS scans. 
Precursor ion charge state screening was enabled and all unassigned charge states, as well 
as singly charged species, were rejected. The dynamic exclusion was set to an exclusion 
list size of 500 with a maximum retention period of 45secs and an exclusion mass width 
of ±10 ppm. The lock mass option was enabled for survey scans to improve mass accuracy 
(Olsen et al, 2005). Data were acquired using the XCalibur software. 
2.5.6 Abundance quantification  
Orbitrap Velos Pro .RAW data files were imported into Progenesis LC-MS (version 4.0) 
for label-free differential analysis and subsequent identification and quantification of 
relative ion abundance ratios. Following alignment of MS data, principled component 
analysis and preliminary filtering (power <80% and P>0.05, corresponding to an ion score 
threshold of 35), datasets were exported from Progenesis as an .mgf file. These files were 
subsequently used to map the individual peptide sequences to corresponding UniProt 
identifiers using the UniProt database via Mascot Daemon (version 2.4.1). Enzyme 
specificity was set to trypsin, with fixed (quantitative) modifications set to 
carbamidomethyl cysteine (as it is assumed that all cysteines are modified so this does 
not alter the number of potential peptides). To increase the number of potential peptides, 
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parameters for the variable (non-quantitative) modifications were set to methionine 
oxidation, methionine dioxidation, protein N-acetylation, and Gln -> pyro-Glu. Other 
parameters used were as follows: Peptide mass tolerance, ±10ppm; fragment mass 
tolerance, ±0.6 Da; minimum peptide length, 6; and maximum missed cleavages, 2. 
Statistical P-values as shown in Tables 6.3, 6.4 and Appendix B were automatically 
generated using Progenesis software through a one way Anova on the ArcSinh transform 
of the normalised data. 
2.5.7 Peptide/protein identification 
The filtered Mascot search results were reimported into the Progenesis LC-MS and 
conflicts for peptide assignments at protein level were examined and resolved 
appropriately. 
2.5.8 Pathway and network analysis 
To explore the biological processes associated with the differentially expressed proteins, 
I performed Gene Ontology (GO) pathway analysis using the functional analysis tools 
VLAD (Richardson and Bult, 2015), PANTHER (Mi, Muruganujan and Thomas, 2012), 
and g:Profiler, gOST (Reimand et al., 2007). For the main analysis, g:Profiler was used 
to look for overrepresentation of GO terms in the differentially expressed protein lists, 
relative to the whole human proteome. The Ensembl 87 GO annotation dataset was used 
with the associated ontology file, released on 13 December 2016. 
Only proteins with an average of >1.5 fold higher level in both runs for each twin were 
used to seed each network, using Cytoscape (Smoot et al., 2010) version 3.3.0. The 
following parameters were applied: Hypergeometric test, Benjamini & Hochberg False 
Discovery Rate correction, significance level 0.05 and the human proteome as the 
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reference set. The network view was modified using the following options: 
NetworkAnalyzer: ‘map nodes size’, degree, low values to small sizes; edit, ‘remove 
duplicate edges’ and selectively removed all edges describing identical protein binding 
interactions; layout, ‘Allegro Fruchterman-Reingold’, all nodes. The GO terms associated 
with this network were then identified using GOlorize (Garcia et al., 2006) with the 
BinGO plugin (Maere, Heymans and Kuiper, 2005) within the Cytoscape tool, and 
including the GO term ontology (10th February 2017) and the 13th March 2017 gene 
association files (a combination of two 166 gaf files goa_human, goa_human_isoform). 
 
 Validation techniques 
To determine the genotype of the two of the most common SNPs known to be associated 
with lactase non-persistence, and confirm candidate mosaic discordant SNVs found 
between co-twins, PCR and Sanger sequencing was employed. Various SNP assays were 
employed for variants that had low-level mosaicism, potentially undetectable with 
conventional Sanger sequencing. CNVs found between co-twins were validated using 
ddPCR, and gene expression analysis was performed to confirm the up- and down-
regulated proteins found in twins discordant for ischaemic stroke.  
2.6.1 PCR and gel electrophoresis 
Primers were designed using Primer 3 software (Koressaar and Remm, 2007). PCR 
amplifications of the genes of interest were performed in a Mastercycler pro Thermal 
Cycler (Eppendorf). PCR reactions were performed in a 10μL volume containing 1μL of 
genomic DNA (10–30ng/µL), 0.1μL of DreamTaq DNA Polymerase (Thermo 
Scientific), 1.0μL of 10X DreamTaq Green Buffer (Thermo Scientific), 0.4μL of a dNTP 
mix containing dATP, dTTP, dCTP, and dGTP at a concentration of 5mM (Thermo 
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Scientific), 0.4μL of each primer (Sigma-Aldrich) at a concentration of 5pmol, and 
distilled deionised water. The reaction conditions were as follows: 95°C for 3mins, 
followed by 40 cycles at 94°C for 30secs, 54-61°C for 30secs, 72°C for 30secs, and a 
final extension at 72°C for 7mins. PCR products were separated by electrophoresis in 
1.3% agarose gels made with 1x Tris-acetate-EDTA buffer (Alpha laboratories) in order 
to confirm the amplification of the desired PCR product. These were then purified 
following the Exonuclease I (New England Biolabs, US) - Shrimp Alkaline Phosphatase 
(Affymetrix, US) (ExoSAP) protocol for sequencing reactions. The mixtures were 
incubated at 37°C for 5mins to digest the remaining primers and dNTPs into nucleosides 
and inorganic phosphate followed by deactivation of the ExoSAP in the Mastercycler pro 
Thermal Cycler at 95°C for 5mins. 
2.6.2 Sanger sequencing 
Sequencing was performed bidirectionally using the BigDye Terminator Chemistry 
(Sequenase v3.1 Cycle Sequencing Kit; Applied Biosystems, CA, USA). The sequencing 
reactions were performed in a 10μL volume containing 1.0μL of primer (5pmol), 2.0μL 
of the PCR product, 2.0μL of 5x BigDye Buffer, 0.5μL of BigDye Terminators and 4.5μL 
of distilled deionised water. The BigDye XTerminator Purification Kit (Applied 
Biosystems, CA, USA) was used to eradicate unincorporated dye terminators and free 
salts by adding 20μL of the SAM solution and 5μL of the XTerminator to each of the 
10μL sequencing reactions. The mixture was placed on a shaker at full speed for 30min 
and then centrifuged at 13,000rpm for 2mins. A 3130xl automated DNA sequencer 
(Applied Biosystems) was used to run the samples. The sequencing data was analysed 
using the CodonCode Aligner v.4.2.4 (CodonCode Co., USA) and Finch TV (GeoSpiza, 
Seattle, WA). Wild-type sequence was derived from the Ensembl Genome Browser 
(Wellcome Trust Sanger Institute, Cambridge, UK). 
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2.6.3 SNP validation using CloneJET PCR Cloning Kit  
PCR amplified fragments resolved on 1.3% agarose gel were extracted using the 
GeneJET Gel Extraction Kit (Fermentas, Thermo Fischer Scientific). The separated DNA 
fragment was visualised using a UV-transilluminator, and quickly excised to minimise 
DNA damage due to UV exposure. After weighing, a 1:1 ratio of Binding Buffer volume 
(500μL) to the gel slice weight (500mg) was added. The gel mixture was incubated at 
55oC for 10mins, whilst intermittently inverting the tube. The solution was transferred to 
the GeneJET Purification Column and centrifuged at 13,000rpm for 1min. The flow-
through was discarded. 700μL of Wash Buffer was added and centrifuged for 1min at 
13,000prm. The flow-through was again discarded and the empty column was centrifuged 
for 1min. The column was placed into a fresh 1.5mL microcentrifuge tube. 50μL of 
Elution Buffer was added to the column and centrifuged for 1min at 13,000rpm. The flow-
through containing the purified DNA was collected.  
To confirm the potential variant on EML5 in subject RT1b, and its absence in co-twin 
RT1a, the PCR product spanning this SNP was cloned for each of the twins separately. 
Amplified fragments were ligated to PCR vectors with CloneJET™ PCR Cloning Kit 
(Thermo Scientific) according to the manufacturer’s instructions. The protocol for 
cloning PCR products with 3’-dA overhangs, generated by DreamTaq DNA polymerase, 
was followed. This involved setting up a blunting reaction on ice, containing 10μL of 2x 
reaction buffer, 1μL of the purified PCR product, 1μL of the DNA blunting enzyme, and 
6μL of nuclease-free water. The mixture was briefly vortexed and centrifuged, and then 
incubated at 70oC for 5mins to inactivate the enzyme before being placed back on the 
ice. The ligation reaction was set up on ice by adding the following to the blunting 
reaction mixture: 1μL of pJET1.2/blunt cloning vector (50ng/μL) and 1μL of T4 DNA 
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ligase, thus making a total volume of 20μL. The ligation mixture was incubated at room 
temperature for 5mins and used directly for transformation. 
For bacterial transfection, 10μL of the mixture was mixed with 100μL of HB101 E. coli 
competent cells and incubated on ice for 45mins. The mixture was then heat-shocked at 
42°C for 2mins, put on ice again for 5mins, 1mL of LB medium added, and incubated at 
37°C for 45mins at 450rpm. The bacteria were spun down for 4mins and resuspended in 
SOC medium. The pellet was cultured overnight (18hrs) at 37°C on an LB agar plate 
containing 100μg/mL of Ampicillin. The following day, a total of 96 individual bacterial 
colonies were randomly picked per twin for colony screening by PCR using the plasmid-
derived pJET1.2 forward and reverse primers (Thermo Scientific). The resulting PCR 
products were subsequently Sanger sequenced. 
2.6.4 SNP validation using KASP assay: 
To determine the potential mosaic variant found in subject RT1b, DNA samples of both 
MZ twins and variant flanking sequence were submitted to LGC Genomics for 
Kompetitive Allele Specific PCR (KASP) assay design and genotyping. This uses 
fluorescent resonance energy transfer to quench fluorescence in reporter oligonucleotides 
until they are incorporated into allele-specific PCR products. Concordance between the 
other genotyping methods would provide validation of the SNP. 
2.6.5 SNP validation using Sequenom MassARRAY assay 
In parallel, DNA samples were further genotyped for the potential variant by NewGene 
using the Sequenome MassAssay genotyping (Sequenom, San Diego, CA, USA), 
according to the manufacturer’s instructions (Fumagalli et al., 2010). Briefly, 2µL of 
template genomic DNA was amplified by multiplex PCR to extend wild-type and mutant 
DNA. This was followed by treatment with shrimp-alkaline-phosphatase to inactivate 
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unincorporated nucleotides. A primer extension reaction (iPLEX Pro) was then 
performed using mass-modified terminators, and the products were spotted on a 
SpectroCHIP (Sequenom). MALDI-TOF mass-spectrometry was used for allele-specific 
detection. Automated genotyping calls were generated using the MassARRAY RTTM 
software and were validated by manual review of the raw mass spectra. 
2.6.6 RNA extraction 
Gene expression analysis is currently being carried out to confirm the up- and down-
regulated proteins found in KG. Future projects beyond the scope of this thesis would 
include performing RNA sequencing (whole-transcriptome shotgun sequencing) on twin 
pairs to determine downstream consequences of potential (epi)genetic alterations. Thus, 
whole blood samples of co-twins were collected in PAXgene Blood RNA Tubes (Qiagen, 
UK) and the total RNA was isolated using the PAXgene Blood RNA Kit (Qiagen, UK) 
according to manufacturer’s instructions. The PAXgene Blood RNA tubes were 
centrifuged for 10mins at 4000rpm. The supernatant was removed by pipetting. 4ml of 
RNase-free water was added to the pellet and vortexed until the pellet had thoroughly 
dissolved, and then centrifuged for 10mins at 4000rpm. The supernatant was discarded. 
350μl of resuspension buffer (BR1) was added and vortexed until the pellet had 
thoroughly dissolved. The sample was pipetted into a 1.5ml microcentrifuge tube, and 
300μl binding buffer (BR2) and 40μl proteinase K was added. The contents were mixed 
by vortexing for 3secs and incubated for 10mins at 55°C using a shaker–incubator at 
1,000rpm. The lysate was pipetted into a PAXgene Shredder column placed in a 2ml 
processing tube, and centrifuged for 3min at 15,000rpm. The supernatant was transferred 
to a 1.5ml microcentrifuge tube without disturbing the pellet. 350μl of 98% ethanol was 
added to the tubes, mixed by vortexing, and centrifuged briefly for 3secs. 700μl of the 
sample was added to the PAXgene RNA spin column placed in a 2ml processing tube and 
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centrifuged for 1min at 15,000rpm. The PAXgene column was placed in a new 2ml 
processing tube, and the old processing tube containing flow-through was discarded. This 
step was repeated of the remaining sample. 350μl of wash buffer (BR3) was added to the 
PAXgene spin column and centrifuged at 15,000rpm for 1min.  
10μl DNase I (RNFD) stock solution was added to 70μl digestion buffer (RDD) in a 1.5ml 
microcentrifuge tube. Contents were mixed by flicking the tube, and centrifuged briefly 
to bring any residual liquid to the bottom. 80μl DNase I incubation mix was added onto 
the PAXgene spin column membrane and incubated at room temperature for 15mins. 
350μl of BR3 was added to the PAXgene spin column and centrifuged for 1min at 
15,000rpm. The flow through was discarded and 500μl of wash buffer 2 (BR4) was added 
into the spin column and centrifuged at 15,000rpm for 1min. After discarding the flow 
through, 500μl of BR4 was again added to the column and centrifuged at 15,000rpm for 
2mins. The spin column was transferred to a 1.5ml elution tube, 40μl elution buffer (BR5) 
was pipetted to the centre of the column and the tube was centrifuged at 15,000rpm for 
1min. Another 40μl of BR5 was added to the column and centrifuged at 15,000rpm to 
elute RNA. The eluate was incubated at 65°C for 5mins in shaker-incubator and then 
chilled immediately on ice. The RNA samples were diluted with 10mM Tris-HCl pH 7.5 
for accurate quantification by absorbance at 260nm. The quality of RNA was checked 
using an Agilent Bioanalyzer and the stock RNA was stored at -80°C. 
2.6.7 Identifying ARHGAP11B copy number using droplet digital PCR 
All DNA samples from twin pairs were sent to The Jackson Laboratory for Genomic 
Medicine for CNV validation. To determine ARHGAP11B copy number, ddPCR was 
used with a QX200 instrument (Bio-Rad, Hercules, CA, USA) following the 
manufacturer’s instructions. The gDNA from all twin pairs was first digested by EcoRI 
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(New England Biolabs) enzyme for 1hr at 37oC. Digested gDNA (4 ng) was assayed per 
20μl reaction. Initially, three primers and probes were designed bioinformatically using 
Primer3 (http://frodo.wi.mit.edu/). Individual primer sets were assayed by PCR and gel-
electrophoresis to test for primer-dimers and non-specific product amplification, and one 
set was chosen for the study. The CN assay primers and probes for ARHGAP11B were 
as follows:  ARHGAP11BF: AGCTACAGGTATGGAGACAG, ARHGAP11BR: 
TTAACGTAATTCACCTGCCC, ARHGAP11B MGB probe: FAM-
AGAGAAGCTGATCATGTTTCAGCA) at a final concentration of 900 nM primers and 
250 nM probe. Amplicon coordinates were chr15:30676855-30676927 (hg38). After 
droplet generation, the reaction mixes proceed to thermal cycling as 95 °C × 10 min (1 
cycle), 94 °C × 30 s, and 60 °C × 60 s (40 cycles), 98 °C × 10 min (1 cycle), and 12 °C 
hold. After thermal cycling, plates were transferred to a droplet reader (Bio-Rad) that 
flows droplets single-file past a two-colour fluorescence detector. Differentiation between 
droplets that contain target and those that did not was achieved by applying a global 
fluorescence amplitude threshold in QuantaSoft (Bio-Rad). Confirmed CNV duplications 
had approximately 50% increase in the ratio of positive to negative droplets as did the 
reference channel. Conversely confirmed CNV deletions had approximately half the ratio 
of positive to negative droplets as did the reference channel. 
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 Web Resources 
The URLs for data presented herein are as follows: 
1000 Genomes, http://browser.1000genomes.org 
ALSGene, http://www.alsgene.org/_green 
ALSoD, http://alsod.iop.kcl.ac.uk/_green 
com/public-data/69-Genomes 
CompleteGenomics cg69database: http://www.completegenomics. 
dbSNP, http://www.ncbi.nlm.nih.gov/projects/SNP/ 
Decipher, http://decipher.sanger.ac.uk/ 
ExAC Browser, http://exac.broadinstitute.org/ 
Genome Analysis Toolkit (GATK), http://www.broadinstitute.org/gatk/ 
GenomeComb, http://genomecomb.sourceforge.net 
G-profiler: http://biit.cs.ut.ee/gprofiler/index.cgi 
KEGG, http://www.genome.jp/kegg/ 
MutationTaster, http://www.mutationtaster.org/ 
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, 
NHLBI Exome Sequencing Project (ESP) Exome Variant Server, 
http://evs.gs.washington.edu/ 
Online Mendelian Inheritance in Man (OMIM), http://www.omim.org 
PDGene, http://www.pdgene.org  
PolyPhen-2, http://www.genetics.bwh.harvard.edu/pph2/ 
RefSeq, http://www.ncbi.nlm.niv.gov/RefSeq 
SAMtools, http://samtools.sourceforge.net 
SIFT, http://sift.bii.a-star.edu.sg/ 
SZDB, http://www.szdb.org 
SZGene, http://www.szgene.org 
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Chapter 3. Investigating the genetics of amyotrophic 
lateral sclerosis 
 
 Overview 
Amyotrophic lateral sclerosis (ALS) is a devastating neurogenerative disease of upper 
and lower motor neurons with no effective treatment (Kiernan et al., 2011), or definitive 
diagnostic test (Cirulli et al., 2015) – although multiple genes have been implicated in the 
disorder, including: ALS2, ANG, DCTN1, FIG4, FUS, NEFH, SLC52A1, SLC52A2, 
SLC52A3, SOD1, TARDBP, UBQLN2, VAPB and VCP (Meltz Steinberg et al., 2015; 
Morgan et al., 2015).  
Familial ALS accounts for approximately 10% of cases, and is inherited in an autosomal 
dominant, autosomal recessive, or X-linked fashion. The remaining 90% of cases are 
believed to be sporadic (Renton et al., 2013; Cirulli et al., 2015). Of familial ALS, 
approximately 33% worldwide is due to hexanucleotide (GGGGCC) repeat expansions 
in the intron between non-coding exons 1a and 1b of C9orf72. These are also present in 
8% of sporadic ALS cases, highlighting a major role for C9orf72 in neurodegeneration 
(Farg et al., 2014). It also accounts for approximately 25% of frontotemporal dementia 
(FTD), a disorder that has clinical, pathophysiological and genetic overlaps with ALS. 
Using twin data to estimate the heritability of ALS, Al-Chalabi et al. (2010) found that 
90% of the MZ twins investigated were discordant for the disorder. This high ALS 
discordant rate is further corroborated by studies where either eighteen of twenty-one 
(Graham et al., 1997), or all twelve (Dellefave et al., 2003) MZ twin pairs investigated 
were clinically discordant for ALS. A low disease concordance rate may point to 
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environmental influences as a possible explanation. Another possibility, however, is the 
occurrence of de novo mutations early in development of the affected twin. 
In this study, genetic and clinical differences were compared between four ALS-
discordant twin pairs. Three twin pairs were obtained from The Coriell Institute 
(catalogue IDs: ND08242 and ND08242; ND12421 and ND12422; ND12218 and 
ND14318). One twin pair (LAS and SUS) was referred to this study by Niranjanan 
Nirmalananthan (St George's University Hospitals NHS Foundation). Genetic screening 
of the hexanucleotide repeat expansion in C9orf72 involved rpPCR and Southern blotting. 
The Coriell DNA samples were derived from immortalised lymphoblastoid cell lines 
(LCLs); DNA samples of LAS and SUS were obtained from buccal swab samples. To 
determine the sensitivity and specificity of repeat length calculation using LCL-derived 
DNA we additionally compared C9orf72 repeat lengths in DNA derived from whole 
blood and DNA derived from LCLs. Samples from LAS and SUS were screened on a 25-
ALS gene panel. Demographic and clinical information for each subject is summarised 
in Table 2.1. 
 
 Results 
3.2.1 Repeat-primed PCR 
C9orf72 hexanucleotide repeats were screened in four ALS-discordant twin pairs using 
rpPCR. One MZ twin pair (421 and 422) had abnormally-enlarged (>30) C9orf72 repeat 
expansions, although they were reported to be discordant for the disease. A twin pair of 
35-year-old males of European descent (242 and 243), had normal and equal numbers of 
C9orf72 repeats (n=2). One twin pair (218 and 318) had normal, but different, numbers 
of C9orf72 repeats (n=2 and n=8, respectively). An expansion size >30 is beyond the 
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resolution of rpPCR, thus southern blotting was used to confirm and quantify the 
expansion. 
 
 
 
 
 
 
 
 
 
Figure 3.1. C9orf72 repeat genotyping. a) The presence of a homozygous C9orf72 hexanucleotide 
expansion in subject 421 is shown. The rpPCR result demonstrates a saw-tooth pattern, typical of a 
pathological expansion. Expansions are measurable up to 40-60 hexanucleotide repeats. b) A wild-type 
control result is shown for comparison. Fluorescence intensity is recorded on the vertical axis. DNA 
fragment peaks are sized based on the sizing curve produced from the points on the internal size standard, 
which is shown as consecutive red dots at 300, 340, 350, 400, 450, 490 and 500bp. 
 
3.2.2 Southern blotting 
Southern blotting was performed on Coriell DNA samples of three MZ twin pairs (242 
and 243; 421 and 422; 218 and 318), using a modified protocol as previously described 
(DeJesus-Hernandez et al., 2011). Somatically unstable expanded repeats were confirmed 
in subjects 421 and 422 (Figure 3.2). 
b. 
a. 
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Figure 3.2. Southern blotting showing data from three ALS-discordant twin pairs. Positive for expansion 
was seen in twins 421 and 422. Typical LCL banding patterns can be seen and might represent 
pauciclonality of LCL DNA. Repeats associated with LCL DNA are smaller in size than repeats seen in 
peripheral-blood DNA. The positive control DNA source is from blood. 
 
Total gDNA was digested with a restriction enzyme and hybridised with a single copy 
probe. A large band representing the C9orf72 repeat expansion was detected in samples 
421 and 422. A 6.2 kb wild-type band was seen in all other samples. The pattern of the 
expansion in these samples is as expected for LCL-derived DNA. The multiple bands 
seen are likely to be smaller than when compared to the actual average size in blood. 
Somatic instability of the C9orf72 repeat is known to occur in LCL-derived DNA 
compared with DNA derived from whole blood from the same patient. Accurate repeat 
length determination in immortalised cell lines is therefore difficult to ascertain (Hübers, 
et al., 2014). Southern blotting was not performed on samples LAS and SUS due to 
limited DNA sample availability, however rpPCR did not reveal expanded alleles. 
 
 
 
Wild-type 
Expanded 
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Sample 
IDs 
C9orf72 
repeat no. 
Southern 
blot 
242 2 Wild type 
243 2 Wild type 
  
421 >30 Expansion 
422 >30 Expansion 
  
218 2 Wild type 
318 8 Wild type 
  
LAS 10 n/a 
NAS 10 n/a 
 
Table 3.1. Repeat length determination using rpPCR and Southern blotting. 
 
3.2.3 NGS multigene panel 
One twin pair (SUS and LAS) were further screened on a comprehensive assay containing 
25 genes that have previously been implicated in ALS. Sequence analysis involved full 
exomes of known ALS-candidate genes (BSCL2, CEP112, FUS, MATR3, OPTN, SOD1, 
SPG11, TARDBP, UBQLN2, and VCP), and other genomic areas of potential importance 
(ALS2, ANG, CHMP2B, DAO, DCTN1, FIG4, NEFH, PON1, PON2, PON3, PRPH, 
SETX, SQSTM1, VAPB, and VEGFA) (Morgan et al., 2015). A possible mutation in SOD1 
(c.65A>G; p.E22G) was identified in both the twins; however, when viewed in IGV the 
region showed evidence of sequencing artefacts. 
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 Discussion 
The rpPCR method used in this study to screen for expanded C9orf72 repeats can only 
accurately be determined for up to 60 repeats (Renton et al., 2011). Repeat expansions of 
>30 are considered pathological, and <20 repeats are considered normal. This range is 
based on a study of the repeat expansion in a Finnish cohort of 402 ALS cases and 478 
controls. Of the ALS patients, rpPCR showed the repeat expansion to be in 28.1% cases 
with an average number of repeats of 53 (range 30 to 71). The control group had an 
average of 2 (range 0 to 22). Further, it was determined that the expansion accounts for 
46.0% of familial ALS, and 21.1% of sporadic ALS in that Finnish population. 
A definitive demarcation between normal and pathological repeat sizes is not known, 
however this study used the usual cut-off points described in previous studies in C9orf72-
associated disorders (Majounie et al., 2012). All patients with a normal repeat range in 
our cohort had <20 units. As no subjects presented with the border-zone range of 20 to 
30 units, there was no ambiguity between our normal and abnormal classification. 
Three twin pairs had normal numbers of C9orf72 repeats; of these, one pair (218 and 318) 
had different numbers of C9orf72 repeats (n=2 and n=8). Although this would not cause 
phenotypic discordance, Dols-Icardo et al. (2014) found subtle differences in the repeat 
length between two MZ twins discordant for the disease. This suggests that stochastic 
expansion events do occur during cell division in this region, leading to somatic 
mosaicism, thereby contributing to the repeat expansion variation within and between the 
twins. 
Abnormal C9orf72 repeat expansions (>30) were found in one twin pair (421 and 422), 
yet they were reported to be discordant for the disorder. This finding was confirmed with 
southern blotting. Unfortunately, it has not been possible to obtain follow-up clinical 
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details for these twins, to find out if the initially unaffected twin developed ALS over 
time. This is nevertheless an interesting finding, as only one other ALS-discordant twin 
pair case is reported, where both twins have abnormally expanded C9orf72 repeats (Xi et 
al., 2014). DNA is not available from other family members to confirm whether or not 
this is sporadic or familial C9orf72 repeat-related ALS; however, clinical records have 
indicated an absence of ALS and other related neurodegenerative disorders in the family. 
The affected twin (LAS) in this MZ twin cohort died at the age of 71, shortly after 
agreeing to partake in this study. The clinical phenotype in LAS was characterised by 
predominant lower motor neuron signs, with clinical onset at 67 years of age. Initial 
symptoms involved the distal muscles, predominantly of the lower limbs, with late bulbar 
and respiratory involvement. The ALS clinical course in the affected twin demonstrated 
slow progression with a long survival time. Interestingly, the unaffected twin (SUS) was 
asymptomatic two years after her twin was diagnosed. Thus, it remains possible that there 
has been a yet undiscovered de novo mutation event unique to the affected twin, or that 
both twins share a pathogenic mutation beyond the regions examined. If the latter, a 
possible explanation for the different intrafamilial phenotypic expression could involve 
putative modifier genes, epigenetic differences and/or environmental factors. 
A limitation of the study is that the DNA samples obtained from Coriell were LCL 
derived. This poses a disadvantage for whole-exome sequencing analysis, as it has been 
shown that the process of cell line creation and culturing itself induces de novo mutations 
(Veltman and Brunner, 2012). Analysis of post-mortem brain biopsies would be more 
suitable to investigate neurodegenerative diseases. For LAS and SUS, DNA from 
mucosal epithelial cells was obtained, as an ectodermally-derived tissue would be 
preferable over peripheral blood when looking for CNS somatic variations. 
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In conclusion, a rare and interesting scenario has been identified, where one ALS-
discordant MZ twin pair were concordant for the C9orf72 repeat expansion. The 
phenotypic discordance observed between the twins in this cohort raises the possibility 
of environmental factors having an influence in disease manifestation. An environmental 
contribution in ALS has been determined to be in the order of 40% in previous twin 
studies (Al-Chalabi et al., 2010), and disease expression in patients with mutations in 
SOD1 seem to be largely determined by the environment (Fogh et al., 2007). The 
phenotypic disparity between the twin pairs with similar C9orf72 repeat sizes could also 
signify hitherto unexplored modifying genes, epigenetic mechanisms, or environmental 
causes. 
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Chapter 4. Whole-exome sequencing analysis 
 Overview 
Over the past decade, investigations of de novo mutations have called into question the 
assumption that MZ twins are genetically identical. Indeed, it has been shown that the 
underlying genetic differences between co-twins may arise during embryonic 
development, giving rise to SNVs, indels, gene conversion, CNVs and postzygotic 
mitotic recombination. These variations have been proposed as potential genetic 
mechanisms resulting in discordant MZ twins (Ketelaar, Hofstra and Hayden, 2011). 
Comparing MZ twins discordant for complex traits has been previously suggested for 
discovering disease-relevant variants in candidate genes (Mansilla et al., 2005). Chapter 
1 outlines numerous studies that have discovered genetic differences between MZ twins 
that account for their discordant phenotypes. Such mechanisms include chromosomal 
mosaicism, as seen in trisomy 21 and 45,X0 (Nieuwint et al., 1999), and dominant gene 
mutations, which was first shown for Van der Woude and popliteal pterygium syndromes 
(Kondo et al., 2002). These post-twinning mutations would result in somatic mosaicism, 
a phenomenon defined as two or more genetically distinct populations of cells in an 
individual that were developed from a single fertilised egg (Freed, Stevens and Pevsner, 
2014). 
Comparing the genomes of discordant MZ twins signifies a promising opportunity for the 
search of novel candidate variants implicated in disease, which may ultimately narrow 
the conceptual gap of missing heritability. With the cost of current NGS sequencing 
methods dramatically lowering, whole genome- and exome-wide comparisons of MZ 
twins can be made more affordable and readily available. This circumvents the need to 
focus merely on a set of candidate genes, as previously suggested.  
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Whole-exome sequencing has proved to be a fruitful tool for identifying genetic causes 
of human diseases. This technique involves sequencing the annotated protein coding 
exons of the genome with nearby flanking intronic regions (Magne et al., 2014; Lin et al., 
2012). Most known mutations causing high-penetrance genetic disorders are found in or 
adjacent to the coding regions, thereby justifying the use of whole-exome sequencing to 
explore potential genetic causes of complex disorders.  
Considering the estimated somatic mutation rate is extremely low and that these variants 
can be obfuscated by the relatively high error rate of NGS (Aparicio and Huntsman, 2009; 
Kuhlenbäumer, Hullmann and Appenzeller, 2011), a highly sensitive filtering method 
with high specificity, sequence resolution and coverage should be implemented (Aparicio 
and Huntsman, 2009). 
We performed whole-exome sequencing analysis of DNA from thirteen twin pairs 
discordant for a range complex disorders. We also performed whole-exome sequencing 
on DNA obtained from blood and saliva samples for a MZ twin pair discordant for stroke, 
and parent-offspring trio analysis using DNA obtained from the parents of the twins 
discordant for ADHD and Tourette’s syndrome. 
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 Results 
4.2.1 Quality control and pre-analysis 
Whole gDNA obtained was evaluated for quality and quantity by densitometry analysis 
using 1.2% agarose gel electrophoresis, as shown in Figure 4.1, and spectrophotometric 
measurement. Agarose gel electrophoresis showed that the molecular weight extracted 
was more than 10kb with uniform brightness and all samples had a 260/280 ratio of ~1.8, 
suggesting that the DNA was integrated, stable and that the extraction was successful. 
 
Figure 4.1. Agarose gel electrophoresis of gDNA. DNA samples had a tight band with minimal smearing, 
therefore passing quality control. 
 
4.2.1.1 Hereditary spastic paraplegia 
HSP-discordant twins (VF and LF) were recruited into the study through collaboration 
with Niranjanan Nirmalananthan (St George's University Hospitals NHS Foundation). 
VF was diagnosed with a complex form of HSP and was therefore assigned to an NGS 
panel of 41 HSP-linked genes. DNA sequencing was performed on the following genes: 
AFG3L2, ALS2, AP5Z1, ATL1, B4GALNT1, BSCL2, C12orf65, CYP27A1, CYP2U1, 
CYP7B1, DDHD1, DDHD2, FA2H (excluding exon 1), FIG4, GBA2, GCH1, HSPD1, 
KIAA0196, KIF1A, KIFSA, L1CAM, MTPAP, NIPA1, PLP1, PSEN1, REEP1, RTN2, 
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SACS, SIGMAR1, SLC16A2, SLC2A1, SPAST, SPG11, SPG20, SPG21, SPG7, VAMP1, 
VPS37A, WDR45, ZFYVE26, and ZFYVE27.  
VF was also screened for GLUT1 deficiency syndrome and DYT1 early-onset primary 
dystonia. However, no clearly pathogenic mutations were detected in VF. This result 
reduces the likelihood that the symptoms seen in this individual are caused by pathogenic 
mutations in these genes, suggesting that other rare mutational mechanisms not detectable 
by this analysis may be present. The difficulty in determining the aetiological basis of 
complex movement disorders means that a diagnosis of HSP must currently rest on 
clinical grounds alone. 
4.2.1.2 Lactase persistence 
The LCT gene is 49.3 kb in length and located on the chromosome 2q21. It contains 17 
exons and is translated into a 6 kb transcript (NCBI Reference Sequence NG_008104.1). 
There are at present five different functional alleles that have been associated with lactase 
persistence: -14010G>C (rs145946881); -13915T>G (rs41380347); -13910C>T 
(rs4988235); -13907C>G (rs41525747); and -22018G>A (rs182549). To determine the 
genotype of these alleles in the twins discordant for lactase persistence (KEL and KIR), 
approximately 300bp surrounding -13910C>T and ~200bp surrounding -22018G>A was 
analysed by Sanger sequencing. Both twins had an identical genotype for these SNPs, and 
no mosaicism could be seen in the sequence traces. The potential lactase non-persistence 
genotypes that have been reported in people of Northern European ancestry (Tishkoff et 
al., 2006; Ingram et al., 2008) were absent in the twins. The SNPs associated with lactase 
non-persistence in African populations and other genetically diverse groups were also 
absent (Friedrich et al., 2013; Ranciaro et al., 2014; Jones et al., 2013). These results 
suggest that both twins are genetically lactase-persistent. Known causes of secondary 
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lactase deficiency could be ruled out based on the clinical history of the twins, such as 
gastroenteritis, coeliac disease, Crohn's disease, ulcerative colitis, chemotherapy, or long 
courses of antibiotics. Thus, other yet unidentified SNPs associated with lactose 
intolerance could be present in the affected twin. 
 
                                                                                                                                                                        
Figure 4.2. Sanger sequencing in individuals KIR (a) and KEL (b) reveals heterozygosity for variants -
13910C>A and -22018G>A, and homozygosity for variants -13907C>G and -13915T>G. Variant -
14010G>C was not checked using Sanger sequencing, however it was later confirmed to be homozygous 
for the G allele with exome sequencing and SNP array data. 
 
4.2.2 Whole-exome sequencing analysis 
Three different methodological approaches were applied to analyse the exome sequence 
data. We initially prioritised candidate discordant variants in seven MZ twin pairs 
(Pipeline 1). Three twin pairs were selected to explore an alternative method using 
GenomeComb (Pipeline 2). Finally, all samples were pooled together and re-analysed by 
combining two updated variant callers for increased specificity (Pipeline 3). 
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Samples Pipeline 1 Pipeline 2 Pipeline 3 
IP16 and IP17 ✓ ✓ ✓ 
RT1a and RT1b ✓ ✓ ✓ 
PD821 and PD161 ✓ ✓ ✓ 
HG(b) and KG(b) ✓ - ✓ 
HG(s) and KG(s)) ✓ - ✓ 
VL and FL ✓ - ✓ 
KIR and KEL ✓ - ✓ 
AFF and UNAFF ✓ - ✓ 
LAS and SUS - - ✓ 
218 and 318 - - ✓ 
421 and 422 - - ✓ 
242 and 243 - - ✓ 
RP and OH - - ✓ 
489 and 490 - - ✓ 
 
Table 4.1. Comparing bioinformatics approaches for the analysis of MZ twins. The sequence read files 
were analysed using three pipelines: Pipeline 1 was developed by Michael Simpson, Pipeline 2 by Peter De 
Rijk, and Pipeline 3 by Alan Pittman.  
 
4.2.2.1 Pipeline 1: VarScan2 
On average, over 98% of the accessible regions were covered of the whole-exome 
reference. After short read alignment, variant calling and gene annotation, the exomes 
yielded a mean value of 25,082 total candidate variants, of which on average 171 were 
novel. Prior to filtering, pair-wise comparisons of exonic variants between co-twins 
contained on average 1,390 putative discordant variants unique to the affected or 
unaffected co-twin. 
As the rate of somatic mutations has been estimated to be between 0.82-1.70x10-8 (Kong 
et al., 2012; Campbell et al., 2012; Dal et al., 2014), it was expected that a considerable 
proportion of the candidate discordant variants represented technical artefacts. This could 
be the result of errors occurring in the exome sequencing itself, or incorrect read 
alignments to the reference genome. The latter would be particularly common in regions 
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containing segmental duplications or repetitive elements, including genes with processed 
or unprocessed pseudogenes. Additional restrictive filters were applied to eliminate 
germline variants that were under-called in either co-twin due to low coverage at the end 
of reads, and false-positive variants due to various cryptic paralogous sequences. An in-
house database with over 1,000 exome sequences was also used to further eliminate 
variants arising recurrently through misalignments, including ubiquitous variants that had 
perhaps resulted through recurring mutations at hypermutable sites – variants that would 
likely have little or no biological relevance. Further, only variants with a somatic allele 
frequency of >15% in one twin that had no representation in the other twin were retained. 
Application of this filtering criteria resulted in approximately 20-50 candidate discordant 
somatic variants between co-twins. Details of coverage statistics for the first seven MZ 
twin pairs are in Appendix C. 
The short read genomic alignments for these potential variants were manually inspected 
using IGV, to remove additional artefacts that bypassed prior filtering parameters. These 
included variants located at the start and end position of reads, base quality scores that 
were less than 20 on average, homopolymer runs, and variants seen in genomic 
neighbourhoods with multiple nearby rare variants (suggestive of alignment artefacts 
caused by nearby indels). These variants were further inspected for intrinsic genome 
characteristics, such as segmental duplication, micro-satellites, and simple tandem repeats 
using online genome browsers Ensembl and UCSC. 
After application of the initial filtering criteria and manual reviewing, each co-twin 
typically had no candidate somatic variants. However, for the MZ twins discordant for 
schizophrenia, a non-synonymous SNV on EML5 (chr14:89151465; G>A substitution) 
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was found in subject RT1a with an allele frequency of 17.24%, which was absent in the 
co-twin (Figure 4.3).  
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4.2.2.2 Pipeline 2: GenomeComb 
Distinguishing true SNVs from errors in exome sequencing data remained challenging. 
Before analysing the rest of the dataset with Pipeline 1, more comprehensive 
bioinformatics approaches were explored to identify SNVs with high confidence. By 
testing a variety of different strategies to reduce errors, a refined method for the 
prioritisation of high confidence SNVs could be developed to analyse our twin cohort. At 
the time of this investigation, a study proposing an optimised filtering method that 
selectively reduces error rates in whole-genome sequencing was published (Reumers et 
al., 2012). The authors applied twelve individual filters in 1,048 combinations and 
determined the most effective in terms of having the highest specificity and sensitivity. 
This facilitated the identification of SNV differences in MZ twins discordant for 
schizophrenia (Reumers et al., 2012). 
To test if this novel strategy could identify biologically relevant variants in whole-exome 
sequencing, a pairwise comparison between three MZ twin pairs from our cohort was 
made (IP16 and IP17; RT1a and RT1b; PD821 and PD161). 
4.2.2.3 Assessment of accuracy filters 
Pairwise comparisons between three twin pairs revealed that on average 98.1 (97.4-98.4) 
[median(0.25-0.75quartile)] of the reference genome was sequenced in co-twins, 
allowing, on average, the more than 96% concordance between co-twins. 
As mentioned above, prior studies investigating genetic differences between twin pairs 
have illustrated that most discordant SNV calls are in fact false positives (Dal et al., 2014; 
Kong et al., 2012; Campbell et al., 2012). It is therefore assumed that most discordant 
SNVs in our twin exomes represent sequencing errors, and that shared SNVs reflect true 
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genetic variation. The filters were considered effective when at least twice as many 
discordant SNVs were removed compared to shared SNVs. 
With GATK and SAMtools combined, an average of 127,325 variants were detected 
between the co-twins, of which 10,701 were discordant. Closer inspection of the sequence 
surrounding putative discordant SNVs revealed that many of them were due to an 
uncertain call in either twin or in regions where several other SNVs were clustered. In 
addition, many discordant SNVs were in genomic regions containing tandem repeats, 
segmental duplications or at positions with low (<15) or very high (>100) coverage. Thus, 
two types of accuracy filters were employed: filters that detect genomic regions with 
insufficient sequence quality, and filters that target genomic regions with repetitive DNA 
sequences. 
Several parameters can be used to apply filters based on the quality of whole-exome 
sequencing data. These include the coverage depth of a given sequence, a quality score 
for every SNV that is detected (referred to as the ‘variant score’), and the presence of 
clustered SNVs in the genomic region. For each of these parameters, thresholds at which 
a sequence can be considered high quality were defined. Standard receiver operating 
characteristic (ROC) curves and distribution analyses revealed that a coverage depth and 
variation score threshold of ≥15 and ≥70, respectively, were most optimal (Figures 4.4 
and 4.5). 
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Figure 4.4. Coverage depth filter. The distribution graphs depict the frequency of shared and discordant 
SNVs against a coverage depth ranging from 1 to 100 in the three twin pairs analysed. A coverage depth 
threshold of ≥15 was used on all samples to remove sequencing artefacts from the data.  
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Figure 4.5. Variant score filter. The distribution graphs depict the frequency of shared and discordant SNVs 
against a variant score ranging from 1 to 100 in the three twin pairs. The data are difficult to interpret due 
to the irregular shape of the distributions. It is, nevertheless, clear that lower variant scores are characterised 
by a higher fraction of discordant SNVs. A variant score threshold of ≥70 was used on all samples to remove 
sequencing artefacts from the data. 
 
0
200
400
600
800
1000
1200
1400
0 20 40 60 80 100
V
ar
ia
n
ts
Variant score
IP16 and IP17
0
500
1000
1500
2000
0 20 40 60 80 100
V
ar
ia
n
ts
Variant score
RT1a and RT1b
0
500
1000
1500
2000
2500
0 20 40 60 80 100
V
ar
ia
n
ts
Variant score
PD821 and PD161
108 
 
The ratio of ‘the proportion of discordant SNVs removed’ to ‘the proportion of shared 
SNVs removed’ (Fdiscordant/Fshared) was calculated after application of individual filters. 
Each of the three individual quality filters was found to remove a Fdiscordant/Fshared ratio 
of >2, suggesting that they were efficient in removing genotype calling errors. The 
‘variant score’ and ‘clustered SNV’ filters discarded a relatively small mean percentage 
of the shared twin exomes, whereas the ‘coverage depth’ filter removed a more significant 
portion (6.6%, 13.5% and 28.3%, respectively). However, the combination of these three 
quality filters substantially lowered the average number of discordant SNVs between the 
three co-twins: 4,076 (38.09%) discordant SNVs and 97.816 (76.82%) shared SNVs 
remained, with a Fdiscordant/Fshared ratio of 5.61. 
Repetitive DNA sequences such as simple tandem repeats, microsatellites and segmental 
duplications often contain errors due to incorrect mapping to the reference genome. These 
regions, together with self-chained regions, interspersed repeats and low-complexity 
regions were identified using the UCSC genome browser database. Filters targeted at 
short repeats, such as tandem repeats and microsatellites were very selective 
(Fdiscordant/Fshared >5) and removed only small portions of the exome for all three twin pairs. 
The segmental duplication filter was moderately successful, yielding a mean 
Fdiscordant/Fshared of 2.77. In contrast, the RepeatMasker and self-chained filters were too 
restrictive while not being very selective (Fdiscordant/Fshared <2). Moreover, the filter for 
homopolymer regions yielded a Fdiscordant/Fshared ratio of <2 for all three twin pairs, thereby 
precluding the usefulness of this filter. 
With cumulative application of the filters, the predicted error ratio dropped considerably 
for all twin pairs (Table 4.2). Intrinsic to this study design is the retrieval of many 
sequencing errors, mixed with a potential few real SNV differences. Thus, most of the 
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putative discordant SNVs even after application of the filters are expected to be false 
positives. However, the probability of finding a real difference after systematic optimised 
filtering is theoretically better. 
Twin pair 
Before cumulative application of filters After cumulative application of filters 
Discordant 
SNVs 
Shared 
SNVs 
Per variant 
error rate 
Discordant 
SNVs 
Shared 
SNVs 
Per variant 
error rate 
IP17 and 
IP17 
4793 
(4.81%) 
94975 
(95.19%) 
4.80% 40 (0.08%) 51121 
(99.92%) 
0.08% 
RT1a and 
RT1b 
12397 
(9.07%) 
124168 
(90.92%) 
9.08% 48 (0.07%) 62350 
(99.92%) 
0.08% 
PD821 and 
PD161 
14913 
(10.24%) 
130730 
(89.13%) 
10.24% 73 (0.12%) 64313 
(99.89%) 
0.11% 
 
Table 4.2. The effects of various quality and repetitive DNA filters were assessed on the total number of 
shared and discordant SNVs between MZ co-twins. Per variant error rate is the number of discordant SNVs 
divided by the total variants detected. This is considerably reduced after cumulative application of the 
filters. 
 
When combining both quality and repetitive filters together, a total of only 161 putative 
discordant SNVs remained between the three twin pairs. However, after manually 
reviewing each variant by viewing the .bam files in IGV, none of the variants were 
deemed convincing. This suggests that although the filters based on quality and repetitive 
DNA regions considerably reduced the predicted error rate, there were still many false-
positive SNVs remaining. 
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4.2.2.4 Pipeline 3: VarScan2 and MuTect2 
Whole-exome sequencing data were reanalysed by means of VarScan2 and MuTect2 
using the annotated variant and genotype attained by the Haplotype Caller-based analysis 
as reference to explore the possible occurrence of low-frequency variants compatible with 
a mosaicism state. 
As there is a possibility of the unaffected twin having a de novo mutation that is not 
present in the affected twin, a reverse pairwise analysis was also performed where the 
affected twin was classified as the ‘normal’ sample and unaffected twin as the ‘tumour’ 
sample (Table 4.4). 
The resulting discordant variants were further filtered by excluding those variants that 
were likely to be non-functional, e.g., synonymous variants and/or variants outside the 
exonic regions. There are exceptions to this rule, such as for the twin pair discordant for 
lactase non-persistence (KEL and KIR), where causally-linked variants are likely to be 
found in intronic regions, with an MAF greater than 0.01. 
Consistent with the literature, DNA samples that were LCL-derived yielded a higher-
than-average discordant call rate (218 and 318; 421 and 422; 242 and 243). To reduce 
potential for bias in these samples, only variants found in genes previously implicated in 
ALS were considered for downstream analysis. 
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Description 
Twin 
pair 
Total 
germline 
variants 
detected 
Discordant 
MuTect2 
Discordant 
VarScan2 
Shared 
discordant 
variants 
VQS >90 
Not within 
segmental 
duplications 
MAF 
<1% 
Exonic and 
non-
synonymous 
ALS 
LAS 91,434 
6,964 5,964 555 63 33 16 4 
SUS 112,182 
ALS 
218 97,037 
18,302 12,465 10,847 7,857 7,616 651 159 
318 93,543 
ALS 
421 85,247 
23,796 822 520 257 248 53 11 
422 107,451 
ALS 
242 92,502 
2,851 2442 346 130 107 32 13 
243 96,855 
Stroke 
 
KG(s) 103,110 
858 619 64 4 2 0 0 
HG(s) 98,053 
 
KG(b) 105,715 
1,302 735 95 8 4 1 0 
HG(b) 105,223 
Lactose 
intolerance 
KEL 94,388 
1,573 1,186 116 18 8 2 1 
KIR 108,944 
Inclusion 
body myositis 
AFF 103,017 
902 515 58 0 0 0 0 
UNAFF 92,857 
ADHD 
RP 100,518 
1,895 2,173 115 16 8 0 0 
OH 100,085 
Tourette’s 
syndrome 
490 95,279 
1,088 1,412 99 7 4 0 0 
489 87,799 
Parkinson’s 
disease 
PD821 102,750 
1,498 1,148 111 7 7 0 0 
PD161 104,715 
Hereditary 
spastic 
paraplegia 
LF 101,483 
1,537 1,249 99 15 6 2 0 
VF 103,849 
Schizophrenia 
RT1b 78,727 
1,870 1,490 127 8 6 1 0 
RT1a 104,366 
Schizophrenia 
IP16 87,063 
1,246 1,243 95 10 8 2 0 
IP17 92,607 
 
Table 4.3. Filtering protocol for SNVs and indels used to identify differences of functional variants between 
twin siblings. Discordant variants that were not shared between MuTect2 and VarScan2 were filtered out, 
and the shared discordant calls were then further filtered according to our exclusion criteria: VQS <90, 
within segmental duplications (SDs), MAF >1% (as per 1000g, cg69, ExAC), exonic, and non-
synonymous. 
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Table 4.4. Somatic variants specific to the affected twin were assumed to be of biological significance, but 
to determine the total amount of somatic mutations, variants specific to the unaffected twin were also 
checked. Discordant variants that were not shared between MuTect2 and VarScan2 were filtered out, and 
the shared discordant calls were then further filtered according to our exclusion criteria: VQS <90, within 
segmental duplications (SDs), MAF >1% (as per 1000g, cg69, ExAC), exonic, and non-synonymous. The 
VarScan2 analysis of twins 421 and 422 failed due to technical issues that are currently being resolved. 
This data is currently omitted. 
 
Description 
Twin 
pair 
Total 
germline 
variants 
detected 
Discordant 
MuTect2 
Discordant 
VarScan2 
Shared 
discordant 
variants 
VQS >90 
Not within 
segmental 
duplications 
MAF 
<1% 
Exonic and 
non-
synonymous 
ALS 
LAS 91,434 
2,158 3,600 525 13 10 10 4 
SUS 112,182 
ALS 
218 97,037 
3,781 3,862 566 243 220 20 4 
318 93,543 
ALS 
421 85,247 
15,600 - - - - - - 
422 107,451 
ALS 
242 92,502 
14,328 9,976 8,072 5,528 5,343 376 84 
243 96,855 
Stroke 
 
KG(s) 103,110 
1,430 914 100 13 8 1 0 
HG(s) 98,053 
 
KG(b) 105,715 
1,189 676 70 6 5 2 1 
HG(b) 105,223 
Lactose 
intolerance 
KEL 94,388 
745 558 85 7 4 4 1 
KIR 108,944 
Inclusion 
body myositis 
AFF 103,017 
1,688 1,300 92 11 7 3 0 
UNAFF 92,857 
ADHD 
RP 100,518 
1,933 2,175 109 13 7 0 0 
OH 100,085 
Tourette’s 
syndrome 
490 95,279 
2,081 1,941 149 20 10 1 0 
489 87,799 
Parkinson’s 
disease 
PD821 102,750 
1,276 1,082 106 8 7 2 1 
PD161 104,715 
Hereditary 
spastic 
paraplegia 
LF 101,483 
1,389 1,104 102 12 8 0 0 
VF 103,849 
Schizophrenia 
RT1b 78,727 
1,354 1,145 115 6 4 1 1 
RT1a 104,366 
Schizophrenia 
IP16 87,063 
860 912 20 0 0 0 0 
IP17 92,607 
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The bam files for each twin were loaded into IGV and the short read genomic alignments 
for the potential discordant variants were manually inspected to remove additional 
artefacts that bypassed prior filtering parameters. These included variants located at the 
start and end position of reads, base quality scores that were less than 20 on average, 
homopolymer runs, and variants seen in genomic neighbourhoods with multiple nearby 
rare variants (suggestive of alignment artefacts caused by nearby indels). These variants 
were further inspected for intrinsic genome characteristics, such as segmental duplication, 
micro-satellites, and simple tandem repeats using online genome browsers Ensembl and 
UCSC. 
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Twin pair Gene Region Type Chr Position 
Genotype 
Depth of coverage 
(proband) Variant 
frequency 
(proband) 
Depth of coverage 
(MZ twin) Variant 
frequency 
(MZ twin) 
Reference Variant Reference Variant Reference Variant 
LAS and SUS DENND5B Exon Stopgain 12 31632586 C A 48 4 8% 12 0 0% 
 
LOXHD1 Exon Nonsynonymous 18 44157785 G A 150 9 6% 40 0 0% 
BTK 5’UTR Substitution X 100645610 C A 58 0 0% 14 3 18% 
 SLC26A1 Exon Nonsynonymous 4 985253 C A 70 0 0% 22 3 12% 
218 and 318 FBXO38 Exon Nonsynonymous 5 147805180 G A 11 12 52% 12 0 0% 
 
RIT2 Exon Nonsynonymous 18 40323567 C T 15 11 42% 8 0 0% 
GRM6 Exon Nonsynonymous 5 178417745  C T 11 10 48% 14 0 0% 
PPARGC1A Exon Nonsynonymous 4 23814713 T C 69 0 0% 18 5 22% 
421 and 422 KIAA1107 Exon 
Nonframeshift 
deletion 
1 92647643 CTT - 16 0 0% 26 4 14% 
 
C8orf48 Exon 
Frameshift 
deletion 
8 13425060 AG - 13 0 0% 22 9 29% 
ATP6V1B2 Exon 
Nonframeshift 
deletion 
8 20054932 
GATGCG
GGG 
- 12 0 0% 16 5 24% 
NR1H2 3’UTR Deletion 19 50885933 C - 15 0 0% 19 7 24% 
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Table 4.5. Details of candidate discordant variants from whole-exome sequencing data after cumulative application of the filters and manual reviewing using IGV. 
 
242 and 243 
GS1-
259H13.2 
Exon 
Frameshift 
deletion 
7 99208104 G - 11 0 0% 15 9 38% 
ACTR3C 5’UTR Substitution 7 150020654 G A 10 0 0% 10 8 44% 
KBTBD3 Exon Nonsynonymous 11 105924526 A G 20 0 0% 45 7 14% 
TUBGCP4 Exon Nonsynonymous 15 43678059 C T 20 0 0% 43 15 26% 
TFIP11 Exon 
Frameshift 
deletion 
22 26888040 A - 70 0 0% 83 48 36% 
PHKA2 Exon Nonsynonymous X 18924724 C T 14 0 0% 28 3 10% 
GNL3L Exon Nonsynonymous X 54581036 A G 11 0 0% 20 15 42% 
RT1a and RT1b EML5 Exon Nonsynonymous 14  89151456 G A 53 0 0% 24 5 14% 
KEL and KIR PLCB1 Exon 
Frameshift 
deletion 
20 8637865 A - 37 12 26% 60 0 0% 
 TMEM87A 3’UTR n/a 15 42503678 C T 8 0 0% 13 5 28% 
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Figure 4.6. Venn diagram illustrating the overlap between MuTect2 and VarScan2. The two somatic 
mutation callers were used to detect differences between co-twins; only those that were shared were 
considered for downstream analysis. The figure shows the average number variants called in the total 28 
pairwise comparisons. 
 
4.2.3 Validation of twin-specific de novo SNVs 
The candidate variant found on EML5 (chr14:89151465; G>A substitution) in subject 
RT1a (Figure 4.3) had a somatic allele frequency of 17.24% according to pipeline 1. The 
same variant was detected in pipeline 3 with a 13.6% allele frequency (Table 4.5). In both 
cases, the variant was absent in the co-twin. When subjected to conventional Sanger 
sequencing, the electropherogram of the candidate variant on EML5 showed no 
differences between the twins. The limitations of Sanger sequencing in its ability to detect 
low-level mosaicism has been previously documented (Rohlin et al., 2009). 
Constitutional heterozygosity is indicated on a Sanger sequence trace where the two 
nucleotides at a position are approximately of equal peak heights. Mosaicism lower than 
20% is difficult to quantify, let alone detect, as the variant can be buried in the baseline 
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of the sequence trace. Thus, combinations of the conventional methods ought to be used 
to acquire an adequate sensitivity (Rohlin et al., 2009). 
To verify this finding, three additional methods were used: Colony PCR (Figure 4.7), 
Sequenom MassARRAY genotyping (Figure 4.8) and Kompetitive Allele Specific PCR 
(KASP) genotyping (Figure 4.9). However, none of the employed SNP validation 
techniques confirmed the observed mosaic SNV, but rather showed identical wild-type 
genotypes. The variant seen in subject RT1a was determined to be a false-positive finding 
of high genotype quality, which was likely due to a PCR-induced mutation during the 
exome library preparation. 
 
 
 
 
 
 
Figure 4.7. Bidirectional capillary Sanger sequencing was performed directly on bacterial colonies for the 
SNV on EML5. The picture shows one of the sequence traces (forward strand) of subject RT1a at position 
chr14:89151456. The PCR product spanning the variant was cloned for both twins. None of the 96 
individual bacterial colonies that were randomly picked for colony screening showed the G>A substitution 
in either twin.  
 
 
 
c.C2876T 
118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Sequenom MassARRAY genotyping was performed to validate the candidate variant 
(NewGene). The ‘T’ allele was not detected in either twin. The blue vertical dashed lines above the wave 
peak indicate the resulting genotypes, whereas the red ones indicate the expected location of the variant 
allele at the transcribed SNP. 
 
 
Figure 4.9. Genotyping of the SNV on EML5 was performed using competitive allele-specific PCR using 
KASP assays (LGC genomics). This method utilises fluorescent resonance energy transfer to quench 
fluorescence in reporter oligonucleotides until they are incorporated into allele-specific PCR products. The 
results also showed that the ‘T’ allele was not present in either twin. 
RT1a 
 
 
 
 
 
 
RT1b 
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4.2.4 Identifying pathogenic concordant variants 
To test the hypothesis that rare, dominant or recessive variants could contribute to the 
complex disorders investigated, potentially damaging concordant exonic variants were 
examined. Several variants were identified in known disease-associated loci that could 
potentially explain disease onset according to a model taking into account the possibility 
of incomplete penetrance.  
After application of the filtering criteria, each co-twin typically had 200 potentially 
damaging, rare concordant variants. All concordant variants were screened against lists 
of disease-specific susceptibility genes, which were obtained from various databases, 
including PubMed, OMIM, NIH GTR, DisGeNET, ALSoD, ALSGene, PDGene, SZDB, 
and SZGene. This produced a total of 113 variants in the twin cohort; however, by 
manually reviewing them in IGV we could remove mutations that are obvious artefacts 
of short-read sequencing and alignment. Mutations that looked real and were 
unambiguous were retained. These variants with their functional categories are shown in 
Table 4.6. 
Homozygous variants with allele frequencies >1% are unlikely on their own to be 
pathogenic and were therefore filtered out of that data. Concordant homozygous recessive 
variants not found in public databases (i.e. novel variants) that also do not overlap 
segmental duplications or RepeatMasked sequence are not shown. Further studies are 
ongoing, particularly related to several genetic variants of high interest (not located in 
genes previously shown to be associated with human disease) that were found in both 
twins, and which may act as susceptibility factors in concert with putative interacting 
genetic and/or environmental factors.
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Twin pair Gene Region Type Chr Position 
RefSeq accession 
number 
c.DNA position Amino acid change 
LAS and SUS CNTN6 5’UTR n/a 3 1134367 NM_014461 c.-55326G>A n/a 
 CRIM1 Exonic Nonsynonymous 2 36737128 NM_016441 c.G1504A p.E502K 
218 and 318 AMPH Exonic Nonsynonymous 7 38574539 NM_001635 c.C142T p.R48W 
 INA Exonic Nonsynonymous 10 105038008 NM_032727 c.A1040G p.H347R 
242 and 243 DOC2B Exonic Nonsynonymous 17 11873 NM_003585 c.C637T p.R213W 
 HFE Exonic Nonsynonymous 6 26093125 NM_139010 c.G289A p.E97K 
 VAPB Exonic Nonframeshift deletion 20 57016040 NM_004738 c.474_476del p.158_159del 
KEL and KIR LCT 3’UTR n/a 2 136545844 NM_002299 c.*50G>C n/a 
 LCT Exonic Nonsynonymous 2 136555659 NM_002299 c.A4916G p.N1639S 
 LCT Intronic n/a 2 136570613 n/a n/a n/a 
 LCT Intronic n/a 2 136590558 n/a n/a n/a 
 GLB1L Intronic n/a 2 220108217 n/a n/a n/a 
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Table 4.6. Concordant variants in known disease-linked genes. 
PD821 and 
PD161 
HTR6 Exonic Nonsynonymous 1 20005151 NM_000871 c.C806T p.T269M 
 UNC5C Exonic Nonsynonymous 4 96141217 NM_003728 c.C1219T p.R407C 
LF and VF ZFR2 Exonic Nonsynonymous 19 3834902 NM_015174 c.G133A p.V45M 
490 and 489 AADAC Exonic Stop loss 3 151545958 NM_001086 c.T1198C p.X400Q 
 PDLIM5 Exonic Nonsynonymous 4 95585202 NM_001256425 c.A800G p.H267R 
RP and OH DPP6 Exonic Nonsynonymous 7 154519496 NM_001290252 c.A461G p.N154S 
 CHD7 Exonic Nonsynonymous 8 61777986 NM_017780 c.G8488A p.A2830T 
RT1a and RT1b SEMA6C Exonic Nonsynonymous  151106475 NM_001178062 c.C1696T p.P566S 
 GABRR3 Exonic Unknown 3 97753727 Unknown Unknown Unknown 
 PCLO Exonic 
Nonframeshift 
insertion 
7 82784833 NM_014510 
c.1123_1124insC
TCTTGGTCCTG
CTAAGCCTCC
AGCTC 
p.Q375delinsPLGP
AKPPAQ,PCLO 
IP16 and IP17 VLDLR Exonic Nonsynonymous 9 2645718 NM_001018056 c.C1457G p.A486G 
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4.2.5 Validation of the concordant variants 
Based on Bayes theorem, the positive predictive value (PPV) of the pipeline depends on 
the number of mutations in the sample. In this context, the PPV can be defined as the 
percentage of variants identified by exome sequencing analysis that were validated as true 
variants – that is, [true positive/(true positive+false positive)]*100.  
A high sensitivity and high specificity, whilst desirable, do not ensure a high PPV (which 
is also desirable). The PPV depends very much on the prevalence of de novo mutations. 
Validation rates from The Genome Institute tumour project ranged from 20% to >90%. 
This is because different types of cancer have different rates of mutation (Alexandrov et 
al., 2013; Meltz Steinberg et al., 2015). The validation rate was high for tumours that have 
a high somatic mutation prevalence (such as melanoma), and low for tumours that have 
a low mutation rate (such as acute myeloid leukaemia). 
In MZ twins, it is expected that there will be a small number of de novo mutations (Kong 
et al., 2012, Campbell et al., 2012; Dal et al., 2014), rendering the PPV low relative to a 
tumour sample (with varying degrees depending on the type of tumour). Nevertheless, 
for germline variants, Meltz Steinberg et al. (2015) performed an evaluation of their own 
pipeline using a mixture of samples and found a sensitivity of 96.8% and a PPV of 93.1% 
for all SNVs. Considering that the concordant variants between co-twins were absent in 
all other samples, it would be extremely unlikely to obtain false-positives in the same 
gene location in both twin siblings. It was therefore deemed unnecessary – not to mention 
unfeasible – to validate all concordant variants with Sanger sequencing. 
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4.2.6 Parent-offspring trio analysis 
A total of 217,290 variants were called in GATK’s joint analysis. Variants shared by the 
MZ twins, but absent in their parents, were considered to be de novo germline mutations. 
After applying this initial exclusion criteria, a total of 424 and 412 putative de novo SNVs 
and indels were detected in twin pairs discordant for ADHD and Tourette’s syndrome, 
respectively. Variants were further filtered as per similar parameters set for postzygotic 
de novo detection. Upon manual review in IGV most variants could be excluded on the 
basis that they were falsely miscalled in one of the parents. However, a nonsynonymous 
mutation in RASD2, a gene encoding for a GTP-binding protein Rhes on chromosome 22 
(NM_014310:exon2:c.G170A:p.R57H), was found in the ADHD-discordant pair (Table 
4.7). The variant is not reported in the dbSNP, 1000 Genomes, cg69 nor in the in-house 
database of 6,000 exomes. In the ExAC database containing more than 60,000 human 
exome data, the variant was found with an allele frequency of 8.13E-06 in the total 
population (allele count of 1/121112). The variant is also highly conserved across 
multiple species and predicted to be deleterious in online available bioinformatics tools. 
 
 
 
 
 
Table 4.7. Filtering for germline de novo detection. A de novo mutation in RASD2 was identified in the 
twins discordant for ADHD. 
 
 
ADHD 
Tourette’s 
syndrome 
Shared heterozygous variants in twins, but absent in parents 424 412 
Remove segmental duplications 356 341 
Variants in only exonic, splice site, 3’UTR and 5’UTR regions 98 84 
Remove synonymous variants 70 60 
Remove variants with MAF > 0.01 13 9 
Variants remaining after manual review in IGV 1 0 
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Figure 4.10. IGV screenshots showing a germline de novo mutation in the twin pair discordant for ADHD (OH and RP), which is absent in the parents (DS and DV). This 
region had a high depth of coverage, with the number of reads ranging from 70-100. 
DS DV OH RP 
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Because the father of the twins discordant for Tourette’s syndrome also has the condition, 
it is likely that both twins had inherited variants associated with the disorder. We focused 
our attention on variants consistent with a dominant mode of inheritance – namely, 
variants that are homozygous or heterozygous in the affected father, absent in the mother, 
and heterozygous in the twins. 
A filtering for rare or novel variants that were predicted to be damaging by at least one of 
the pathogenic prediction tools led to the identification of 41 variants shared between the 
twins. Only one of the variants found to be inherited from the father has previously been 
implicated in Tourette’s syndrome, per our comprehensive list of 138 genes mined from 
various databases and search of literature. This was a stop loss mutation in AADAC, a 
gene encoding for arylacetamide deacetylase on chromosome 3 
(NM_001086:exon5:c.T1198C:p.X400Q). This variant was also found in the concordant 
variant analysis (Table 4.6).  
4.2.7 Mitochondrial DNA analysis 
We next tested the hypothesis that different levels of mtDNA heteroplasmy might account 
for the phenotypic discordance between the twins. After applying a minimum read count 
threshold of 10, a total of 399 shared and discordant variants were identified between the 
twins. These variants included 34 heteroplasmic variants and 365 homoplasmic variants. 
A total of 36 variants unique to either the affected or unaffected twin were verified using 
IGV. Among these, 23 were distributed on 12 genes throughout the mitochondrial 
genome, and 8 were localised at the hypervariable segments HV1 (16024–16383) and 
HV2 (57–372). 
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Figure 4.11. An allele frequency vs read count graph was plotted to get a visual representation of what variants were discordant between the twin pairs. Most of the variants 
clustered around 0.5 mark are from twin pairs 421 and 422. The DNA samples used for this pair are LCL-derived, and de novo mutations are known to be caused by the cell 
line transformation and culturing (Veltman and Brunner, 2012). 
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Table 4.8. Discordant mtDNA variants between twin pairs. 
 
Twin pair Gene Position 
Genotype 
Depth of coverage 
(proband) Variant 
frequency 
(proband) 
Depth of coverage 
(MZ twin) Variant 
frequency 
(MZ twin) 
Reference Variant Reference Variant Reference Variant 
LAS and SUS MT-ND5 13596 C A 227 0 0% 136 10 9% 
242 and 243 - 482 T C 85 11 14% 93 0 0% 
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Most of the discordant variants came from twin pairs 421 and 422. These samples were 
excluded from further analysis due to the likelihood of artefacts created from transformed 
immortalised cell lines. Variants in hypervariable segments were also removed. This 
resulted in 2 high-confidence discordant variants between two twin pairs (Table 4.8). In 
twin 242 a variant was detected with 14% minor allele frequency in a non-coding region, 
which was not present in the unaffected twin. Further, a novel nonsynonymous mutation 
(c.1260A:p.S420R) was detected in twin SUS, which was not present in the co-twin 
affected with ALS. 
No mtDNA sequence differences or different degrees of heteroplasmy were detected 
between any other individuals of the same pair. Thus, the phenotypic discordance of MZ 
twins with complex disorders investigated herein cannot be sufficiently explained by 
skewed distribution of mtDNA mutations. 
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 Discussion 
4.3.1 Assessment of variant calling pipelines 
Advances in NGS technologies have improved our ability to characterise genomic 
sequence variation at a scale and resolution not previously possible. This has opened new 
avenues for studying how genetic variation contributes to human disease. A major 
challenge is how to process the copious information generated by the new technologies 
to yield high-quality data for downstream analyses. A variety of computational tools have 
been developed for this purpose. 
However, each of these applications comes with a significant number of challenges. The 
most pertinent challenge is to determine which of the identified variants are errors, benign 
or pathogenic.  
A whole-genome sequencing effort on four family members revealed, for instance, that 
sequencing errors are about 1,000 times more prevalent than true differences between the 
participants (Roach et al., 2010). A large proportion of these errors could be eliminated 
by sequencing a higher number of related individuals in this family. However, as 
mutations are expected to occur during every meiosis cycle, these de novo mutations may 
be missed when direct comparison to family members is used as a measure to decide 
which variants are errors. Furthermore, in many cases whole-genome sequences of related 
individuals may not be available or irrelevant to the study design. In such cases, other 
methods to distinguish sequencing errors from true variants are clearly needed. The 
situation becomes even more complex in the case of cancer genomes, in which numerous 
amplifications and deletion patterns are known to influence the effective depth of 
sequencing and alter the allelic balance for a given single nucleotide difference.  
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Thus far, large-scale validation with other sequencing methods has been used to 
independently validate SNVs detected in whole-genome sequences. For example, over 
500 somatic variants in a tumour-normal sample from a lung cancer patient were validated 
using targeted mass spectrometry (Lee et al., 2010), whereas several other studies 
validated hundreds of SNVs using capillary Sanger sequencing (Pleasance et al., 2009; 
Friedberg, 2010; Dalgliesh et al., 2010; Reumers et al., 2012). This poses a considerable 
disadvantage as the independent validation of SNVs may quickly become as expensive 
and protracted as the analysis of the initial genome itself. To circumvent the need for such 
extensive validation analyses, sequencing projects in other smaller species have 
combined different technologies (e.g., long- and short-read technologies) to achieve more 
accurate sequencing (DiGuistini et al., 2009). At present, such an approach is, however, 
not cost- or time-effective for human genomes. 
We hypothesised that prior to performing expensive validation or de novo sequencing 
experiments, in-depth bioinformatics analyses could be used to identify SNVs with high 
confidence. Thus, a reliable method for the prioritisation of high confidence SNVs was 
employed. Pipeline 2 was based on a) stringent sequence quality measures, b) the 
identification of error-prone regions in the genome and c) consensus calling of SNVs 
identified with different sequence mapping and variation calling algorithms. Using this 
approach, we could significantly lower the genome-wide error rate in MZ twin pairs, and 
provide more accurate theoretical estimates of the number of SNVs identified in their 
exomes. 
Pipeline 3 was developed with the aim to rapidly identify and annotate variants. It utilises 
GATK for variant calling, which is based on the best practices for variant discovery 
analysis outlined by the Broad Institute. When comparing SNV calls from GATK and 
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SAMtools in Pipeline 2, it was found that GATK yields very high quality variant call 
data. Congruent with other studies (DePristo et al., 2011; Li et al., 2009), it was observed 
that recalibration of base quality scores before variant calling and realignment of mapped 
sequence reads around putative indels are important determinants of good performance. 
Several previous studies have investigated factors that influence the accuracy of variant-
calling algorithms with sequence data (DePristo et al., 2011; Liu et al., 2013; Li, Ruan 
and Durbin, 2008). One study sequenced 15 exomes from four families and processed the 
raw data using different alignment and variant-calling pipelines and found that there was 
low concordance between approaches (Liu et al., 2013). Another study used exome 
sequence data on 20 individuals and simulated whole-genome sequence data to compare 
different algorithms for variant-calling. Consistent with our results, this study found that 
GATK outperformed SAMtools, especially for low coverage data, and yielded the most 
accurate data with multi-sample calling (Ruan and Durbin, 2008). 
Pipeline 1 used an older version of VarScan, and only showed variants with a somatic 
allele frequency of >15%. While this helped reduce putative discordant variants to a more 
manageable number, it may have eliminated variants with low level mosaicism. 
Interestingly, none of the putative discordant variants identified in Pipeline 2 were 
identified with the other methods, demonstrating the limitations of current variant calling 
algorithms. To detect low-level mosaic variants that were potentially missed using 
Pipeline 1, two tools were used in parallel in Pipeline 3, and the results were separately 
evaluated to attain the highest possible sensitivity and hence lowest false-negative ratio. 
Using VarScan2 and MuTect2 to identify discordant somatic variants demonstrates an 
innovative technique in twin research. In contrast to other variant detection tools 
(including EBCall, JointSNVMix, LoFreq, SomaticSniper and Strelka), VarScan2 had a 
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lower false-positive rate and identified more true somatic SNVs (Wang et al., 2013; 
Huanget al., 2015). Moreover, VarScan2 was found to have the highest specificity 
(99.9998%) and sensitivity (97%), and was best at detecting variants present at low-allelic 
fractions (as low as 1%), and had perfect precision and recall for calling indel variants 
(Stead et al., 2013; Spencer et al., 2014; Kockan et al., 2016; Liu et al., 2016). However, 
MuTect2 identified more low coverage somatic variants (Cai et al., 2016). Although 
MuTect2 returned fewest candidates, it had excellent capability in both control of false 
calls and discovery of potential true positives. MuTect2 refers to dbSNP database to aid 
its classifier in discrimination between germline and somatic variants, and is shown to be 
efficacious. Although VarScan2 was as efficient in low-frequency mutations detection, it 
exhibited an advantage in discovering somatic SNVs with relatively high frequencies, 
which makes it a beneficial supplement of MuTect2 (Cai et al., 2016). As the two variant 
callers have their strengths and weaknesses, taking the union would avoid biases from 
either one.  
It would be no surprise if the bioinformatics methods and protocols outlined herein soon 
become outdated. This is owed to the fact that the methodological approaches for 
processing NGS data are continually evolving. It is therefore important to stay abreast of 
these techniques, and evaluate which one would yield the highest quality data for the 
desired study design. 
4.3.2 Discordant variants 
Analysing the exome sequencing data in accordance with Pipeline 3 yielded twenty-two 
high-confidence discordant variants within the thirteen twin pairs investigated. Putative 
discordant variants could be excluded upon manual reviewing in IGV if they were deemed 
to be artefacts – that is, variants were either called incorrectly in one of the co-twins (false 
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positive), or incorrectly not called in one of the co-twins (false negative). False negatives 
are likely to be the result of sequence data issues or stochastic sampling bias in the twin 
exome that lacked the variant. 
A nonsynonymous exonic variant was identified in PPARGC1A 
(NM_013261:exon9:c.A1829G:p.H610R), in the unaffected twin of the ALS-discordant 
pair 218 and 318. The affected twin (218), a fifty-four-year-old Caucasian male, 
experienced signs of ALS from the age of fifty. The site of symptom onset was in the 
upper limbs. Additional clinical features supporting the diagnosis were upper motor 
neuron signs in bulbar, cervical (upper limbs) and lumbosacral (lower limbs) regions, 
with definite lower motor neurone signs in bulbar and cervical regions. The 
electromyogram (EMG) studies, a test used to record the electrical activity of muscles, 
demonstrated acute cervical denervation. The affected twin was prescribed riluzole since 
the diagnosis was made. 
The revised ALS Functional Rating Scale (ALSFRS-R) provides an estimate of the 
patient’s degree of functional impairment based on a series of questions. Each question 
is graded from 1 to 4, and scores are summed to produce a reported score ranging from 0 
to 48. The higher the score the more function is retained. At the time of diagnosis, the 
ALSFRS-R of the affected twin (218) was 41, however follow up data (duration of 
interval not known) showed a marked reduction to 27. 
There was no family history of ALS or other motor neurone disorders, however his father 
and paternal grandfather had the diagnosis of Alzheimer’s disease, and several paternal 
aunts and uncles were diagnosed with a non-specified form of dementia. Both twins were 
diagnosed with hypertension. 
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The clinical finding of signs suggestive of combined upper and lower motor neurone 
lesions that cannot be explained by any other disease process, together with progression 
compatible with a neurodegenerative disorder, led to a primary clinical diagnosis of ALS 
in the affected twin. However, the unaffected twin remained asymptomatic. 
Paradoxically, the mutation occurring in the unaffected twin might explain their 
discordance. PPARGC1A encodes for peroxisome proliferator-activated receptor gamma 
coactivator 1-alpha (PGC-1α), a nuclear transcriptional coactivator that plays a vital role 
in mitochondrial biogenesis, respiration, insulin secretion, gluconeogenesis, and muscle 
fibre-type switching (Lin et al., 2004; Albani et al., 2016). It is interesting to note that the 
role of PPARGC1A in ALS is well-documented (Qi et al., 2015; Albani et al., 2016; Bayer 
et al., 2017; Buck et al., 2017). This gene has also been related to molecular pathways 
involved in other neurological disorders, including Parkinson’s, Huntington’s and 
Alzheimer’s disease, stroke and multiple sclerosis (Cui et al., 2006; Róna-Vörös and 
Weydt, 2010; Ghosh et al., 2015). 
Mouse models of ALS and Duchenne muscular dystrophy have demonstrated that 
increased expression and activity of PGC-1α can lead to an improved clinical outcome 
(Handschin et al., 2007b; Liang et al., 2011) by augmenting mitochondrial biogenesis and 
reactive oxygen species detoxification (Austin and St-Pierre, 2012). ALS is in effect a 
motor neuronal disorder of a degenerative origin, and oxidative stress appears to play a 
key role in the pathogenesis. 
Although recessive mutations tend to inactivate the affected gene and lead to a loss-of-
function (LoF), dominant mutations often lead to a gain of function by, for example, 
increasing the activity or conferring a new activity of a given gene product. Thus, it is 
possible that the mutation in PPARGC1A in the unaffected twin has resulted in an 
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increased expression of the protein, thus providing a protective effect from an already 
predisposing illness in the twin pair. This is supported by the effects of PGC-1a in 
transgenic models of ALS, as well as human studies. For instance, in a genetic association 
study, Eschbach et al. (2013) found that SNPs in the brain-specific promoter region of 
PGC-1a modifies the clinical manifestation of human ALS. Remarkably, the modifier 
effect of PGC-1a on ALS onset and survival was in a strictly male-specific manner, and 
was more pronounced in humans than in mice (Eschbach et al., 2013). 
Our finding has the potential to further elucidate the role of this antioxidant defence 
transcriptional coactivator in ALS. Validation of our findings using additional 
technologies, such as Sanger sequencing or allele-specific PCR capable of detecting low-
level mosaicism, will be implemented as part of future studies, a lack of which herein is 
acknowledged as a limitation.  
4.3.3 Concordant variants 
In addition to identifying discordant variants, we sought to examine shared variants with 
predicted pathogenicity. This included rare homozygous and heterozygous variants, and 
those in known disease-susceptibility genes. Phenotypic discordance between twin pairs 
could be explained in a number of ways. For instance, if the variants exhibited incomplete 
penetrance, the unaffected twin could develop the disorder later (for example, Chapter 2 
documents a shared pathogenic hexanucleotide repeat expansion in ALS-discordant twins 
421 and 422). Oligogenic mechanisms may also be a factor. 
Concordant variants in exonic, splice site, promotor, 5’UTR and 3’UTR regions were 
cross-compared against a list of disease-linked genes formulated via a comprehensive 
search of literature and gene databases. The number of concordant variants could be 
further reduced by removing those found in multiple other samples, repetitive sequences 
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or systematic mismapping of paralogous sequences. In total, 23 shared variants were 
identified in known disease-susceptibility genes. 
As there will likely be a larger number of shared variants in novel genes (previously not 
related to the primary diagnosis of the affected twin), the search was restricted to only 
nonsynonymous variants in exonic regions, the data for which is not shown. The 
concordant variants found in exome sequencing should ideally be validated with an 
independent method, but this is impractical for the many variants identified. Nevertheless, 
as described above, it would be very unlikely for both twins to receive false-positive 
readings at the same gene location. 
It may prove insightful to analyse the genes harbouring potentially pathogenic variants 
using pathway analysis tools, such as Ingenuity Pathway Analysis or Cytoscape. This 
would have the potential to identify major canonical pathways as well as networks 
overexpressed in the gene lists and describe the intricate relationships between the genes 
in the pathway. These pathway analysis tools are also able to identify potential disease 
associations through gene ontology classification. The lists of concordant variants 
identified within each twin pair will thus be of use to future genetic studies related to the 
disorders investigated. 
4.3.4 De novo mutation detection in parent-offspring trio analysis 
4.3.4.1 Attention deficit hyperactivity disorder 
A nonsynonymous mutation (c.G170A:p.R57H) within the RASD family member 2 
(RASD2) was found in both ADHD-discordant twins (OH and RP), but absent in their 
parents. RASD2 belongs to the Ras superfamily of small GTPases and is enriched in the 
striatum and involved in the modulation of dopaminergic neurotransmission (Vitucci et 
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al., 2015). RASD2 is located on chromosome 22q12.3, a region that harbours numerous 
susceptibility loci for psychosis (Potash et al, 2003), and has been suggested to be a 
vulnerability gene for neuropsychologically defined subgroups of schizophrenic patients 
(Liu et al., 2008). Currently, the co-twin has not been officially diagnosed but anecdotally 
has been showing clinical features of ADHD.  
In a knockout mice model with targeted deletion of Rasd2, Vitucci et al. (2015) found 
that the absence of Rasd2 significantly increases the behavioural sensitivity to motor 
stimulation with administration of psychotomimetic drugs, such as amphetamine and 
phencyclidine. Based on these findings, and the postulate that RASD2 influences 
prefronto-striatal phenotypes in humans, the authors hypothesise that a genetic mutation 
resulting in a reduction of this G-protein might play a role in cerebral circuitry 
dysfunction, resulting in exaggerated psychotomimetic drug responses and the 
development of specific phenotypes linked to schizophrenia-like symptoms (Vitucci et 
al., 2015). Interestingly, people who have ADHD (Kim-Cohen et al., 2003), or a family 
history of the disorder (Larsson et al., 2013), are more likely to develop psychotic 
disorders. The co-occurrence of ADHD and schizophrenia is suggested to be due to 
shared genetic factors, rather than aetiologically distinct subsyndromes (Larsson et al., 
2013). Moreover, stimulants, such as amphetamines, are the most common 
pharmacological treatment for ADHD (Bolea-Alamañac et al., 2014). It is not known if 
the affected twin (RP) was prescribed medication for the condition. 
4.3.4.2 Tourette's syndrome 
For an individual to be diagnosed with Tourette’s syndrome, they must display multiple 
motor tics (e.g. blinking or shrugging the shoulders) and at least one vocal tic (e.g. 
humming, throat clearing, or shouting out a phrase), both of which must be ongoing for 
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at least one year. Tics are abrupt, rapid, non-rhythmic, persistent, stereotyped motor 
movements or vocalisations. Individuals who have either motor or verbal tics (but not 
both) for more than a year are given diagnoses of chronic motor tics or chronic verbal 
tics, respectively. 
The forty-four-year-old father (487) of American Indian descent was given a diagnosis 
of Tourette’s syndrome at seven years of age, but experienced motor and vocal tics from 
the age of six. This follows the typical development of Tourette’s syndrome, which 
manifests in early childhood with symptoms peaking before puberty. Tourette’s 
syndrome can often co-occur with other neuropsychiatric disorders, such as ADHD and 
obsessive-compulsive disorder (OCD), and it is often these co-occurring conditions that 
bring affected individuals to seek medical attention. In line with this, the father had a 
secondary lifetime clinical diagnosis of OCD (onset nine years) and ADHD (onset twelve 
years). Although there is no prior family history of Tourette’s syndrome, OCD or ADHD, 
his mother had a diagnosis of anxiety disorder. 
The affected twin (490) similarly experienced tics from the age of seven, and was given 
a diagnosis of Tourette disorder at eight. No other conditions (such as ADHD or OCD) 
were evident in the affected twin by fifteen years of age, when DNA samples were 
collected from the family. The unaffected twin (489), moreover, remained asymptomatic 
for all conditions. The twins have a fourteen-year-old brother who is also asymptomatic 
(DNA samples for this individual was not obtained). The forty-four-year-old mother 
(488) of Caucasian descent has no primary lifetime clinical diagnosis or family history of 
related disorders. The racial category in the medical notes classify the twins as 
‘Caucasian’, however it is evident that twins have mixed heritage parents. 
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No pathogenic germline de novo mutations were identified in the twin pair. However, a 
shared stop loss mutation in AADAC, a gene encoding for arylacetamide deacetylase on 
chromosome 3 (NM_001086:exon5:c.T1198C:p.X400Q), was inherited from the father.  
In a recent study by Bertelsen et al. (2016), the authors identified eight patients with 
overlapping deletions of AADAC in a Danish cohort of 243 patients with Tourette’s 
syndrome and 1571 ancestry-matched control subjects. Although there was no statistical 
significance in this cohort, the gene remained their most promising candidate. The authors 
proceeded to investigate cohorts from an additional five countries; namely, Iceland, the 
Netherlands, Hungary, Germany, and Italy. A final meta-analysis of 1181 patients and 
118,730 control subjects from these countries determined the association to be significant. 
Further, functional studies demonstrated that AADAC is expressed in several brain regions 
previously implicated in the pathophysiology of Tourette’s syndrome, including the 
Purkinje cell layer of the human cerebellum (Bertelsen et al., 2016). The CNV 
overlapping AADAC is the only one to date that has been successfully associated with 
Tourette’s syndrome. A previous CNV study found a tentative link between the gene 
FHITT and the disorder, however on closer inspection this association was determined to 
be the result of population stratification (Fernandez et al., 2012). Bertelsen et al. (2016) 
avoided this Type 1 error, which was caused by within-population differences in ancestry 
between cases and control subjects, by ensuring uniform ancestry within each population. 
The BrainSpan Atlas of the Developing Human Brain provides RNA sequencing and 
exon microarray data of various cortical and subcortical structures across the full course 
of human brain development (http://www.brainspan.org). Remarkably, the publicly-
available transcriptome profiling data illustrates that AADAC expression peaks in the 
striatum between birth and adolescence. This is consistent with the typical clinical time 
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course of tic onset, and indeed the age of onset of Tourette’s syndrome in the father and 
the affected twin investigated herein. 
Considering the above evidence, AADAC remains an interesting candidate susceptibility 
gene for Tourette’s syndrome. The stop loss mutation detected in the father and twins 
warrant functional studies to investigate the role of this gene in the pathogenesis of this 
disorder. 
4.3.5 Mitochondrial DNA analysis 
The mitochondrial genome, unlike nuclear DNA, is located in mitochondria and is 
exclusively inherited from the mother through the cytoplasm (Falkenberg, Larsson and 
Gustafsson, 2007). Previous studies have suggested an uneven distribution of 
mitochondria at the time of embryo separation, which starts from the two-cell stage and 
leads to the differential pattern of mtDNA heterogeneity between daughter cells (Lee et 
al., 2012). These findings indicated that the variability of mtDNA heterogeneity may exist 
between identical twins.  
Thus, we also investigated differences of the mtDNA variants and levels of heteroplasmy 
between the twin pairs. However, no clear evidence was found for an mtDNA 
contribution to the phenotypic difference in these MZ twins, suggesting that heteroplasmy 
of common mtDNA variants might significantly contribute to the risk of the complex 
traits investigated herein.  
However, there were an unusually high number of discordant variants in one twin pair 
(421 and 422), mainly detected in the affected twin. This is consistent with the somatic 
variant analysis on this twin pair (Tables 4.3 and 4.4), whose DNA samples, as mentioned 
previously, were derived from EBV-transformed B-lymphocytes. Other studies have 
shown a significant bias in using LCL-derived DNA, as de novo mutations can result 
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from cell line transformation and culturing (Veltman and Brunner, 2012). It has been 
shown that EBV promotes genetic instability in the host (Gruhne et al., 2009), and can 
cause mutations through integration and disintegration into the host’s genome (Morissette 
and Flamand, 2010). 
This preliminary analysis will be part of a larger project looking at sequence variations in 
the mitochondrial genome of over 5,000 individuals, where a more comprehensive 
analysis will take place. Albeit, the findings of the present analysis agree with previous 
studies concerning the role of mtDNA heteroplasmy in discordant MZ twins with other 
human disorders (Detjen et al., 2007), indicating that factors, such as epigenetic changes 
and environmental factors, may play a more important role in shaping the discordance 
between MZ twins with these conditions. 
4.3.6 Considerations and limitations 
A major strength of this study is the presence of discordant MZ twins for a range of 
clinical phenotypes. We included the genomes of parents of RP and OH, and 489 and 490 
for parent-offspring trio analysis. We also cross-compared DNA obtained from blood and 
saliva in subjects HG and KG for exome sequencing analysis. 
Ideally, DNA obtained directly from affected tissues would be more reliable in detecting 
de novo mutations and somatic mosaicism, especially if the timing of mutagenesis 
occurred later in development. However, this was impractical as the nature of most of the 
disorders investigated in this study entails obtaining brain, muscle or bowel biopsies. 
Ectodermally-derived buccal epithelial cells have a closer embryological connection to 
brain tissue than leukocytes from blood. The epithelial lining of the mouth and the 
nervous system are both ectodermal derivatives, whereas the mesoderm ultimately gives 
rise to muscle, vascular tissue and the haematopoietic system (Freshney, 1987). This was 
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corroborated in a study looking at the aetiological basis of DNA methylation in 
psychiatric disorders. DNA methylation in saliva resembled patterns from each of the 
different brain regions more closely than methylation in blood (Smith et al., 2014). Thus, 
our choice of tissue samples did not pose a major challenge in mosaicism detection. 
Although the identification of high-confidence discordant de novo variants between co-
twins have the potential to offer novel insight into the extensive aetiological heterogeneity 
implicated in complex traits, they remain to be independently validated. Discordant 
variants were not identified in several twin pairs. The low rate of de novo mutations 
within the exonic regions of the genome is consistent with other published data (Li et al., 
2014; Dal et al., 2014). Where no differences were found, it is therefore possible that the 
analysed exomes are truly genetically identical between these co-twins. However, while 
we have obtained good data quality and applied thorough analytical methodologies, it 
remains the case that we may have overlooked existing differences in somatic mutation 
detection. 
One reason for this is that exome sequencing covers a mere 1-2% of the genome, and 
does not assess variation in noncoding gene regulatory elements, apart from when they 
are near exonic regions. However, our hypothesis of postzygotic mutations to explain 
twin discordance renders exome sequencing highly appropriate, given that phenotypic 
differences are more likely to be caused by nonsynonymous mutations in protein-coding 
regions of the genome. Nevertheless, it remains possible that discordant somatic 
mutations affecting the phenotype in our twin cohort may be found in regions outside the 
accessible exonic regions of the genome. 
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4.3.7 Summary 
The discordant MZ twin strategy employed in this study to identify candidate genes 
involved in the pathogenesis of complex traits is reasonable and practical. 
Notwithstanding, the actual search for discordant variants is not an easy task. For some 
of the twin pairs, no convincing variants were found to explain their discordant 
phenotypes. This suggests that genetic alterations in these twins might lie outside the 
accessible regions, or have yet uninvestigated epigenetic differences. 
Several studies failed to find somatic mutations using NGS technology between 
discordant MZ twins, such as for multiple sclerosis (Baranzini et al, 2010), VACTERL 
association (Solomon et al, 2013), congenital renal agenesis (Jin et al, 2014), Crohn’s 
disease (Peterson et al, 2014), congenital heart defect and epilepsy (Chaiyasap et al, 
2014), congenital hypothyroidism due to thyroid dysgenesis (Magne et al, 2015), and 
ALS (Meltz Steinberg et al, 2015). And in studies where differences were found, they 
were masked by a substantial number of false positives. For instance, Reumers et al. 
(2012) used whole-genome sequencing on MZ twins discordant for schizophrenia, and of 
the 846 potential discordant variants found post-filtering, only two were confirmed by 
Sanger sequencing. This filtering method was employed in our Pipeline 2 analysis, which 
confirmed the high miscall error rate of whole-genome and -exome sequencing. Indeed, 
Neilson et al. (2011) found the error rate of the Illumina platform to be approximately 
1%. Considering this, and given that there are ~3 billion base pairs in the human genome, 
one can anticipate to find ~30 million miscalled positions by whole-genome sequencing. 
However, with the rapidly evolving bioinformatics tools at our disposal and advances in 
genomic technologies, a comprehensive search for somatic mosaicism is becoming 
realistic. 
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This study supports the polygenic nature of the complex disorders investigated and the 
threshold model for their manifestation. Taking the union of MuTect2 and VarScan2 to 
identify somatic variants offers a proof of concept for assessing the genetic aetiology of 
complex traits in discordant MZ twins. As well as individual-specific variants, various 
potentially pathogenic concordant SNVs were identified in disease susceptibility genes. 
While the latter may suggest a reason for disease manifestation in the affected twins, it 
does not explain their discordant phenotypes. Future work will involve investigating other 
potential contributory factors, such as epigenetic changes, discordant SNVs in non-coding 
regions of the genome, oligogenic mechanisms, environmental agents, or tissue-specific 
somatic mutations. 
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Chapter 5. Copy number variation in discordant 
monozygotic twins 
 Overview 
In Chapter 4 we explored methodological approaches in identifying germline and somatic 
variants and their theoretical role in complex disorders. This chapter documents high-
density microarray analysis with the aim to identify large genomic structural 
rearrangements of potential clinical significance. 
Redon et al. (2006) defined a CNV as a section of DNA that is ≥1 kb and present at 
variable CN when compared to a reference genome. CNVs are structural variations that 
comprise deletions, insertions, duplications and complex multi-site variants, which alter 
the diploid status of DNA. They have been found in all human populations and are 
widespread throughout the genome (Freeman, 2006). Previous studies have demonstrated 
that postzygotic CNVs can cause discordant phenotypes in MZ twin pairs that otherwise 
are genetically identical (Bruder et al., 2008).   
There is now overwhelming evidence that CNVs play a significant role in normal 
population variation and evolution (Ionita-Laza et al., 2009; Wong et al., 2007; McCarroll 
et al., 2008) and significant CNV associations have been found to underlie disease. 
Although postzygotic de novo CNVs have been detected in discordant MZ twins, many 
studies testing this hypothesis have reported no or limited evidence (Abdellaoui et al., 
2015; Laplana et al., 2014) Additionally, there are reports of CN differences in MZ twin 
pairs without discordant phenotypes (Abdellaoui et al., 2015; Magnusson et al., 2016). 
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Some CNVs represent recurrent polymorphisms occurring at a low rate in the population 
and have no known clinical significance. However, is it estimated that 4.8–9.5% of the 
genome contributes to CNV, many of which are in areas of known genes and have the 
potential to impact phenotype (Zarrei et al., 2015; Iafrate et al., 2004)). The average 
number of CNVs per person ranges from 10-50 based on several reports using current 
SNP-based microarrays (Iafrate et al., 2004; McCarroll et al., 2008), with an estimated 
rate of de novo CNVs lying between 0.01 and 0.02 events per generation (Acuna-Hidalgo, 
Veltman and Hoischen, 2016). 
In this study, we used a SNP microarray platform and various computational methods to 
identify CNVs in thirteen pairs of MZ twins with varying phenotypic discordances for 
complex disorders. With the aim to identify potential genetic factors that influence 
disease manifestation, it was hypothesised that shared or discordant CNVs could increase 
the risk of disease onset even in discordant twin pairs. To investigate this hypothesis, the 
burden of rare CNVs and CNVs overlapping disease-linked genes were analysed. 
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 Results 
DNA from the entire twin cohort (n=26) and two sets of parents (n=4) recruited in this 
study were processed on the Illumina HumanCore BeadChip 12v1. All processing was 
carried out in accordance with the Infinium HD Ultra Assay protocol (Rev B, 2010, 
Illumina Inc, San Diego, USA).  
5.2.1 CNVs affecting disease-susceptibility genes  
After CNV merging, a total of four discordant de novo CNV duplications were found in 
three subjects – namely, chr1:231711489-231803604 in UNAFF; chr4:15776181-
15840839 and chr4:139790626-139915883 in RP; and chr8:105981846-106108593 in 
490. However manual inspection revealed that these variants are shared with each of the 
corresponding co-twins. In other words, the apparent discordant CNVs were undercalled 
(false negative) in the twin that originally didn’t have the CNV called by pennCNV. 
CNVs were called if they are covered by ≥10 probes, but in some instances, they spanned 
<10 probes so were filtered out of the data. Next, we lowered the probe threshold to ≥3 
to detect smaller CNVs that would potentially be filtered out of the data. As this is 
expected to result in a higher frequency of false positive calls, CNVs were also called 
using cnvPartition, and CN segments were only included in further analysis if the CN 
calls agreed between both algorithms. The results obtained from SNP array analysis are 
summarised in Table 5.1. 
These putative CNVs were compared against exome sequencing CNV calls. Only 
samples from Pipeline 1 (Table 4.1) were analysed using ExomeDepth. ExomeDepth 
yielded approximately 130 CNVs per sample, of which about 90% calls per sample are 
known in the population. This estimate was determined by comparing the probe locations 
matching with published CNVs (Conrad et al., 2009; Durbin et al., 2010). Most of the 
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samples had around a 1:1 deletions/duplications ratio. CNVs that were consistent between 
both SNP array and exome sequencing platforms were considered for experimental 
validation using ddPCR. 
We focused on subsets of genes that are associated with known phenotypes in disease 
databases such as OMIM and DisGeNET, or genes that are intolerant to LoF mutations 
based on the Residual Variation Intolerance Score (RVIS) or the probability of being loss-
of-function intolerant (pLI) score (Petrovski et al., 2013) (Table 5.2). An RVIS <0.0 
means that a given gene has less common functional variation than expected, and is 
referred to as ‘intolerant’; whereas an RVIS >0.0 indicates that a gene has more common 
functional variation. Genes with high pLI scores (pLI ≥ 0.9) are extremely LoF intolerant, 
whereas genes with low pLI scores (pLI ≤ 0.1) are LoF tolerant. 
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Disease status ID Chr 
Start 
position 
End 
position 
CN 
1(0or1) 
2(3or4) 
Size (bp) 
No of 
probes 
Genes 
ALS 
LAS 
2 203553836 203665782 2 111946 8 FAM117B, ICA1L 
12 31266287 31406907 2 140620 19 OVOS2 
SUS 
2 203553836 203665782 2 111946 8 FAM117B, ICA1L 
12 31296219 31406907 2 110688 15 OVOS2 
 
ALS 
218 
3 160154258 160156933 2 2675 8 TRIM59 
21 14669931 14844368 1 174437 9 FGF7P2, C21orf110 
318 
3 160154258 160156933 2 2675 8 TRIM59 
21 14669931 14844368 1 174437 9 FGF7P2, C21orf110 
 
ALS 
421 - - - - - - - 
422 - - - - - - - 
 
ALS 
242 
4 116880079 117095295 1 215216 14 - 
4 131965131 132177937 2 212806 17 - 
22 33875161 33928049 2 52888 7 LARGE1 
243 
4 116880079 117095295 1 215216 14 - 
4 131965131 132218117 2 252986 19 - 
22 33875161 33928049 2 52888 7 LARGE1 
 
Stroke 
KG(s)  
4 111079337 111173378 2 94041 12 ELOVL6 
12 106077858 106177127 2 99269 18 - 
20 23677829 23725019 2 47190 8  
HG(s) 
4 111079337 111173378 2 94041 12 ELOVL6 
12 106077858 106154088 2 76230 16  
20 23671740 23725019 2 53279 9  
 
KG(b) 
4 111079337 111173378 2 94041 12 ELOVL6 
12 106077858 106177127 2 99269 12 - 
20 23671740 23725019 2 53279 9  
HG(b) 
4 111079337 111173378 2 94041 12 ELOVL6 
12 106077858 106177127 2 99269 10 - 
20 23677829 23725019 2 47190 8  
 
Lactose 
Intolerance 
KEL 
1 49580287 49672039 1 91752 8 AGBL4 
19 6904195 7103542 2 199347 40 
ZNF557, MBD3L2, 
MBD3L5, ADGRE4P, 
FLJ25758, MBD3L4, 
MBD3L3, ADGRE1 
KIR 
1 49580287 49672039 1 91752 8 AGBL4 
19 6904195 7103542 2 199347 40 
ZNF557, MBD3L2, 
MBD3L5, ADGRE4P, 
FLJ25758, MBD3L4, 
MBD3L3, ADGRE1 
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Inclusion body 
myositis 
AFF 
1 231730121 231767890 2 37769 7 DISC1 
7 69966192 70022011 2 55819 8 AUTS2 
7 70137165 70295629 2 158464 19 AUTS2 
19 54731679 54740705 2 9026 5 LILRB3 
UNAFF 
1 231711489 231803604 2 92115 11 DISC1 
7 69966192 70022011 2 55819 8 AUTS2 
7 70014509 70295629 2 281120 31 AUTS2 
19 54731679 54740705 2 9026 5 LILRB3 
 
ADHD 
DS 4 161953729 162002921 2 49192 6 - 
DV - - - - - - - 
RP 
4 139790626 139915883 2 125257 16 - 
4 15776181 15840839 2 64658 10 CD38 
4 161953729 162002921 2 49192 6 - 
13 64378676 64390470 2 11794 3 - 
OH 
4 139790626 139915883 2 125257 9 - 
4 15776181 15840839 2 64658 10 CD38 
4 161953729 162002921 2 49192 6 - 
13 64346536 64390470 2 43934 5 - 
 
Tourette's 
Syndrome 
487 2 90108545 90109261 1 716 5 - 
488 
2 90108545 90109261 1 716 5 - 
3 173259356 173289281 2 29925 4 NLGN1 
8 105981846 106021780 2 39934 4  
8 106095659 106115255 2 19596 6  
10 45218841 45359483 2 140642 14  
12 8035139 8101326 2 66187 9 
SLC2A3, NANOGP1, 
NECAP1 
22 22313954 22560977 2 247023 37 
IGLV4-69, IGLV4-60, 
IGLV8-61, IGLV6-57, 
TOP3B 
490 
2 89987044 90109261 1 122217 8 
IGKV2D-29, 
IGKV2D-28, 
IGKV2D-26, 
IGKV3D-20 
3 173259356 173289281 2 29925 4 NLGN1 
5 113429984 113435957 1 5973 4 - 
8 105981846 106108593 2 126747 14 - 
10 45218841 45359483 2 140642 14 - 
22 22313954 22560977 2 247023 33 
IGLV4-69, IGLV4-60, 
IGLV8-61, IGLV6-57, 
TOP3B 
489 
2 89987044 90109261 1 122217 8 
IGKV2D-29, 
IGKV2D-28, 
IGKV2D-26, 
IGKV3D-20 
3 173259356 173289281 2 29925 4 NLGN1 
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5 113429984 113435957 1 5973 4 - 
8 105981846 106052343 2 70497 9 - 
10 45218841 45359483 2 140642 14 - 
22 22313954 22550078 2 236124 30 
IGLV4-69, IGLV4-60, 
IGLV8-61, IGLV6-57, 
TOP3B 
 
Parkinson's 
disease 
PD821 
3 173259356 173289281 2 29925 4 NLGN1 
17 34458934 34461869 2 2935 4 - 
PD161 
3 173259356 173289281 2 29925 4 NLGN1 
17 34450463 34461869 2 11406 5 - 
 
Dystonia/HSP 
VF 
1 248789519 248813267 1 23748 9 
OR2T11, OR2T35, 
OR2T27 
2 40447587 40509154 1 61567 14 SLC8A1 
22 25669569 25875573 2 206004 7 LRP5L 
LF 
1 248789519 248813267 1 23748 9 
OR2T11, OR2T35, 
OR2T27 
2 40447587 40509154 1 61567 14 SLC8A1 
22 25669569 25905668 2 236099 10 LRP5L 
 
Schizophrenia 
RT1b 
4 161861640 161924832 2 63192 6 - 
13 23548470 23586366 2 37896 18 - 
15 30950529 31088443 1 137914 9 ARHGAP11B 
15 32513176 32514341 2 1165 4 - 
22 49565404 49570587 2 5183 6 - 
RT1a 
4 161861640 161924832 2 63192 6 - 
13 23548470 23586366 2 37896 18 - 
15 30950529 31088443 1 137914 9 ARHGAP11B 
15 32513176 32514341 2 1165 4 - 
22 49566426 49570587 2 4161 5 - 
 
Schizophrenia 
IP16 
14 32204263 32563640 2 359377 40 NUBPL, ARHGAP5 
17 34450463 34461869 2 11406 5 - 
19 54731679 54844626 2 112947 17 
LILRA6, LILRB5, 
LILRB2, LILRA3, 
LILRA5 
IP17 
14 32164373 32563640 2 399267 41 NUBPL, ARHGAP5 
17 34450463 34461869 2 11406 5 - 
19 54749011 54844626 2 95615 12 
LILRA6, LILRB5, 
LILRB2, LILRA3, 
LILRA5 
 
Table 5.1. CNVs identified by PennCNV and cnvPartition where merged and manually screened in 
GenomeStudio. False negative CNV calls are included in the list. CN 1 = duplication, CN 2 = deletion. 
Putative de novo CNVs are highlighted in yellow. 
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Diagnosis of 
affected twin 
Gene Description 
Disease association 
(DisGeNET) 
Gene ontology (functioning of gene products) RVIS pLI %HI 
ALS LARGE1 
LARGE xylosyl- and 
glucuronyltransferase 
1 
Congenital muscular 
dystrophy; mental 
retardation syndromes; 
GO:0005515 [protein binding] 
GO:0005794 [Golgi apparatus] 
GO:0006044 [N-acetylglucosamine metabolic 
process] 
GO:0006486 [protein glycosylation] 
GO:0006688 [glycosphingolipid biosynthetic 
process] 
GO:0008375 [acetylglucosaminyltransferase 
activity] 
GO:0009101 [glycoprotein biosynthetic process] 
GO:0015020 [glucuronosyltransferase activity] 
GO:0016757 [transferase activity, transferring 
glycosyl groups] 
GO:0030145 [manganese ion binding] 
GO:0030173 [integral component of Golgi 
membrane] 
GO:0035269 [protein O-linked mannosylation] 
GO:0042285 [xylosyltransferase activity] 
GO:0043231 [intracellular membrane-bounded 
organelle] 
GO:0043403 [skeletal muscle tissue regeneration] 
GO:0046716 [muscle cell cellular homeostasis] 
GO:0060538 [skeletal muscle organ 
development] 
-1.11 
(10.98%) 
0.96 4.10 
HSP SLC8A1 
Solute carrier family 
8 member A1 
Myocardial ischemia; 
status epilepticus; 
GO:0002026 [regulation of the force of heart 
contraction] 
GO:0002027 [regulation of heart rate] 
GO:0005432 [calcium:sodium antiporter activity] 
-1.41 
(6.88%) 
0.99 6.09 
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GO:0005509 [calcium ion binding] 
GO:0005515 [protein binding] 
GO:0005516 [calmodulin binding] 
GO:0005829 [cytosol] 
GO:0005886 [plasma membrane] 
GO:0005887 [integral component of plasma 
membrane] 
GO:0006811 [ion transport] 
GO:0006816 [calcium ion transport] 
GO:0006883 [cellular sodium ion homeostasis] 
GO:0006936 [muscle contraction] 
GO:0007154 [cell communication] 
GO:0007596 [blood coagulation] 
GO:0008092 [cytoskeletal protein binding] 
GO:0010649 [regulation of cell communication 
by electrical coupling] 
GO:0010881 [regulation of cardiac muscle 
contraction by regulation of the release of 
sequestered calcium ion] 
GO:0010882 [regulation of cardiac muscle 
contraction by calcium ion signaling] 
GO:0014704 [intercalated disc] 
GO:0014829 [vascular smooth muscle 
contraction] 
GO:0016020 [membrane] 
GO:0016021 [integral component of membrane] 
GO:0030018 [Z disc] 
GO:0030315 [T-tubule] 
GO:0030501 [positive regulation of bone 
mineralization] 
GO:0030506 [ankyrin binding] 
GO:0034614 [cellular response to reactive oxygen 
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species] 
GO:0035725 [sodium ion transmembrane 
transport] 
GO:0035994 [response to muscle stretch] 
GO:0042383 [sarcolemma] 
GO:0044325 [ion channel binding] 
GO:0044557 [relaxation of smooth muscle] 
GO:0051481 [negative regulation of cytosolic 
calcium ion concentration] 
GO:0055013 [cardiac muscle cell development] 
GO:0055074 [calcium ion homeostasis] 
GO:0055085 [transmembrane transport] 
GO:0055119 [relaxation of cardiac muscle] 
GO:0060048 [cardiac muscle contraction] 
GO:0060401 [cytosolic calcium ion transport] 
GO:0060402 [calcium ion transport into cytosol] 
GO:0070509 [calcium ion import] 
GO:0070588 [calcium ion transmembrane 
transport] 
GO:0071313 [cellular response to caffeine] 
GO:0071436 [sodium ion export] 
GO:0086012 [membrane depolarization during 
cardiac muscle cell action potential] 
GO:0086064 [cell communication by electrical 
coupling involved in cardiac conduction] 
GO:0097369 [sodium ion import] 
GO:0098735 [positive regulation of the force of 
heart contraction] 
GO:1901660 [calcium ion export] 
Ischaemic 
stroke 
ELOVL6 
ELOVL fatty acid 
elongase 6 
Heart failure; Psoriasis; 
obesity; atherosclerosis; 
atopic dermatitis 
GO:0005515 [protein binding] 
GO:0005783 [endoplasmic reticulum] 
GO:0005789 [endoplasmic reticulum membrane] 
-0.27 
(36.97%) 
0.97 3.68 
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GO:0016021 [integral component of membrane] 
GO:0016747 [transferase activity, transferring 
acyl groups other than amino-acyl groups] 
GO:0019367 [fatty acid elongation, saturated 
fatty acid] 
GO:0019432 [triglyceride biosynthetic process] 
GO:0030176 [integral component of endoplasmic 
reticulum membrane] 
GO:0030497 [fatty acid elongation] 
GO:0035338 [long-chain fatty-acyl-CoA 
biosynthetic process] 
GO:0042759 [long-chain fatty acid biosynthetic 
process] 
GO:0044255 [cellular lipid metabolic process] 
GO:0044281 [small molecule metabolic process] 
Lactose 
intolerance 
MBD3L2 
Methyl-CpG binding 
domain protein 3 like 
2 
Stomach neoplasms 
GO:0000122 [negative regulation of transcription 
from RNA polymerase II promoter] 
GO:0005634 [nucleus] 
GO:0006346 [methylation-dependent chromatin 
silencing] 
GO:0008327 [methyl-CpG binding] 
n/a n/a 95.74 
ADGRE4P 
Adhesion G protein-
coupled receptor E4, 
pseudogene 
Colorectal cancer n/a n/a n/a n/a 
ADGRE1 
Adhesion G protein-
coupled receptor E1 
Liver cirrhosis; 
secondary periodontitis 
GO:0002250 [adaptive immune response] 
GO:0004888 [transmembrane signalling receptor 
activity] 
GO:0004930 [G-protein coupled receptor 
activity] 
GO:0005509 [calcium ion binding] 
GO:0005515 [protein binding] 
2.21 
(97.76%) 
0.00 90.69 
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GO:0005887 [integral component of plasma 
membrane] 
GO:0007155 [cell adhesion] 
GO:0007166 [cell surface receptor signalling 
pathway] 
GO:0007186 [G-protein coupled receptor 
signalling pathway] 
GO:0016020 [membrane] 
GO:0016021 [integral component of membrane] 
ADHD CD38 CD38 molecule 
Autism spectrum 
disorders 
GO:0001666 [response to hypoxia] 
GO:0003953 [NAD+ nucleosidase activity] 
GO:0005634 [nucleus] 
GO:0005829 [cytosol] 
GO:0005886 [plasma membrane] 
GO:0007165 [signal transduction] 
GO:0007204 [positive regulation of cytosolic 
calcium ion concentration] 
GO:0007565 [female pregnancy] 
GO:0008152 [metabolic process] 
GO:0009725 [response to hormone] 
GO:0009986 [cell surface] 
GO:0016020 [membrane] 
GO:0016021 [integral component of membrane] 
GO:0016740 [transferase activity] 
GO:0016798 [hydrolase activity, acting on 
glycosyl bonds] 
GO:0016849 [phosphorus-oxygen lyase activity] 
GO:0030307 [positive regulation of cell growth] 
GO:0030890 [positive regulation of B cell 
proliferation] 
GO:0032024 [positive regulation of insulin 
secretion] 
0.47 
(70.44%) 
0.00 77.57 
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GO:0032355 [response to estradiol] 
GO:0032526 [response to retinoic acid] 
GO:0032570 [response to progesterone] 
GO:0033194 [response to hydroperoxide] 
GO:0034097 [response to cytokine] 
GO:0042493 [response to drug] 
GO:0043066 [negative regulation of apoptotic 
process] 
GO:0043231 [intracellular membrane-bounded 
organelle] 
GO:0045779 [negative regulation of bone 
resorption] 
GO:0045892 [negative regulation of transcription, 
DNA-templated] 
GO:0045893 [positive regulation of transcription, 
DNA-templated] 
GO:0045907 [positive regulation of 
vasoconstriction] 
GO:0050135 [NAD(P)+ nucleosidase activity] 
GO:0050853 [B cell receptor signaling pathway] 
GO:0060292 [long term synaptic depression] 
GO:0070062 [extracellular exosome] 
GO:0070555 [response to interleukin-1] 
GO:0097190 [apoptotic signaling pathway] 
Tourette’s 
syndrome 
TOP3B 
DNA topoisomerase 
III beta 
Cognitive impairment; 
schizophrenia 
GO:0003677 [DNA binding] 
GO:0003916 [DNA topoisomerase activity] 
GO:0003917 [DNA topoisomerase type I activity] 
GO:0005515 [protein binding] 
GO:0005634 [nucleus] 
GO:0005654 [nucleoplasm] 
GO:0006265 [DNA topological change] 
GO:0044822 [poly(A) RNA binding] 
-0.34 
(33.91%) 
0.11 15.86 
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Tourette’s 
syndrome/Par
kinson’s 
disease 
NLGN1 Neuroligin 1 
Autistic disorder; 
schizophrenia; bipolar 
disorder; depression; 
memory impairment 
GO:0002087 [regulation of respiratory gaseous 
exchange by neurological system process] 
GO:0004872 [receptor activity] 
GO:0005515 [protein binding] 
GO:0005794 [Golgi apparatus] 
GO:0005886 [plasma membrane] 
GO:0005887 [integral component of plasma 
membrane] 
GO:0006605 [protein targeting] 
GO:0007157 [heterophilic cell-cell adhesion via 
plasma membrane cell adhesion molecules] 
GO:0007158 [neuron cell-cell adhesion] 
GO:0007399 [nervous system development] 
GO:0007416 [synapse assembly] 
GO:0009897 [external side of plasma membrane] 
GO:0009986 [cell surface] 
GO:0010841 [positive regulation of circadian 
sleep/wake cycle, wakefulness] 
GO:0014069 [postsynaptic density] 
GO:0016080 [synaptic vesicle targeting] 
GO:0016339 [calcium-dependent cell-cell 
adhesion via plasma membrane cell adhesion 
molecules] 
GO:0017146 [NMDA selective glutamate 
receptor complex] 
GO:0023041 [neuronal signal transduction] 
GO:0030054 [cell junction] 
GO:0030165 [PDZ domain binding] 
GO:0030425 [dendrite] 
GO:0031175 [neuron projection development] 
GO:0032230 [positive regulation of synaptic 
transmission, GABAergic] 
-1.26 
(8.92%) 
0.76 1.37 
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GO:0032433 [filopodium tip] 
GO:0035418 [protein localization to synapse] 
GO:0042043 [neurexin family protein binding] 
GO:0043197 [dendritic spine] 
GO:0043198 [dendritic shaft] 
GO:0045184 [establishment of protein 
localization] 
GO:0045202 [synapse] 
GO:0045211 [postsynaptic membrane] 
GO:0045664 [regulation of neuron 
differentiation] 
GO:0046983 [protein dimerization activity] 
GO:0048488 [synaptic vesicle endocytosis] 
GO:0048489 [synaptic vesicle transport] 
GO:0048511 [rhythmic process] 
GO:0048789 [cytoskeletal matrix organization at 
active zone] 
GO:0050804 [modulation of synaptic 
transmission] 
GO:0050808 [synapse organization] 
GO:0050839 [cell adhesion molecule binding] 
GO:0051260 [protein homooligomerization] 
GO:0051290 [protein heterotetramerization] 
GO:0051491 [positive regulation of filopodium 
assembly] 
GO:0051965 [positive regulation of synapse 
assembly] 
GO:0051968 [positive regulation of synaptic 
transmission, glutamatergic] 
GO:0060076 [excitatory synapse] 
GO:0060291 [long-term synaptic potentiation] 
GO:0060999 [positive regulation of dendritic 
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spine development] 
GO:0061002 [negative regulation of dendritic 
spine morphogenesis] 
GO:0072553 [terminal button organization] 
GO:0097091 [synaptic vesicle clustering] 
GO:0097104 [postsynaptic membrane assembly] 
GO:0097105 [presynaptic membrane assembly] 
GO:0097110 [scaffold protein binding] 
GO:0097113 [AMPA glutamate receptor 
clustering] 
GO:0097114 [NMDA glutamate receptor 
clustering] 
GO:0097115 [neurexin clustering involved in 
presynaptic membrane assembly] 
GO:0097119 [postsynaptic density protein 95 
clustering] 
GO:0097120 [receptor localization to synapse] 
GO:0097481 [neuronal postsynaptic density] 
GO:1900029 [positive regulation of ruffle 
assembly] 
GO:1900244 [positive regulation of synaptic 
vesicle endocytosis] 
GO:1902474 [positive regulation of protein 
localization to synapse] 
GO:1902533 [positive regulation of intracellular 
signal transduction] 
GO:2000302 [positive regulation of synaptic 
vesicle exocytosis] 
GO:2000310 [regulation of N-methyl-D-aspartate 
selective glutamate receptor activity] 
GO:2000311 [regulation of alpha-amino-3-
hydroxy-5-methyl-4-isoxazole propionate 
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selective glutamate receptor activity] 
GO:2000463 [positive regulation of excitatory 
postsynaptic potential] 
GO:2000809 [positive regulation of synaptic 
vesicle clustering] 
Inclusion body 
myositis 
AUTS2 
AUTS2, activator of 
transcription and 
developmental 
regulator 
Neurological disorders; 
acute lymphoblastic 
leukaemia; aging of the 
skin; early-onset 
androgenetic alopecia; 
cancer 
GO:0003674 [molecular function] 
GO:0003682 [chromatin binding] 
GO:0005515 [protein binding] 
GO:0005575 [cellular component] 
GO:0005634 [nucleus] 
GO:0008150 [biological process] 
GO:0045944 [positive regulation of transcription 
from RNA polymerase II promoter] 
GO:0051571 [positive regulation of histone H3-
K4 methylation] 
GO:0060013 [righting reflex] 
GO:0098582 [innate vocalization behaviour] 
GO:2000620 [positive regulation of histone H4-
K16 acetylation] 
-1.94 
(3.32%) 
1.00 0.51 
LILRB3 
Leukocyte 
immunoglobulin like 
receptor B3 
Lung diseases; 
Takayasu's arteritis 
GO:0002250 [adaptive immune response] 
GO:0004872 [receptor activity] 
GO:0004888 [transmembrane signalling receptor 
activity] 
GO:0005515 [protein binding] 
GO:0005887 [integral component of plasma 
membrane] 
GO:0006952 [defence response] 
GO:0007166 [cell surface receptor signalling 
pathway] 
GO:0045671 [negative regulation of osteoclast 
differentiation] 
0.79 
(81.49%) 
0.00 97.17 
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Schizophrenia 
ARHGAP11B 
Rho GTPase 
activating protein 
11B 
15q13.3 microdeletion 
syndrome 
GO:0005829 [cytosol] 
GO:0007165 [signal transduction] 
GO:0007264 [small GTPase mediated signal 
transduction] 
GO:0021987 [cerebral cortex development] 
GO:0051056 [regulation of small GTPase 
mediated signal transduction] 
0.07 
(52.75%) 
0.07 81.20 
ARHGAP5 
Rho GTPase 
activating protein 5 
Liver carcinoma; breast 
cancer 
GO:0003924 [GTPase activity] 
GO:0005096 [GTPase activator activity] 
GO:0005515 [protein binding] 
GO:0005525 [GTP binding] 
GO:0005737 [cytoplasm] 
GO:0005829 [cytosol] 
GO:0007155 [cell adhesion] 
GO:0007165 [signal transduction] 
GO:0007264 [small GTPase mediated signal 
transduction] 
GO:0007266 [Rho protein signal transduction] 
GO:0016020 [membrane] 
GO:0042169 [SH2 domain binding] 
GO:0043547 [positive regulation of GTPase 
activity] 
GO:0051056 [regulation of small GTPase 
mediated signal transduction] 
-1.31 
(8.10%) 
0.99 8.15 
 
Table 5.2. Selected genes within CNV regions of interest. Genes that are in the RefSeq database (http://www.ncib.nlm.nih.gov/gene) and Ensembl database 
(http://www.ensembl.org) are reported. Gene ontology data from the Gene Ontology Project (http://www.geneontology.org). RVIS v4 is constructed on the ExAC v2 data 
release (Petrovski et al., 2013).  
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5.2.1.1 Inclusion body myositis (AFF and UNAFF) 
The twin pair discordant for inclusion body myositis yielded four CNVs. This included a 
92115bp CNV duplication containing DISC1 (chr1:231711489-231803604), located in 
the region 1q42.2; two CNV duplications overlapping AUTS2, which is likely a larger 
CNV falsely called as two (chr7:69966192-70295629); and finally, a CNV duplication 
(chr19:54731679-54740705) in the region 19q13.42 overlapping LILRB3. An important 
paralog of this gene is LILRB1, which has been associated with idiopathic inflammatory 
myopathies (Schleinitz et al., 2008). Although DISC1 and AUTS2 are known to be 
strongly implicated in schizophrenia (Ayalew et al., 2012) and autism (Oksenberg and 
Ahituv, 2013) respectively, neither twin presented with psychiatric symptoms to our 
knowledge. CNVs overlapping AUTS2 and LILRB3 were validated with ExomeDepth. 
5.2.1.2 Attention deficit hyperactivity disorder (RP and OH) 
Three putative de novo CNVs were detected in both twins, but were absent in the parents 
(Table 5.1). The CNV duplication on chromosome 4p15.32 covers >85% proximal of 
CD38, a gene encoding for a multifunctional ectonucleotidase involved in signal 
transduction, cell adhesion and calcium signalling. Interestingly, CD38 has previously 
been implicated in ADHD (Ebstein et al., 2014), including social memory, amnesia and 
autism spectrum disorder (Higashida et al., 2012). This gene was called as discordant, 
however manual reviewing revealed that it was falsely undercalled in the unaffected twin. 
These CNVs were not analysed by ExomeDepth or experimentally validated. 
 
164 
 
5.2.1.3 Tourette’s syndrome (489 and 490) 
The twins discordant for Tourette’s syndrome inherited four CNVs from the mother. An 
apparent CNV deletion (CN=1) in the mother and father (chr2:90108545-90109261) was 
also present in the twins, but was expanded by 121,501bp. This resulted in a loss of 
immunoglobulin kappa variable genes in the twins. CNVs have been found to undergo 
modification in size when transmitted from parent to offspring (South et al., 2008). 
However, this CNV should be at best regarded as tentative, as it is in close proximity to 
the centromere. Various CNV analysis protocols recommend removing called CNVs in 
HLA regions, and genomic regions that are near centromeres and telomeres. Conversely, 
enrichments of germline CNVs near assembly gaps and in regions of low-mappability 
have shown to be reliable (Monlong et al., 2015), as they can be the result of reduced 
selection pressure, rather than faults of the detection tools. 
The multiple CNVs in the twins include maternally-inherited duplications of NLGN1 and 
TOP3B. A CNV duplication on chromosome 22q11.22 (22313954-22550078) 
overlapped >90% of TOP3B, a gene that has been implicated in neurodevelopmental 
disorders (Stoll et al., 2013). Further, a CNV duplication on chromosome 3q26.31 
contained NLGN1, a gene involved in forming excitatory synapses and maintaining 
synaptic plasticity (Hoy et al., 2013).  
The affected twin was diagnosed with Tourette’s syndrome at the age of seven. 
Interestingly, the father was also diagnosed with Tourette’s syndrome at the same age, in 
addition to OCD and ADHD. The mother, however, was reported to be asymptomatic. 
Moreover, both twins have a putative de novo CNV deletion in a non-genic region 
(chromosome 5q22.3; location 113429984-113435957). These CNVs were not 
computationally or experimentally validated. 
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5.2.1.4 Ischaemic stroke (KG and HG) 
DNA from this twin pair was extracted from blood (HG(b) and KG(b)) and saliva (HG(s) 
and KG(s)). A CNV duplication on chromosome 4q25 was found in both twins, containing 
ELOVL6. No intra-tissue CNV differences were detected in the SNP array analysis and 
ExomeDepth analysis confirmed this CNV. ELOVL6 plays an important role in fat 
metabolism and insulin sensitivity (Matsuzaka and Shimano, 2009), and has been 
associated with heart failure, obesity, atherosclerosis, psoriasis, and atopic dermatitis 
(Uchida, 2011). These twins have a family history of hypertension, depression and 
psoriasis, and where diagnosed with atopic dermatitis (HG) and seborrheic dermatitis 
capitis (KG). Chapter 6 contains a detailed clinical history of these twins. 
5.2.1.5 Lactose intolerance (KIR and KEL) 
A large CNV duplication spanning 40 probes was detected on chromosome 19p13.2 
(6904195-7103542) in both twins. Interestingly, the CNV spans genes that are related to 
gastrointestinal disorders, including MBD3L2 (stomach neoplasms), ADGRE4P 
(colorectal cancer metastatic), and ADGRE1 (liver cirrhosis). Lactose intolerance has 
shared genes with colorectal cancer (LCT, CASR, GLB1), and liver cirrhosis (CASR and 
GLB1) (Andrzej et al., 2015). This CNV was validated with ExomeDepth analysis.
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Figure 5.1. Results of chromosomal microarray analysis in KEL and KIR. A duplication (CN = 3) is depicted by the BAF plot splitting into two new populations of data points 
representing the allelic ratios 1:2 and 2:1 (genotypes ABB and AAB). The red rectangle contains the identical 199 kb duplicated genomic region on chromosome 19p13.2. 
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5.2.1.6 Hereditary spastic paraplegia (VF and LF) 
VF was diagnosed with predominant HSP superimposed with dystonia. Her identical twin 
sister (LF) and sixteen-year-old son later presented with similar, but milder, symptoms. 
Further clinical details of VF can be found in section 4.2.1.1. A shared hemizygous 
deletion (CN = 1) of ~60 kb on chromosome 2p22.1 was found in both twins, containing 
SLC8A1 (see Figure 5.1). This gene was not confirmed with ExomeDepth. This could be 
due to the limitations of exome sequencing CNV detection tools in being able to detect 
smaller CNVs that range between 1-4 exons (Yao et al., 2017). Unfortunately, DNA of 
the proband’s son, who was also affected, was not available for segregation analysis. 
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Figure 5.2. Results of chromosomal microarray analysis in VF and LF. A hemizygous deletion (CN = 1) is depicted as a loss of heterozygotes in the BAF plot and loss of signal 
intensity in the LRR plot. The red rectangle contains the identical 62 kb deleted genomic region on chromosome 2p22.1. 
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5.2.1.7 Schizophrenia (IP16 and IP17) 
The largest CNV identified by SNP array analysis was a 399 kb duplication on 
chromosome 14q12 (32164373-32563640) overlapping genes NUBPL and ARHGAP5. 
This was confirmed with exome sequencing CNV calling using ExomeDepth. 
According to the Database of ClinGen Dosage Sensitivity Map, the haploinsufficiency 
score of 8.15% (high rank = 0-10%) and pLI score of 0.99 suggests that duplication of 
ARHGAP5 may be pathogenic. ARHGAP5 also appears to be intolerant of variation 
with a genic intolerance score of -1.31, while being among the top 8% of most 
intolerant genes. 
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Figure 5.3. Results of chromosomal microarray analysis in IP16 and IP17. A duplication (CN = 3) is depicted by the BAF plot splitting into two new populations of data points 
representing the allelic ratios 1:2 and 2:1 (genotypes ABB and AAB). The red rectangle contains the identical 359 kb duplicated genomic region on chromosome 14q12. 
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5.2.1.8 Schizophrenia (RT1a and RT1b) 
Both SNP array and exome sequencing CNV calling revealed a 138 kb hemizygous 
deletion in 15q13.2 (chr15:30950529-31088443) (Figure 5.1) covering ARHGAP11B in 
both twins. Due to lack of probe coverage in this region, it was difficult to ascertain an 
accurate size of the deletion. The CNV could potentially have extended to left-flanking 
neighbouring genes, including CHRFAM7A. 
ARHGAP11B was of particular interest as gene ontology terms include cerebral cortex 
development. It promotes development and evolutionary expansion of the brain neocortex 
and it is able to promote amplification of basal progenitors in the subventricular zone, 
producing more neurons during foetal corticogenesis. CNV deletions containing 
ARHGAP11B has previously been associated with schizophrenia (Levinson et al., 2011). 
The segment overlaps with CNVs recorded in the Database of Genomic Variants 
(http://dgv.tcag.ca/dgv/app/home). There are various syndromes, including 
schizophrenia, associated with this gene in the Database of Chromosomal Imbalance and 
Phenotype in Humans Using Ensemble Resources (DECIPHER), but the region deleted 
in this case is unique in that it encompasses the genes that were not associated with 
schizophrenia on their own. ClinVar has 93 records that mention ARHGAP11B; 38 of 
which are deletions, and of these 36 are considered pathogenic. No variants are confined 
to only ARHGAP11B. 
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Figure 5.4. Results of chromosomal microarray analysis in RT1a and RT1b. A hemizygous deletion (CN = 1) is depicted as a loss of heterozygotes in the BAF plot and loss of 
signal intensity in the LRR plot. The red rectangle contains the identical 138 kb deleted genomic region on chromosome 15q13.2. The full extent of the deletion cannot be 
determined due to the absent probes in the left flanking region. 
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Figure 5.5. Visual representation of protein-coding RefSeq genes that could potentially be included in the CN deletion detected by the SNP array. Screen capture of the deleted 
region in 15q13.2 from UCSC Genome Browser GRCh37/hg19.
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5.2.2 CNV validation with ddPCR 
ddPCR was performed to validate the 138 kb CNV deletion spanning ARHGAP11B in 
the twins with schizophrenia (RT1a and RT1b). This technique uses an emulsion PCR 
approach to create many thousands of microvolume PCR reactions, with droplets counted 
at endpoint for presence or absence of the test and reference PCR products (Ottolini et 
al., 2014). Although the microarray and exome sequencing analyses confirmed the CNV 
in these twins, ddPCR results were inconclusive (Table 5.3). Due to the relatively low 
amounts of DNA required for the ddPCR protocol (~10ng), and the highly complex nature 
of this region, experiments were carried out on all twin pairs in our cohort. 
 
 Gated by NTC Gated by Positive Cluster Copy number 
change Sample ID Well 1 Well 2 Avg. CN Well 1 Well 2 Avg. CN 
NTC 
No 
Amp. 
No 
Amp. 
No 
Amp. 
No 
Amp. 
No 
Amp. 
No 
Amp. 
N/A 
NA12878 2.35 2.80 2.58 1.81 2.22 2.02 Gain 
NA10851 1.94 2.09 2.02 1.00 1.10 1.05 Normal 
NA11892 1.96 2.14 2.05 0.95 0.96 0.96 Normal 
NA11894 2.17 2.12 2.15 1.00 1.00 1.00 Normal 
1P16 1.43 1.40 1.42 0.01 0.04 0.03 Loss 
1P17 1.70 1.52 1.61 0.07 0.08 0.07 Loss 
218 1.96 2.06 2.01 0.95 0.97 0.96 Normal 
318 2.08 1.97 2.03 0.98 0.93 0.95 Normal 
242 1.52 1.35 1.44 0.04 0.05 0.05 Loss 
243 1.54 1.46 1.50 0.04 0.06 0.05 Loss 
421 2.13 2.14 2.14 0.94 1.02 0.98 Normal 
422 2.18 1.95 2.07 1.11 0.98 1.04 Normal 
487 2.65 2.78 2.72 1.93 2.09 2.01 Gain 
488 2.37 1.92 2.15 1.09 0.91 1.00 Normal 
489 2.59 3.03 2.81 1.92 2.33 2.13 Gain 
490 2.82 2.67 2.75 2.12 1.99 2.06 Gain 
AFF 2.24 2.14 2.19 1.04 1.12 1.08 Normal 
UNAFF 1.97 2.22 2.10 0.86 1.00 0.93 Normal 
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DS 2.13 2.30 2.22 0.97 1.11 1.04 Normal 
DV 2.28 2.27 2.28 1.13 1.06 1.10 Normal 
RP 2.15 2.24 2.20 0.99 1.13 1.06 Normal 
OH 2.11 2.09 2.10 1.07 1.10 1.09 Normal 
HG(b) 2.29 2.49 2.39 1.03 1.29 1.16 Normal 
HG(s) 2.30 2.08 2.19 1.03 1.04 1.04 Normal 
KG(b) 2.12 2.17 2.15 1.10 1.00 1.05 Normal 
KG(s) 2.06 2.21 2.14 0.98 1.14 1.06 Normal 
KEL 1.58 1.56 1.57 0.09 0.10 0.09 Loss 
KIR 1.88 1.59 1.74 0.10 0.06 0.08 Loss 
PD161 2.10 2.09 2.10 1.06 1.00 1.03 Normal 
PD821 2.86 2.42 2.64 1.33 1.21 1.27 Gain 
RT1a 1.62 1.83 1.73 1.07 1.23 1.15 Normal or loss 
RT1b 1.76 1.76 1.76 1.08 1.12 1.10 Normal or loss 
LF 2.43 2.25 2.34 1.20 1.09 1.15 Gain 
VF 2.03 2.07 2.05 0.99 0.93 0.96 Normal 
SUS 1.61 1.50 1.56 0.07 0.03 0.05 Loss 
 
Table 5. 3. Summary of ddPCR results. Green and red colours indicate a gain and loss in CN, respectively. 
The yellow highlight shows the results for twins with schizophrenia, in whom the CNV deletion was 
detected by exome sequencing and SNP array CNV calling. One twin (LAS) was not processed due to 
limited DNA availability. Samples NA12878, NA10851, NA11892, NA11894 are individual controls from 
the 1000 Human Genome Project. It was assumed that they will have a CN of 2. NTC = No template control.  
 
There are several reasons why the ddPCR results might be unreliable. The frequency of 
the ARHGAP11B deletion in our twin cohort is incongruent to the frequencies that have 
been observed in other studies with larger sample sizes. For instance, loss of 
ARHGAP11B was detected in 8 of 1257 patients with autism spectrum disorder (0.64%) 
and in 4 of 1577 controls (0.25%) (Leblond et al., 2012). The fact that ddPCR detected a 
deletion in 4 of 13 twin pairs in our cohort (31%), suggests that the probes used may not 
be specific. The twins discordant for Parkinson’s disease, moreover, were discordant for 
the CN, and the microarray and exome sequencing CNV calling did not detect this 
deletion in any of the twin pairs except RT1a and RT1b.  
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Nevertheless, it is interesting to note that the apparent deletion was detected in the other 
twins discordant for schizophrenia (IP16 and IP17), And in RT1a and RT1b, the results 
were borderline when gated by no template control (mean values 1.73 and 1.76, 
respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. 2-D fluorescence amplitude plot shows duplicate wells of each twin sample with the 
ARHGAP11B assay. The black cluster on the plot represents the negative droplets, the blue cluster 
represents the droplets that are positive for ARHGAP11B. Red circle indicates a deletion. 
 
NA10851 NTC 
IP16 IP17 
RT1a RT1b 
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 Discussion 
CNV analysis was carried out to investigate potential structural alterations to support the 
exome sequencing data. After CNV merging and manual reviewing of CNV calls, all 
CNVs between co-twins were found to be concordant. Although these results argue 
against a role of large structural rearrangements as a molecular aetiology of the observed 
clinical differences between the MZ twins, it is interesting to note that some of the genes 
within concordant CNVs have previously been implicated in the corresponding disorder 
of the affected twin. 
5.3.1 Clinical significance of detected CNVs 
5.3.1.1 Tourette’s syndrome: What makes you tic? 
The CNV duplication overlapping TOP3B (chr22:22313954-22560977) that was 
inherited from the mother may have contributed to an existing predisposition inherited 
from the father, and thus contributed to disease manifestation in the affected twin. This 
‘two-hit’ hypothesis of the development of neuropsychiatric disorders may explain 
several observations in this case (Maynard et al., 2001).  
It is likely that both twins (489 and 490) have a predisposition to develop Tourette’s 
syndrome from the father’s side. An inherited stop loss mutation (c.T1198C:p.X400Q) in 
AADAC, a candidate gene for Tourette’s syndrome (Bertelsen et al., 2016), was identified 
in the previous chapter. It is possible that the CNV duplication overlapping TOP3B and 
NLGN1 adds to this predisposition, and thus has a role to play in the manifestation of the 
disorder. TOP3B has previously been implicated in neurodevelopmental disorders (Stoll 
et al., 2013), and CNVs containing NLGN1 have previously been identified in individuals 
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with OCD, Tourette’s syndrome and autism (Pinto et al., 2014; Marshall et al., 2008; 
Gazzellone et al., 2016). 
The unaffected twin (489) remained asymptomatic at the time of DNA sample collection. 
It is not uncommon, however, for the unaffected twin in a discordant pair to have a 
delayed or mild manifestation of the disease in question. Also, where there’s a familial 
involvement, the second hit may not be needed depending on the nature of the 
predisposition. Environmental influences can also add to the familial predisposition and 
play a role in disease manifestation. 
5.3.1.2 Inclusion body myositis 
Previous studies strongly suggest that there is an active interaction between immune and 
muscle cells in the muscle microenvironment in myositis (Zheng et al., 2012). Depending 
on the cell type, this results in either stimulation or inhibition of immune cells. MHC class 
I is highly expressed in myositis muscle fibres, and the receptors that interact with MHC 
class I in myositis are undefined (Hirayasu and Arase, 2015). An important paralog of 
LILRB3, leukocyte immunoglobulin-like receptor 1, has been shown to be highly 
expressed in inflammatory cells in muscle, suggesting active communication between 
immune cells, such as antigen-presenting cells, and skeletal muscle (Hirayasu and Arase, 
2015). The duplication of LILRB3 in these twins could potentially be significant, although 
the pathophysiology of myositis and the role of inflammation in muscle fibre damage 
remain poorly understood at the molecular level. 
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5.3.1.3 Hereditary spastic paraplegia 
SLC8A1 contributes to Ca2+ transport during excitation-contraction coupling in muscle, 
and is required for normal embryonic heart development and the onset of heart 
contractions (Shimizu et al., 2016). With a pLI score of 0.99 and HIS of 6.09%, SLC8A1 
is very intolerant to variation. Based on the allele frequencies from the NHLBI-ESP6500 
data set, this gene has a RVIS of -1.41, and is among the 7% most intolerant of human 
genes (Petrovski et al., 2013;  http://genic-intolerance.org). However, this gene has not 
been linked to dystonia, HSP or other movement disorders. 
5.3.1.4 Ischaemic stroke: The clot thickens 
ELOVL6 is regulated by a variety of methods by the cells, determined though expression 
and direct inhibition. Saito et al. (2011) note that expression of Elovl6 is directly regulated 
by sterol regulatory element-binding protein-1a, -1c, and -2, including other lipogenic 
enzymes such as fatty acid synthase and stearoyl coenzyme A desaturase. Suppression of 
Elovl6 expressioncan be brought about by dietary n-3 polyunsaturated fatty acids, such 
as eicosapentaenoate and docosahexaenoate acid (Kumadaki et al., 2008). 
ELOVL6 is a rate-limiting long-chain fatty acid elongase and specifically catalyses the 
elongation of saturated and monounsaturated fatty acids, providing important constituents 
of triglycerides, esterified cholesterol, and phospholipids (Saito et al., 2011). It has been 
proposed that inhibition of ELOVL6 could be a potential therapeutic target for a variety 
of cardiovascular diseases, such as insulin resistance, diabetes, and atherosclerosis (Saito 
et al., 2011). It is therefore possible that the duplication of this gene has led to an increase 
in the levels of this enzyme and this has contributed to the increased stoke risk experience 
by KG. 
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5.3.1.5 Schizophrenia: Mind the GAP. 
A deletion in ARHGAP11B (CN = 1) and a duplication in ARHGAP5 (CN = 3) were 
identified in two twin pairs discordant for schizophrenia. ARHGAP gene products belong 
to the Rho family of GTP-binding proteins, which are involved in membrane/cytoskeletal 
reorganisation events. There are approximately 80 distinct RhoGAP domain-containing 
proteins that are encoded in human DNA. 
These proteins cycle between active GTP-bound and inactive GDP-bound forms. 
Activation to the GTP-bound state is mediated by specific guanine nucleotide dissociation 
stimulators, whereas acceleration of GTP hydrolysis can be accomplished by GTPase-
activating proteins (GAPs). GTPases are important regulators of signalling pathways that 
link growth factors and/or their receptors to adhesions and associated structures (Potkin 
et al., 2008), and consequently influence the shape and migration of cells. 
Ligand binding to the epidermal growth factor (EGF) receptor initiates numerous 
signalling pathways; one of these is mediated by Ras, which leads to enhanced cell 
proliferation. EGF receptor signalling can also induce cell motility, mitosis, 
differentiation and protein secretion (Wells, 1999). The EGF receptor family of receptors 
are localised on subventricular neural progenitor cells in foetal and adult brains, and these 
progenitors give rise to forebrain neurons in development and after injury in the adult 
(Fallon et al., 2000). 
The ARHGAP5 gene product (a GTPase-activating protein for Rho family members) is 
linked to Ras, and thus to EGF receptor-mediated proliferation, migration and 
differentiation of forebrain progenitors. Therefore, a ARHGAP5 duplication in an MZ 
twin pair discordant for schizophrenia might point to an aetiological basis, because 
schizophrenia has been linked to altered prenatal neurogenesis of cortical neurons 
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(Akbarian, 1993). In addition, ARHGAP5 and ARHGAP11B are contained within regions 
14q12 and 15q13.2, respectively, which have previously been associated with 
schizophrenia (Lavedan et al., 2008: Chen et al., 2016). 
Of special mention is the gene ARHGAP11B, which resides on chromosome 15q13.2, one 
of the most complex and unstable loci in the human genome. Several neurodevelopmental 
disorders have been linked to structural variants in this and nearby regions (Antonacci et 
al., 2014; El-Hattab et al., 2009; Shinawi et al., 2009). ARHGAP11B arose from partial 
duplication of ARHGAP11A in the human lineage, approximately one million years after 
divergence from chimpanzees, but before divergence from Neanderthals (Florio et al., 
2015). This led to the formation of large and complex human-specific segmental 
duplications, mediating recurrent rearrangements contributing to 15q13.3 microdeletion 
syndrome associated with intellectual disability, epilepsy and schizophrenia (Dennis and 
Eichler, 2016). Remarkably, all events were related to the chromosome 15 core duplicon 
containing GOLGA, suggesting that these sequences have a fundamental role in the cycles 
of chromosomal rearrangement and segmental duplication expansions (Antonacci et al., 
2014). GOLGA sequences might possess favoured sites for microhomology-mediated 
break-induced replication, mechanisms which may induce segmental duplication 
formations (Payen et al., 2008). 
ARHGAP11B is, to date, the only human-specific gene shown to promote basal progenitor 
generation and proliferation, including cortical plate augmentation and gyrification 
induction. However, unlike ARHGAP11A, which encodes a RhoGAP, ARHGAP11B does 
not exhibit RhoGAP activity. This is owed to a single C>G base substitution in ancestral 
ARHGAP11B producing a new splice donor site in the modern version of the gene, 
resulting in GAP domain truncation with the addition of a human-specific C-terminal tail. 
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Florio et al. (2016) propose that this small genomic alteration led to increased basal 
progenitors during neocortex development, and plays an important role in the 
evolutionary expansion of the human neocortex.  
Several factors could account for why the CNV identified by SNP array and exome 
sequencing analysis was not validated with ddPCR. The highly complex segmental-
duplication architecture surrounding this region could potentially result in many sites of 
rearrangement and these conformations may vary among individuals. This provides the 
potential for alternate sites of rearrangement. This has been observed for the Angelman 
and Prader-Willi syndromes, for which uncharacteristic breakpoints have been mapped 
to other duplication structures (Locke et al. 2004). Other possibilities include genomic 
misassembly of these regions and incorrect mapping of the ddPCR probes used for CNV 
validation. Finally, if nonallelic homologous recombination is the underlying mechanism 
of rearrangement in this region, then additional repair or recombination events could 
result in more complex rearrangements. Nonetheless, this study shows that segmental 
duplications play an important role in normal variation as well as in genomic disease, 
defining hotspots of rearrangement that are susceptible to variation among the normal 
population. We propose that regions 15q13.2-13.3 are exceptional candidate sites that 
may be associated with neuropsychiatric disorders, and this preliminary study provides 
the necessary baseline to begin future studies on disease populations. 
The duplicated 8 exons of ARHGAP11A is almost identical to the paralogous sequence of 
ARHGAP11B, and thus is not completely queried in high throughput genetic studies. 
Indeed, variations in this region have flown below the radar of available genome-wide 
technologies, which likely has downplayed its hypothesised associations with 
neurodevelopmental disorders. Because of the genomic complexity of the region, the 
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extent of human structural diversity and breakpoints of most rearrangement events are 
poorly understood at the molecular genetic level. Moreover, the wide expression of 
ARHGAP11B, its multiple functions and modes of regulation – not to mention its absence 
in non-human animals – present challenges for its study in disease. 
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Figure 5.7. A schematic diagram showing eight independent rearrangements at the 15q13.2/13.3 region. Coloured boxes indicate the breakpoints identified for each 
rearrangement. The size and percent similarity of the paralogous sequences at the rearrangement breakpoints are shown. Figure from Antonacci et al. (2014).
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Several RhoGAPs have been linked to schizophrenia. For example, a study reported an 
association between variation in the ARHGAP32 gene, a neuron-associated GTPase-
activating protein (Okabe et al., 2003), and schizophrenia and schizotypal personality 
traits (Ohi et al., 2012). ARHGAP33 regulates synapse development and autistic-like 
behaviour (Schuster et al., 2015). A missense polymorphism in CHN2 (also known as 
ARHGAP3) has been associated with schizophrenia in men (Hashimoto et al., 2005).  
In a genome-wide association study (GWAS) from the Han Chinese population, Wong et 
al (2014) identified a schizophrenia susceptibility locus on Xq28, which harbours the 
gene ARHGAP4 (Wong et al., 2013). In a study that used differential brain imaging 
activation patterns to determine candidate genes associated in schizophrenia, two 
candidate genes, RSRC1 and ARHGAP18, were identified, both of which have a function 
in prenatal brain development. 
Considering the above findings, we propose that both ARHGAP5 and ARHGAP11B are 
interesting novel candidate genes for schizophrenia. 
5.3.2 Limitations 
It has become apparent that CNVs are common in human populations and play a 
significant role in the aetiology of complex disorders (Maiti et al., 2011). However, there 
are methodological challenges in identifying disease-specific CNVs and establishing their 
mechanism of action in disease causation. 
It is possible that in the array-based analysis we missed true causative CNVs because our 
filtering criteria involved analysis with both PennCNV and cnvPartition. Using multiple 
software programs to identify CNVs has the advantage of increasing the specificity of 
CNV calls, but will have an undesirable decrease in sensitivity. With the HumanCore-24 
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BeadChips array having a median inter-marker spacing of 10kb, it is possible that we 
have missed smaller CNVs, or that mutational events are present involving small DNA 
changes. However, exome sequencing would have covered some of the areas of the 
genome that are not detectable per se using a SNP-array approach.  
Computational prediction of CNVs from exome sequence data remains challenging. 
There are several algorithms that are commonly used, each having different sensitivities, 
but with a shared limitation in being able to detect small CNVs. Additionally, exonic 
CNV discovery using microarrays has limitations in that some exons would not be 
covered due to the low probe density in those regions. Thus, the rationale for combining 
a computational prediction algorithm for exome sequencing data and a high-resolution 
SNP-array is to increase the sensitivity and specificity of CN detection. 
Moreover, array-based technologies have different degrees of genome coverage and there 
are many CNV calling algorithms. Although the Illumina HumanCore BeadChip 12v1 
appears to meet most of the criteria in terms of coverage for CNV calling, a gold standard 
algorithm for data analysis has not been determined (Castellani et al., 2014; Zhang et al., 
2011). Considering these limitations, whole-genome sequencing would have been an 
ideal choice to look for structural variants, as well as SNVs and indels, as it provides a 
more uniform and complete coverage of coding regions than current exome products 
(Meltz Steinberg et al., 2015). 
The literature contains different results regarding the role that CNVs play in the 
aetiological basis of phenotypic discordance observed in MZ twins (Bloom et al., 2013; 
Ehli et al., 2012; Ono et al., 2010). This study adds to the growing literature that 
postzygotic de novo CN events between twins are rare, as no reproducible CNV 
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differences were found to explain the phenotypic discordance in the MZ twin pairs 
investigated. 
This could be attributable to a relatively small sample size. Due to the statistical rarity of 
discordant MZ twins, this study only assessed thirteen twin pairs. Another explanation is 
that somatic CNVs are more likely to be present as mosaics. This hypothesis is in line 
with previous studies (Bruder et al., 2008; Forsberg et al., 2012; Magaard Koldby et al., 
2016). However, the statistics of identifying somatically mosaic (incomplete) CNVs by 
SNP concordance analysis requires further methodological development beyond the 
scope of this study. 
5.3.3 Conclusion 
In summary, no CNV differences between co-twins or tissue types within a single 
individual were found. While this study did not provide decisive evidence for somatic 
genetic alterations as a mechanism for phenotypic variability, it highlights the need for 
further genome-wide research into the identification of modifying factors in these 
disorders. It also illustrates that shared CNVs overlapping disease-susceptibility genes 
can increase the risk for complex disorders, even in discordant MZ twins. 
Four pre-twinning de novo CNVs were identified by the CN calling algorithms used, but 
were not experimentally validated. Three were found to not overlap any genes or 
regulatory regions. The tentative de novo CNV duplication found in the ADHD-
discordant twin pair overlapped >85% proximal of CD38, and will be validated as part of 
a future study. This data suggests that post-zygotic CNVs may not play a significant role 
in twin discordance. Nevertheless, the shared CNVs detected herein are important, as 
some germline and even common population CNVs may predispose individuals to 
various phenotypes. The ability to better predict the varying degrees of pathogenicity of 
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structural variants and elucidating the role of modifier genes could significantly improve 
medical management and genetic counselling. 
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Chapter 6. Biochemical and proteomic analysis of 
twins discordant for ischaemic stroke 
 Overview 
Stroke is a common disorder with significant morbidity and mortality, and complex 
aetiology involving both environmental and genetic risk factors. Although some of the 
major risk factors for stroke, such as smoking and hypertension, are well-documented, 
the underlying genetic and detailed molecular mechanisms remain largely elusive (The 
Lancet Neurology, 2013). Identification of biomarkers for stroke may help determine the 
aetiology, pathogenesis, clinical diagnosis and prognosis, and predict the outcome of 
pharmacological intervention such as thrombolysis. 
Ischaemic stroke is reported to be misdiagnosed in more than 1 in 7 patients during the 
initial presentation in the emergency department, and increases to two thirds in cases 
where only nontraditional symptoms are present (Lever et al., 2013). It is important to 
distinguish between ischaemic and haemorrhagic stroke, and to identify other mimics 
such as structural brain lesions, epilepsy and migraine (Cordonnier and Leys, 2008). 
Although neuroimaging investigations such as computed tomography (CT) and magnetic 
resonance imaging (MRI) are upheld as the current diagnostic paradigm, they have 
several shortcomings. Ischaemic stroke can often be isodense on CT making it difficult 
to distinguish from haemorrhagic stroke. Stroke diagnosis is, therefore, reliant on 
probability rather than certainty. MRI is more reliable than CT for stroke diagnosis, but 
it is more expensive and not often routinely available at presentation. This delay, along 
with the potential for misdiagnosis, opens the door for molecular biomarkers, in the forms 
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of proteins, lipids and metabolites, to support the clinical diagnosis of stroke, as well as 
to identify patients at risk and provide prognostic indicators. 
There are currently several candidate biomarkers that have been identified for stroke, but 
none are readily used in clinical practice as none have sufficient evidence (Jickling and 
Sharp, 2015). Thus, further studies and research are warranted. 
A pair of MZ twins (KG and HG) discordant for ischaemic stroke were recruited in this 
study. The 62-year-old sisters of Caucasian descent have lived together since birth 
suggesting they share very similar environmental risk factors. They have been with the 
same medical practice for at least 50 years, and there is a family history of hypertension. 
KG presented with a stroke in 2007 (aged 55 years). This has left her with persistent right-
sided weakness affecting her balance, speech, and walking. In 2007 an MRI scan 
confirmed a left ganglion infarct, ischaemic changes in both cerebral hemispheres, and a 
small right temporal infarct. A coincidental finding of a right-sided intracavernous 
internal carotid artery aneurysm measuring 9 mm was made in 2007, prior to the stroke. 
This has been managed conservatively ever since, consisting of routine periodic follow-
up imaging with MR angiography or CT angiography. Patients with significant aneurysm 
growth are strongly considered for interventional treatment, however KG refused this 
intervention despite hers measuring 10 mm in 2009. KG has not smoked for 7 years since 
the stroke, whereas HG, despite sharing the same risk factors and still smoking, has not 
had a stroke. 
In addition, KG was diagnosed with a single patch of alopecia areata in 1995 (aged 44), 
and more recently with seborrhoeic dermatitis capitis in 2012 (aged 60). HG was 
diagnosed with atopic dermatitis in 2004 (aged 53). These problems might be linked to a 
191 
 
family history of psoriasis (in father) and suggest an autoimmune disorder in the family 
(see Appendix D for a detailed medical history of the twins). 
This chapter outlines the clinical, cytogenetic, biochemical and proteomic profile 
comparisons between an MZ twin pair discordant for ischaemic stroke and cerebral 
aneurysm. 
 
 Results 
6.2.1 Cytogenetics 
Chromosome analysis was performed on GTG banded metaphases from synchronised 
peripheral lymphocyte cultures using standard procedures. GTG-banded chromosomes of 
peripheral blood lymphocytes showed a pericentric inversion on chromosome 5 in both 
KG and HG, with breakpoints at 5p13.1 and 5q11.2 (Figure 6.1). This rare pericentric 
inversion has been documented in previous studies, albeit with slightly different 
breakpoints (Concolino, 2002). The breakpoint in the short arm of chromosome 5 in this 
report is not in the cri du chat syndrome critical region, mapped in 5p15.3 for high pitched 
cry and in 5p15.2 for the remaining features (Beemer et al., 2008; Goodart, Butler and 
Overhauser, 1996). Concolino (2002) reports a family with the karyotype 
inv(5)(p15.1q11.2) that segregates with benign familial neonatal convulsions. Affected 
individuals were intellectually normal but had a history of convulsions in infancy and 
afebrile seizures later in childhood. Interestingly, KG was diagnosed with epilepsy and 
HG, although not given this diagnosis, had a marked delta response to photic stimulation 
(Appendix D). 
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Figure 6.1. Idiogram of chromosome 5 and representative G-banded karyotypes of KG. The normal 
chromosome 5 is depicted on the left, and the aberrant chromosome 5 with pericentric inversion, 
inv(5)(p13.1q11.2), is on the right.  
 
6.2.2 Blood biochemistry 
To investigate potential causes or effects of the stroke, a detailed biochemical comparison 
was undertaken on blood samples from the twins.  Blood samples were drawn from the 
twins by standard venesection into plain tubes and fluoride and EDTA anticoagulated 
tubes, just prior to lunch, and processed in parallel. A total of 59 individual markers were 
measured to check for renal, liver, glucose, cardiovascular, blood, immunological, and 
hormonal function (Table 6.1). The data were compared with the corresponding reference 
intervals for the age group. 
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Most of the results were within the normal range and similar between the sisters except 
for g-glutamyltransferase (GGT), an enzyme present in liver, but normally used to 
indicate alcohol-related liver disease, and ESR. A greater than 10-fold increase in GGT 
was identified in KG (244 U/L) compared to HG (23 U/L), the normal reference range 
being 8-40 U/L in females.  An even greater difference of >18-fold was observed for ESR 
(HG=2mm/h; KG=36mm/h; reference interval=1-20 mm/h). Review of the medical notes 
for both the patients established that KG had elevated levels of GGT (81 U/L) 
significantly above the normal range, as far back as 1993 (Figure 6.2), although these 
values continued to increase up to when she had stroke and beyond. By contrast, GGT 
readings for HG have been near constant over the same period, and always within the 
normal range. The medical notes also reveal significantly elevated ESR in KG as far back 
as 2009 (27 mm/h) and 2008 (55 mm/h) following the stroke. These findings were 
subsequently published (Vadgama, et al., 2015). 
 
 
 
 
 
 
 
 
 
194 
 
 
Figure 6.2. A comparison of variation in serum GGT over time. GGT readings were collected from 
patients’ notes. KG has had high GGT values since 1993, prior to the onset of stroke in 2007. The unaffected 
twin, HG, has had consistently low GGT values over time. The dotted horizontal line depicts the upper 
limit of the reference interval. 
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Table 6.1. A comparison of blood markers between MZ twins discordant for stroke. Blood samples were 
taken at the same time prior to lunch, and processed in parallel. GGT and ESR are significantly elevated in 
the affected, relative to the unaffected twin (Vadgama et al, 2015). 
Parameter Units HG KG Reference interval 
Fold 
difference 
                                                            Clinical Biochemistry 
GLUCOSE FLUORIDE mmol/L 4.0 6.6 3.0 — 6.0 (fasting) 1.7 
SODIUM mmol/L 138 134 133 — 146 1.0 
POTASSIUM mmol/L 4.2 4.6 3.5 — 5.3 1.1 
CHLORIDE mmol/L 93 96 95 — 108 1.0 
BICARBONATE mmol/L 31 25 22 — 29 1.2 
UREA mmol/L 4.3 4.0 2.5 — 7.8 1.1 
 CREATININE µmol/L 52 51 60 — 110 1.0 
BILIRUBIN µmol/L 5 3 0 — 21 1.7 
ALANINE TRANSAMINASE U/L 25 24 0 — 52 1.0 
ALKALINE PHOSPHATASE U/L 97 184 30 — 130 1.9 
ALBUMIN g/L 40 35 35 — 50 1.1 
GAMMA GT IU/L 23 244 0 — 38 10.6 
CALCIUM mmol/L 2.50 2.24 2.20 — 2.60 1.1 
PHOSPHATE mmol/L 2.08 1.27 0.80 — 1.50 1.6 
ADJUSTED CALCIUM mmol/L 2.50 2.34 2.20 — 2.60 1.1 
CREATINE KINASE U/L 83 54 40 — 320 1.5 
CHOLESTEROL mmol/L 4.4 3.7 0.90 — 2.20 1.2 
TRIGLYCERIDE mmol/L 1.14 0.56 0.80 — 2.00 2.0 
CHOLESTEROL HDL mmol/L 1.24 2.22 3.3 — 5.2 1.8 
CHOLESTEROL LDL (CALC) mmol/L 2.6 1.2 <3 2.2 
TOTAL CHOLESTEROL/HDL RATIO  3.5 1.7 0.0 — 5.0 2.1 
NON HDL CHOLESTEROL mmol/L 3.2 1.5  2.1 
C REACTIVE PROTEIN mg/L 11.9 25.8 0.0 — 10.0 2.2 
FREE T4 pmol/L 16.5 13.8 10.0 — 23.0 1.2 
TSH mU/L 0.89 1.03 0.40 — 5.00 1.2 
VITAMIN B12 ng/L 372 446 180 — 1000 1.2 
FOLATE µg/L 5.6 13.9 5.0 — 10.0 2.5 
                                                             Serum hormones and natriuretic peptide 
PROLACTIN mIU/L 66 123 86 — 324 1.9 
LH IU/L 21.1    17.1 >15 1.2 
FSH IU/L 60.9 52.0 >30 1.2 
OESTRADIOL pmol/L 100 61 <90 1.6 
PROGESTERONE nmol/L 2 <1 <2 - 
TESTOSTERONE nmol/L 2.2 1.6 0.4 — 2.7 1.4 
CARDIAC TROPONIN I ng/L <17 <17 0 — 50 - 
NT-PRO BNP ng/L 100 192   1.9 
                                                              Haematology 
HB g/L 144.0 105.0 130 — 180 1.4 
WBC 109/L 17.1 7.9 4.0 — 11.0 2.2 
PLATELET 109/L 244 207 150 — 450 1.2 
MCV fL 87.2 86.3 80 — 97 1.0 
ESR mm/h 2 36 1 — 20 18.0 
NEUTROPHIL 109/L 13.8 6.5 1.7 — 8.0 2.1 
LYMPHOCYTE 109/L 2.2 0.6 1.0 — 4.0 3.7 
MONOCYTE 109/L 0.7 0.4 0.24 — 1.1 1.8 
EOSINOPHIL 109/L 0.3 0.4 0.1 — 0.8 1.3 
BASOPHIL 109/L 0.1 0.1 0.0 — 0.3 1.0 
HCT  0.47 0.34 0.41 — 0.52 1.4 
RBC 1012/L 5.34 3.96 4.5 — 6.0 1.3 
MCH pg 26.9 26.5 27 — 33 1.0 
MCHC g/L 308 307  320 — 365 1.0 
RDW % 14.0 14.4 11.5 — 15.0 1.0 
LUC 109/L 0.1 0.1  0.0 — 0.4 1.0 
%Hypo RBC % 13.4 11.2  1.2 
Hb (calc) g/L 142.0 105.0  1.4 
MPXI  1.5 ^3.3 -20 — 100 2.2 
CD4 % 55 60  1.1 
CD3 TruCount 109/L 1.565 0.421  3.7 
CD4 TruCount 109/L 1.151 0.328  3.5 
CD8 TruCount 109/L 0.357 0.092  3.9 
TruCount Lymphs 109/L 2.171 0.550  3.9 
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6.2.3 Label-free proteomics analysis 
Preliminary analysis using unbiased, label-free proteomics technology identified 
potentially new protein biomarkers that are related to the pathophysiology of stroke. 
Proteins were extracted from serum samples collected from each twin. Following staining 
of the gel, a prominent band at approximately 60 kDa, corresponding mainly to albumin, 
was cut out from the gel to enhance the detection of less abundant proteins as albumin 
represents approximately 55% of total cellular protein (Walker, Hall and Hurst, 1990) 
(Figure 6.3). The proteins were eluted from the gel for proteomic studies, as described 
(see Materials and Methods). 
 
 
 
 
 
 
 
 
Figure 6.3. SDS-PAGE gel analysis. The 2 serum samples (KG and HG) were run on a 4-12% bis-tris with 
MOPS running buffer in decreasing concentrations: 0.5ul, 0.1ul, 0.05ul and 0.025ul (i.e. 1X, 1/5X, 1/10X 
and 1/20X dilutions). For the serum loading there appears to be more protein in the KG sample - this is 
based on the intensity of the stain used (Colloidal coomassie blue from Invitrogen) when compared to the 
first serum: HG. 
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The proteomes of the MZ twin pair discordant for stroke were quantified and compared 
at a post-symptomatic stage of the disorder. The proteins were first ranked according to 
the fold difference between the twins, including proteins that were present in only the 
affected or unaffected twin (data not shown). 
The functional analysis tool PANTHER and VLAD was used for statistical analysis. 
PANTHER is a database of gene families and gene attributes (Mi, Muruganujan and 
Thomas, 2012), which provides tools for functional analysis of lists of genes or proteins. 
VLAD is a functional analysis tool (Richardson and Bult, 2015) which uses the most up-
to-date GO annotation files. Gene lists were analysed statistically by enrichment analysis 
on 33 of the proteins that had a fold difference of >1.5 between the twins. The enrichment 
analysis takes a list of genes that have been ascribed with a numerical value, then finds 
functional classes for which the genes of that class have values that are non-randomly 
selected from the genome-wide distribution of values. PANTHER includes a Bonferroni 
correction to counteract the problem of multiple comparisons, whereas VLAD does not 
include any corrections. The summary table shows an interesting enrichment of blood 
coagulation, wound healing and inflammatory response, and a list of genes that have 
previously been implicated in ischaemic stroke (Table 6.2). 
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Term 
Panther VLAD  
P-value P k M Genes 
GO:1903034: regulation of 
response to wounding 
9.02E-15 1.01E-19 15 526 
A2M, AGT, APOA1, APOD, APOE, 
C5, CFH, CFI, F12, F2, HRG, PLG, 
S100A9, SERPINC1, THBS1 
GO:0080134: regulation of 
response to stress 
7.92E-11 2.97E-16 17 1400 
A2M, AGT, APOA1, APOD, APOE, 
C5, CFH, CFI, F12, F2, HP, HPX, 
HRG, PLG, S100A9, SERPINC1, 
THBS1 
GO:0006950: response to stress 7.47E-10 9.27E-15 24 4990 
A2M, AGT, APOA1, APOD, APOE, 
C5, CD5L, CFH, CFI, F12, F2, 
HBA1, HBB, HBD, HP, HRG, 
IGHG2, ORM1, PLG, S100A9, 
SERPINA3, SERPINC1, THBS1, 
VWF 
GO:0050727: regulation of 
inflammatory response 
6.02E-10 1.03E-14 11 367 
A2M, AGT, APOA1, APOD, APOE, 
C5, CFH, CFI, F12, S100A9, 
SERPINC1 
GO:0031347: regulation of 
defence response 
5.78E-08 4.10E-13 12 704 
A2M, AGT, APOA1, APOD, APOE, 
C5, CFH, CFI, F12, HPX, S100A9, 
SERPINC1 
GO:0009611: response to 
wounding 
1.09E-07 5.61E-13 13 951 
A2M, APOA1, APOD, APOE, F12, 
F2, HBB, HBD, HRG, PLG, 
SERPINC1, THBS1, VWF 
GO:0007596: blood 
coagulation 
8.75E-07 1.11E-12 11 564 
A2M, APOA1, F12, F2, HBB, HBD, 
HRG, PLG, SERPINC1, THBS1, 
VWF 
GO:0042060: wound healing 5.68E-07 2.21E-12 12 813 
A2M, APOA1, APOD, F12, F2, 
HBB, HBD, HRG, PLG, SERPINC1, 
THBS1, VWF 
GO:0030193: regulation of 
blood coagulation 
2.17E-07 1.49E-11 7 125 
APOE, F12, F2, HRG, PLG, 
SERPINC1, THBS1 
GO:0050896: response to 
stimulus 
4.64E-04 6.35E-08 26 12252 
A2M, AGT, APOA1, APOD, APOE, 
C5, CD5L, CFH, CFI, DSG1, F12, 
F2, HBA1, HBB, HBD, HP, HRG, 
IGHG2, ORM1, PLG, S100A9, 
SERPINA3, SERPINA7, SERPINC1, 
THBS1, VWF 
 
Table 6.2. Summary findings of PANTHER analysis with results compared to VLAD analysis. P-values 
for PANTHER analysis include Bonferroni correction. For the VLAD analysis, the P-value scoring method 
was selected, thus displaying the node’s scores as a triple (P, k, M). P = the node's P-value; k = the number 
of genes in the query set annotated to that node; M = the number of genes in the database annotated to that 
node. 
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In the preliminary analysis above, only one run was performed per sample as a proof of 
principle. This generated semi-quantitative data as no technical replicates were 
performed, and both the higher and lower level proteins were included in a single analysis, 
rather than separating them. Theoretically, this is a valid approach to take because some 
proteins might positively regulate a process, whereas others negatively regulate a process 
but they would still both regulate the same process. 
For a more comprehensive analysis, and with the aim to overcome the limit of 
reproducibility in the serum preparation, two additional runs were separately performed, 
each containing three technical replicates of control serum and serums of both twins 
(Figure 6.4). Thus 18 samples in total were analysed in nano-scale liquid chromatographic 
tandem mass spectrometry (nLC-MS/MS). 
 
Figure 6.4. Schematic diagram illustrating optimised experimental design for the second label-free 
proteomics comparison of the proteome of a pair of discordant MZ twins. 
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To identify the proteins that were differentially expressed between the affected and 
unaffected twin blood serum, ANOVA test was performed in Progenesis LC-MS that 
identified 179 and 209 proteins (P<0.05) in runs 1 and 2 respectively.  
Several of the proteins detected at higher levels in the serum of the affected twin had 
previously been associated with biological pathways relevant to ischaemic stroke, 
including haemoglobin subunit alpha 1 (Huang et al., 2009), alpha-2-macroglobulin 
(Nezu et al., 2013), hyaluronan binding protein 2 (Hanson et al., 2012), S100A8 (Ziegler 
et al., 2007) (Table 6.3). In addition, fibulin 1, an extracellular matrix protein associated 
with arterial stiffness (Cangemi et al., 2011), was present at a much higher level in the 
affected twin and had the highest fold difference average. Furthermore, the low serum 
levels of desmoplakin in the affected twin (and therefore identified as being at high levels 
in HG serum), has been inversely associated with ischaemic stroke (López-Farré et al., 
2012) (Table 6.4). 
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Gene 
symbol 
Approved gene name UniProt 
ID 
Run 1 Run 2 Average fold 
difference 
fold difference P-value fold 
difference 
P-value 
FBLN1 fibulin 1 P23142 2.79 8.27E-05 23.96 4.49E-02 13.37 
CA1 carbonic anhydrase 1 P00915 5.64 1.12E-05 4.84 5.89E-08 5.24 
PIGR polymeric immunoglobulin receptor P01833 8.29 3.97E-02 1.96 7.36E-05 5.12 
IGKV1-5 immunoglobulin kappa variable 1-5 P01602 2.22 1.31E-06 5.14 1.06E-05 3.68 
GPLD1 glycosylphosphatidylinositol specific phospholipase D1 P80108 3.85 6.56E-06 2.08 1.82E-04 2.96 
IGKV3-20 immunoglobulin kappa variable 3-20 P01620 2.38 3.47E-07 2.88 3.09E-03 2.63 
PZP PZP, alpha-2-macroglobulin like P20742 2.91 4.16E-06 2.03 2.43E-05 2.47 
C5 complement C5 P01031 3.44 4.77E-07 1.39 7.35E-05 2.42 
APOL1 apolipoprotein L1 O14791 1.47 3.61E-03 2.94 2.17E-04 2.21 
HBA1 hemoglobin subunit alpha 1 P69905 1.64 6.91E-07 2.69 5.39E-09 2.17 
A2M alpha-2-macroglobulin P01023 2.78 3.70E-09 1.48 1.00E-05 2.13 
HABP2 hyaluronan binding protein 2 Q14520 2.17 8.05E-04 1.89 1.60E-02 2.03 
IGLV3-19 immunoglobulin lambda variable 3-19 P01714 1.54 2.92E-06 2.14 4.06E-07 1.84 
C4BPA complement component 4 binding protein alpha P04003 2.20 1.05E-08 1.39 3.56E-04 1.80 
C7 complement C7 P10643 2.06 1.38E-04 1.49 1.06E-02 1.78 
FCN3 ficolin 3 O75636 1.76 6.90E-03 1.69 3.64E-04 1.72 
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Table 6.3. The top proteins identified at high levels in the affected twin compared with the unaffected twin (ranked by fold change) that were present in both runs. A fold change 
threshold of >1.5-fold was used as a cut off. Fold difference values in red indicate proteins which had been associated with stroke or stroke risk factors by other studies. 
 
 
 
 
 
 
 
S100A8 S100 calcium binding protein A8 P05109 1.43 1.59E-02 1.89 1.27E-02 1.66 
CD5L CD5 molecule like O43866 1.16 6.30E-03 1.91 2.36E-05 1.53 
F2 coagulation factor II, thrombin P00734 1.29 1.20E-03 1.72 4.26E-05 1.50 
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Table 6.4. The top proteins identified at high levels in the unaffected twin compared with the affected twin (ranked by fold change) that were present in both runs. A fold change 
threshold of >1.5-fold was used as a cut off. Fold difference values in red indicate proteins which had been associated with stroke or stroke risk factors by other studies. 
 
Gene name Protein name 
UniProt 
ID 
Run 1 Run 2 Average 
fold 
difference 
fold difference P-value 
fold 
difference 
P-value 
KRT17 keratin 17 Q04695 13.33 4.42E-05 4.08 1.70E-05 8.71 
SPTB spectrin beta, erythrocytic P11277 13.81 5.55E-07 2.60 7.52E-06 8.20 
SERPINA4 serpin family A member 4 P29622 6.95 3.33E-03 1.25 2.05E-02 4.10 
KRT16 keratin 16 P08779 4.60 1.47E-06 2.99 6.10E-05 3.79 
DSP desmoplakin P15924 2.72 4.11E-05 1.82 1.45E-02 2.27 
IGHG4 immunoglobulin heavy constant gamma 4 (G4m marker) P01861 2.80 2.71E-06 1.60 1.18E-03 2.20 
DSG1 desmoglein 1 Q02413 1.95 1.69E-06 1.99 2.96E-03 1.97 
KRT9 keratin 9 P35527 2.21 4.44E-06 1.60 3.29E-05 1.91 
CPN1 carboxypeptidase N subunit 1 P15169 2.10 8.88E-03 1.50 4.96E-03 1.80 
IGHA2 immunoglobulin heavy constant alpha 2 (A2m marker) P01877 1.80 1.59E-05 1.55 1.34E-03 1.68 
GAPDH glyceraldehyde-3-phosphate dehydrogenase P04406 1.68 2.62E-03 1.63 2.27E-03 1.65 
HPX hemopexin P02790 1.25 6.11E-02 1.81 2.15E-05 1.53 
IGHA1 immunoglobulin heavy constant alpha 1 P01876 1.45 2.37E-04 1.58 6.44E-04 1.52 
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6.2.4 Functional analysis: 
Functional analysis was performed independently on all 4 datasets of differentially expressed 
proteins, to classify the proteins according to ‘biological process’, ‘molecular function’ and 
‘cellular component’. The g:Profiler web server (Reimand et al., 2007; 
http://biit.cs.ut.ee/gprofiler/) comprises several tools to perform functional enrichment analysis 
and mine additional information. The statistical method used by this tool, g:SCS (Set Counts 
and Sizes, Reimand et al., 2007) takes into account the ontology structure supporting the 
annotations and enables significantly enriched GO terms to be identified within short lists of 
proteins (down to lists of only 11 proteins). 
Proteins were only included in the analysis if they were identified as at higher levels in either 
the affected or unaffected twin in both runs, or only one run. Proteins with high levels in one 
run, but low levels in the equivalent other run were excluded from the analysis. After applying 
this exclusion criteria, the number of proteins remaining were 125 and 156 in runs 1 and 2, 
respectively. Some of the protein identifiers associated with the differentially expressed 
peptides did not have any associated GO terms, and thus were not included in the g:Profiler 
analysis. In most cases these peptides were predicted to be derived from an immunoglobulin 
molecule. Overall, 95 and 139 proteins, in runs 1 and 2 respectively, were included in the 
analysis.  
The GO terms enriched in the serum of each twin were relevant to very different biological 
pathways. The ‘biological process’ GO categories overrepresented in the affected twin related 
to cytolysis, response to stress, and blood coagulation (Table 6.5 and Appendix B). With 
between 15-30% of the proteins differentially overexpressed in KG associated with wound 
healing and/or blood coagulation. In HG, the enriched GO terms were almost exclusively 
related to skin development (Table 6.6 and Appendix B).  
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Table 6.5. Selection of enriched GO terms associated with the proteins present at high levels in the affected twin. 
GO terms were identified as significantly enriched in the high level proteins in KG following g:Profiler analysis. 
P-values <0.05 are considered as significantly enriched. S = number of protein identifiers (IDs) in both the study 
dataset and GO term group, T = number of human protein IDs associated with the GO term, t = number of protein 
IDs in study or GO datasets. 
 
 
Table 6.6. Selection of enriched GO terms associated with the proteins at high levels in the unaffected twin. GO 
terms were identified as significantly enriched in the high level proteins in HG following g:Profiler analysis. P-
values <0.05 are considered as significantly enriched. S = number of protein identifiers (IDs) in both the study 
dataset and GO term group, T = number of human protein IDs associated with the GO term, t = number of protein 
IDs in study or GO datasets.
GO term P-value S 
t=50 
T 
t=18,711 
 P-value S 
t=77 
T 
t=18,711 
 Run 1  Run 2 
response to stress 1.59E-11 35 3579  1.28E-08 42 3579 
wound healing 5.06E-11 17 540 1.32E-05 15 540 
haemostasis 7.89E-10 14 357 6.87E-05 12 357 
blood coagulation 6.51E-10 14 352 5.88E-05 12 352 
fibrin clot formation 5.18E-12 8 26 2.75E-08 7 26 
lipoprotein particle 1.42E-04 5 39 3.43E-05 6 39 
GO term P-value S 
t=45 
T 
t=18,711 
 P-value S 
t=62 
T 
t=18,711 
 Run 1  Run 2 
   epidermis development 5.01E-06 10 297  1.55E-02 8 297 
   skin development 1.52E-05 9 242 2.57E-04 9 242 
     establishment of skin barrier 3.04E-02 3 18 8.50E-04 4 18 
   intermediate filament cytoskeleton 1.15E-12 14 247 3.96E-03 8 247 
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A network analysis of the overexpressed proteins in each twin was undertaken. Only 
proteins which were overexpressed in both runs and with an average fold difference >1.5 
were included in the analysis (Tables 6.3 and 6.4). This analysis demonstrated that 8 of 
the proteins overexpressed in KG’s serum can be located within a single network, with 
11 proteins not connected to any network. Further investigation is need to clarify whether 
any of these unconnected proteins are associated. All but one of the 13 proteins 
overexpressed in the unaffected twin’s serum were associated with a close network 
(Figure 6.5). 
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Figure 6.5. Predicted protein networks associated with the proteins upregulated in the serum of the affected 
and unaffected twins. Cytoscape networks were constructed using (A) 19 proteins upregulated in the 
affected twin’s serum (Table 6.3) and (B) 13 proteins upregulated in the unaffected twin’s serum (Table 
6.4). Nodes with a yellow outline indicate the seed proteins; other nodes indicate interacting proteins. Edges 
describe experimentally supported interactions. The superimposed GO terms associated with this network 
were identified using GOlorize with the BinGO plugin. 
 
 Discussion 
6.3.1 The implications of raised GGT and ESR 
Several factors have been linked to an increase in levels of serum GGT, including 
smoking, excessive alcohol consumption, and long-term treatment with the 
anticonvulsant phenobarbital (Whitfield et al., 2002; Lippi et al., 2008).  In women over 
the age of 40, alcohol intake is further influenced by higher than average BMI (Danielsson 
et al., 2013). However, as neither twin drinks appreciable amounts of alcohol, the effect 
of alcohol consumption is unlikely to be significant. In addition, since both twins have 
smoked in the past, this factor is not considered to be of any significance, especially 
considering KG stopped smoking 7 years ago, and the unaffected twin (HG) continues to 
smoke. The drug history of both sisters has been carefully reviewed from medical records 
spanning more than 50 years, and only KG has taken anticonvulsants. However, her GGT 
values are higher than the average GGT values for patients taking the same dose of 
phenobarbital (Lippi et al., 2008).  Phenytoin, another anticonvulsant taken by KG, has 
been reported to cause elevation in serum levels of GGT in children (Whitfield et al., 
1972). However, the study in which this was documented (Whitfield et al., 1972), did not 
contain sufficient data to differentiate between the effects of phenytoin and barbiturate 
drugs such as phenobarbital, so this effect may be negligible, and once again the GGT 
value for KG is significantly higher than the average GGT values reported in that study. 
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Alterations in GGT even within the normal range are significantly correlated with 
ischemic stroke (Fraser et al., 2007).  A genome-wide association study identified 26 loci 
associated with GGT levels (Chambers et al., 2011), and several of these loci, including 
EPHA2, GCKR, MLX1PL, SOX9, NEDD4L and FUT2 have previously been reported to 
be involved in stroke based on other genetic studies.  
GGT, an enzyme present on the surface of most cell types, is responsible for the 
catabolism of the antioxidant, glutathione, and the subsequent generation of reactive 
oxygen species (H2O2), thus acting as a marker for oxidative stress.  It can also form 
complexes with various components in the blood, including circulating lipoproteins, 
which can carry it inside atheromatous plaques. Colocalisation of GGT with oxidised 
LDL and CD68+ foam cells appear to be involved in the pathogenesis of atherosclerosis 
(Lippi et al., 2008; Franzini et al 2009), and GGT activity may also reflect endothelial 
function (Yu et al., 2007).  Furthermore, GGT may also play a role in the proliferation 
and rupture of plaques (Franzini et al 2009), and it has been suggested that some of the 
circulating GGT may originate from such plaques (Whitfield et al., 2002). However, to 
what extent GGT is involved in processes leading to atherosclerosis, or to what extent it 
is a consequence of such pathologies, remains to be determined. 
Raised ESR as a marker of poor prognosis following an ischemic stroke has been reported 
in previous studies (Nikanfar et al 2012; Swartz et al., 2005), but whether this is due to 
GGT elevation, or vice-versa, is not known. We believe GGT and ESR are useful 
biomarkers for ischemic stroke and GGT is a potential useful drug target. Screening 
patients at risk of ischemic stroke for GGT and ESR should be relatively inexpensive, and 
GGT inhibitors are readily available.  Some of these have been shown to be effective in 
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reducing GGT and reducing the risk of cardiovascular events, although large scale 
randomised trials are needed to assess this more directly. 
In summary, GGT has previously been implicated in stroke. However, it is known to be 
influenced by various genetic as well as environmental risk factors. We have been able 
to systematically exclude the main environmental risk factors, including smoking, alcohol 
intake, and certain medications. It was initially hypothesised that a de novo mutation in 
GGT could explain the stroke, but exome sequencing analysis of the twins excluded this. 
However, the possibility of a mutation elsewhere affecting GGT expression remains a 
possibility. 
6.3.2 Label-free proteomic analysis 
Plasma proteomes between MZ twins discordant for ischaemic stroke were compared to 
identify putative disease-associated markers in the affected twin. This approach provided 
a snapshot of proteins expressed in blood and differences in protein expression between 
the affected and unaffected twin. Proteomics has the potential to bridge the gap between 
genetics and biochemistry, identify functional biomarkers for complex conditions, and 
provide important insights into the mechanisms of disease. Like other high-throughput 
‘omics’ technologies, proteomics can capture changes in thousands of variables 
simultaneously and has proved useful in biomarker research (Frantzi et al., 2014). 
Candidate biomarkers found in this study have the potential to be used clinically for 
routine screening (diagnostic), guiding the right course of treatment (therapeutic), and/or 
predicting the outcome of the condition (prognostic). 
Overall, 95 and 139 proteins in runs 1 and 2 were identified as differentially expressed 
and associated with GO terms. With a fold-difference average threshold of >1.5, 19 
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proteins were identified with higher levels in KG’s serum in both runs, and 13 in HG’s 
serum in both runs. Despite the differences in the proteins identified in each run, several 
GO terms were significantly enriched consistently within either the high or low protein 
lists, suggesting that they share common biological pathways. Although there are also 
GO terms which do not show consistency (Appendix B). 
g:Profiler pathway analysis has identified an interesting enrichment of blood coagulation, 
wound healing, clot formation and platelet activation, all of which have previously been 
implicated in ischaemic stroke. This adds to our recently published study on a comparison 
of blood chemistries of this MZ twin pair, showing a >10- and >18-fold elevation of γ-
glutamyltransferase (GGT) and erythrocyte sedimentation rate (ESR) levels respectively 
in the affected twin (Vadgama et al., 2015). 
Moreover, the upregulation of fibulin 1 expression in the affected twin suggests that it is 
a novel candidate biomarker for ischaemic stroke. Fibulin 1 is a secreted calcium-binding 
glycoprotein (Argraves, 1990) that stabilises extracellular matrix integrity surrounding 
vascular smooth muscle. It is known to play important roles in wound repair (Liu et al., 
2016) and mediates platelet adhesion by cross-linking with fibrinogen, forming part of a 
general mechanism by which platelets interact with exposed subendothelial matrices 
following vascular injury (Godyna et al., 1996). 
GO terms associated with the proteins that were present at high levels in the unaffected 
twin (HG) were almost exclusively related to skin development. Interestingly, KG was 
diagnosed with seborrheic dermatitis capitis, whereas HG was diagnosed with atopic 
dermatitis. Atopic dermatitis is characterised by pruritus, erythema, induration, and scale 
(Siegfried and Hebert, 2015), and often affects the hands, feet, face, inside of the elbows 
and behind the knees. Although seborrheic dermatitis is another inflammatory skin 
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condition, this mostly affects sebum-rich skin, and in KG’s case it was only affecting her 
scalp. In addition, seborrheic dermatitis is associated with overgrowth of fungi, typically 
Malassezia species, on sebum-rich skin (Siegfried and Hebert, 2015), whereas atopic 
dermatitis has two main pathological processes; namely, impaired skin barrier function 
and immune dysfunction (Oswald, 2017). Both disorders are characterised by 
spontaneous remissions and exacerbations, but atopic dermatitis has the potential to affect 
a larger area of skin than seborrheic dermatitis. The enrichment of ‘skin development’ 
GO terms associated with the serum of the unaffected twin suggests that HG was 
experiencing an episode of atopic dermatitis at the time the blood sample was taken.  
Several of the proteins present at high levels in the affected twin (Table 6.3) have 
previously been identified as associated with ischaemic stroke. These include: 
6.3.2.1 HBA, hemoglobin subunit alpha 1 
Huang et al. (2009) found that hemoglobin α and β-chains were differentially expressed 
between stroke patients and controls (P<0.0001), with a sensitivity of 70.2% and the 
specificity of 85.3%. The authors conclude that serum free hemoglobin may serve as a 
potential biomarker for the diagnosis of acute ischaemic stroke. In our study, only the 
subunit alpha 1 was identified at high levels in the patient; however, this does support the 
suggestion that this protein could be a useful biomarker for ischaemic stroke. 
6.3.2.2 A2M, alpha-2-macroglobulin 
Alpha-2-macroglobulin is a cytokine transporter and protease inhibitor. It enhances 
procoagulant properties by the neutralisation of plasmin, plasminogen activators and 
metalloproteinases (Nezu et al., 2013). In addition, it functions as an inhibitor of 
fibrinolysis by inhibiting the activity of plasmin and kallikrein (Boer et al., 1993). 
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Interestingly, tissue kallikrein activity can be inhibited by kallistatin (SERPINA4), a 
serine proteinase inhibitor which was found to be at low levels in KG’s serum (see below). 
Alpha-2-macroglobulin is also acts as an inhibitor of coagulation by inhibiting thrombin 
(Boer et al., 1993), which may, at least in part, explain why prothrombin (F2) was present 
at high levels in KG’s serum. Nezu et al. (2013) identified alpha-2-macroglobulin as an 
acute ischaemic stroke biomarker, and Gori et al. (2017) found that alpha-2-
macroglobulin was a factor significantly associated with poor outcome (death within 
three months), suggesting that it contributes to cerebral damage after ischaemic stroke 
and thrombolysis. The authors conclude that high levels of alpha-2-macroglobulin may 
be a useful prognostic biomarker to identify patients with an increased probability of 
death after the administration of tissue plasminogen activator (Gori et al., 2017). 
6.3.2.3 HABP2, hyaluronan binding protein 2 
Hyaluronan binding protein 2, also known as factor VII-activating protease, is a plasma 
serine protease that is predominantly produced in the liver (Römisch et al., 2000). 
Hyaluronan binding protein 2 was first thought to activate pro-urokinase plasminogen 
activator (PLAU) and coagulation factor VII (F7, Römisch et al., 2000). More recent 
studies have demonstrated that factor VII is in fact a weak substrate of hyaluronan-
binding protein 2, pointing to additional substrates that have a more significant interaction 
(Hanson et al., 2012; Kanse et al., 2011). Hyaluronan binding protein 2 has been shown 
to inhibit tissue factor pathway inhibitor in clotting assays, and has been purported to also 
regulate the signalling functions of tissue factor (thromboplastin) (Kanse et al., 2011). 
This, and the fact that the enzyme has high homology with ﬁbrinolytic and coagulation 
enzymes, demonstrates the role of hyaluronan binding protein 2 in haemostasis (Hanson 
et al., 2012). 
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Hyaluronan binding protein 2 is found to accumulate in lipid-rich areas within the necrotic 
core of atherosclerotic plaques, but not in normal vessels (Kannemeier et al., 2004); and 
a single nucleotide polymorphism in the gene, which attenuates its capacity to activate 
pro-urokinase, is associated with carotid stenosis (Willeit et al., 2003). In a more recent 
study, increased hyaluronan binding protein 2 antigen levels and activity were 
independently associated with all main aetiologic subtypes of ischaemic stroke, 
suggesting a potential role in the pathophysiology of the condition through prothrombotic 
mechanisms (Hanson et al., 2012). 
6.3.2.4 S100A8, Protein S100-A8 
Several studies have demonstrated a detrimental role of Toll-like receptors in cerebral 
ischaemia (Ziegler et al., 2007). S100A8 has been characterised as an endogenous ligand 
which activates TLR-signalling (Vogl et al., 2007), and has been shown to promote 
atherogenesis in mice (Schiopu and Cotoi, 2013). Thus, it has been postulated that 
upregulation and signalling of S100A8 contributes to neuroinflammation and the 
progression of ischaemic damage (Ziegler et al., 2007).  
Wang et al. (2014) identified a molecular pathway of thrombosis that involves platelet 
S100A8, suggesting that targeting this protein has potential for treating atherothrombotic 
disorders, including myocardial infarction and stroke. Interestingly, blockers for the 
S100A8/A9 heterodimer (calprotectin) have been developed and are approved for clinical 
testing (Schiopu and Cotoi, 2013). 
Several of the proteins that were at low levels in the affected twin could play an important 
role in the pathogenesis of ischaemic stroke. These include: 
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6.3.2.5 SERPINA4, serpin family A member 4 (kallistatin) 
Kallistatin is a human serine proteinase inhibitor that binds strongly to tissue kallikrein, 
preventing the production of kinins (bradykinin and kallidin). These are potent 
vasodilators that are released by cleaving the kininogen substrate (Chao et al., 1996). 
Animal models and studies involving human participants have shown that reduced levels 
of tissue kallikrein are associated with hypertension, restenosis, stroke, and 
cardiovascular and renal disease (Chao and Chao, 2005). The major function of tissue 
kallikrein is blood pressure regulation through the kinin B2 receptor (BDKRB2), 
ultimately providing a protective role against ischaemic stroke-induced injuries, and 
cardiovascular and renal dysfunction (Chao et al., 2006). 
Kallistatin has also been found to have direct actions independent of its binding to tissue 
kallikrein, such as reduction of blood pressure, stimulation of neointima formation and 
inhibition of angiogenesis and tumour growth (Miao et al. 2000, 2002). Paradoxically, 
while kallistatin inhibits the liberation of kinins from the kininogens, thus preventing 
vasodilatation, it is itself a potent vasodilator. However, kallistatin-mediated vasodilation 
is thought to be unrelated to the tissue kallikrein-kinin system (Chao et al., 1997). 
Moreover, it has been shown that serum kallistatin levels are considerably reduced in 
hypertension, diabetes, cardiovascular and renal injury (Chao et al., 2015). 
Collectively, the downregulation of kallistatin in KG is consistent with the literature and 
adds weight to its potential usefulness as a molecular biomarker for patients with 
cardiovascular disorders. 
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6.3.2.6 DSP, desmoplakin 
Desmoplakin is an important component of desmosome structures in cardiac muscle and 
epidermal cells (Mueller and Franke, 1983; Stokes, 2007), and abnormalities in its 
expression results in cardiomyocyte death, changes in lipid metabolism, and defects in 
cardiac development (Yang et al. 2006). In a proteomics study set out to identify novel 
plasma biomarkers associated with vascular recurrence in post-stroke patients, it was 
found that patients taking statins for 3 months following the ischaemic stroke, and who 
did not experience a vascular recurrence during the follow-up period, had higher plasma 
levels of desmoplakin. This suggests that desmoplakin may be protective against a new 
vascular event, lending its usefulness as a prognostic biomarker (López-Farré et al., 
2012). Decreased levels of plasma desmoplakin in KG could be a risk factor for the 
reoccurrence of vascular events. In addition, desmoglein 1 is also present at low levels in 
KG serum. Desmoplakin and desmoglein 1 associate as a heterodimer to form the 
desmosome, a key adhesion molecule, present at cell-cell junctions and is also associated 
with keratin filaments. 
6.3.3 Limitations of approaches to identify proteomic biomarkers:  
Proteomics has led to the identification of several serum biomarkers for a wide range of 
conditions, including cancer, autoimmune diseases, infectious diseases, stroke, 
schizophrenia, and bipolar disorder (Ray et al., 2011; O'Hanlon et al., 2011; Kazuno et 
al., 2013). Despite methodological advances, several biological and technological 
challenges remain for serum proteomics. These include the detection of a wide dynamic 
range of protein concentrations, low-abundance proteins being masked by high-
abundance proteins (such as albumin and immunoglobulins), various interfering 
compounds such as salts, and not to mention, lack of reproducibility. Serum proteome 
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analysis can also be obfuscated by variations in storage, collection and handling 
procedures (Ray et al., 2011). In addition, there is great variability in protein expression 
between individuals, due to differences in lifestyle and dietary habits, among other 
factors. This introduces several confounding factors, which necessitates investigation of 
large sample sizes to exclude them. 
The methodological approaches adopted in this study minimised some of the biological 
and technological limitations. MZ twins share identical genetic backgrounds and greater 
levels of consistency in their proteome, making them the ideal subjects for proteome 
analyses to identify differentially-expressed proteins. 
This is the first study, to our knowledge, to apply a proteomics approach to analyse MZ 
twins discordant for stroke. The twins in this study have lived in the same environment 
since birth, which further reduces the interference of non-specific causal factors. 
However, a limitation of this approach is that the analysis only includes a single pair of 
MZ twins; thus, these results may not be applicable to stroke in general.  
Further, protein levels were measured several years after the stroke, which may reflect 
changes associated with addressing the lesion (e.g. wound healing) and not necessarily 
predict the susceptibility to stroke. Despite the identification of a number proteins unique 
to each run, pathway analysis revealed that each list of differentially-expressed proteins 
includes representatives from common pathways. Both twins, despite having identical 
genomes, exhibited unique enriched GO terms. In KG, biological processes were 
predominantly related to wound healing and blood coagulation, whereas in HG processes 
relevant to epidermis development were enriched. Disturbances in epigenetic 
mechanisms can lead to changes in gene expression, which can in turn result in 
dysfunction or disease. Therefore, epigenetic factors may explain these differences. 
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6.3.4 Conclusion 
The pathogenesis of ischaemic stroke is very complex, involving multiple molecular 
mechanisms (Xing et al., 2012). This makes it unlikely for a single biomarker to 
sufficiently reflect the underlying complexity. Thus, multiple biomarkers combined in a 
panel may be required to capture the dysregulation of several processes which converge 
to lead to susceptibility to an ischaemic event, thereby improving the diagnostic 
sensitivity and specificity.  
Despite the above limitations, many of the candidate biomarkers and molecular pathways 
identified in our study are consistent with previous studies related to ischaemic stroke. 
The present findings also suggest future new targets that may be relevant to the pathology 
of ischaemic stroke. 
The exact role of fibulin 1 in ischaemic stroke not clear. Further investigations into 
increased expression of fibulin 1 in stroke patients may add weight to its potential 
usefulness as a biomarker; and large-scale proteomic studies may further elucidate the 
common biochemical pathways and mechanisms associated with ischaemic stroke. 
 
 
 
 
 
 
220 
 
Future directions 
Follow up from current work 
This study identified somatic and germline de novo variants in a sample of MZ twins 
discordant for a range of complex disorders. Based on their biological functions and 
previous published data, the results are compatible with their potential role in the 
aetiology of the complex disorders investigated. This warrants independent validation 
using additional technologies such as Sanger sequencing, which will be considered as 
part of ongoing studies and its lack of herein is acknowledged as a limitation. 
Computational analysis of CNVs using the already-generated exome sequencing data 
from all samples will be performed and compared with the microarray CNV analysis. 
CNVs that are confirmed by the two platforms will be put forward for experimental 
validation using ddPCR. The next step would be to determine the functional significance 
of validated CNVs and the impact of these variations on disease in larger patient cohorts. 
Future studies would also involve validating the missense variant in PPARGC1A 
(c.A1829G) identified in the unaffected twin of the ALS-discordant twin pair (318), and 
determining whether the mutated form of the PGC-1a protein (p.H610R) affects 
expression at the RNA and protein level, and confirm in genetic studies with a larger 
patient cohort. Considering the role of this antioxidant defence transcriptional coactivator 
in ALS, targeting this pathway pharmacologically could be of therapeutic benefit. 
Parent-offspring trio analysis revealed a rare, highly conserved de novo mutation in 
RASD2 (c.G170A:p.R57H) in the ADHD-discordant twins, and an inherited stop loss 
mutation in AADAC (c.T1198C:p.X400Q) in twins discordant for Tourette’s syndrome. 
Functional assays should be performed to elucidate the biological implications of these 
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missense mutations in cell culture and ultimately animal studies – including subcellular 
localisation of normal verses mutant protein, RNA and protein expression. 
In addition to identifying discordant variants, rare concordant, potentially-damaging 
variants were also sought from the exome sequencing data. Biological processes 
associated with these shared variants in each twin pair will be identified with Gene 
Ontology classification using the functional analysis tool g:Profiler. Pathway analysis 
will determine the combined effect of estimated polygenic factors on the disorders 
investigated. 
The ddPCR experiment was not able to unequivocally validate or refute the presence of 
the 138 kb CNV deletion in the twins with schizophrenia (RT1a and RT1b). This highly 
complex duplicated region on chromosome 15q13.2-13.3 likely prevented adequate probe 
specificity. This necessitates setting up robust genotyping assays capable of deducing 
both the sequence content and structure of this region. Unfortunately, functional studies 
assaying duplications are not well established. While CRISPR/Cas9 technology has 
facilitated knockouts within human induced pluripotent stem cells, the high degree of 
sequence identity between paralogs renders such a task challenging, and may even 
promote the formation of large structural rearrangements. Whole-genome sequencing has 
the potential to assay ARHGAP11B variation in disease cohorts. Although there are 
limitations in using short reads to assay variation between highly similar paralogs, recent 
advances in synthetic long read methods via barcoding (for example, 10X Genomics) 
may pave the way for improved variant calling and characterising the complexity of 
structural alterations in this region. 
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Future work 
Our strategy of investigating MZ discordant twins collectively using genomic, proteomic 
and bioinformatics approaches was successful. More discordant MZ twins have since 
been recruited in the study and DNA samples have been obtained; these will be analysed 
using the strategies described in this thesis. This includes twins that are discordant for 
ulcerative colitis and Crohn’s disease. For the twins discordant for inclusion body 
myositis, a muscle biopsy has been obtained, and future investigations will include 
performing multi-omic analyses to determine potential mechanisms that contribute to the 
discordant phenotype in those twins. 
Transcriptome and proteome quantification will also be performed on other recruited 
twins using multiple tissues to provide novel insights into post-transcriptional gene 
regulation. Further, functional studies will be carried out for any interesting biological 
findings that emerge out of (epi)genetic or proteomic analyses. Initially, these findings 
will be confirmed using real-time PCR on RNA samples that we have already obtained. 
The biological functions of these proteins can be further characterised by over-expressing 
the genes, or using siRNA knockdown approaches in cell-culture models. Although this 
is beyond the scope of the present study, these findings could lead to screening small 
molecules that could ultimately be of therapeutic benefit.  
 
Conclusion 
The comedian Steven Wright wryly remarked, ‘a conclusion is the part where you got 
tired of thinking’. I am not sure if he’s right this time. It is inevitable that this work will 
have raised more questions than it answers, and generated complex epicycles of 
223 
 
additional hypotheses that need to be followed though in much greater detail and to a 
greater depth. 
The primary hypothesis of the present study was stimulated by several recent studies that 
showed de novo mutations and somatic mosaicism to have a significant impact on disease 
aetiology. Using the case co-twin design, with the assumption that twins may acquire de 
novo mutations during ontogeny that causally relate to their discordant phenotypes, we 
endeavoured to search for such variants. New technologies have enabled unprecedented 
capabilities for genetic research and demonstrate that somatic mosaicism might be more 
representative of the true range of de novo mutations observed in disease, since many 
mutations are lethal when constitutional. This fact may in future change the way we look 
at the human genome and cause us to reassess the genetic predisposition for many 
complex traits. 
Although twenty-two discordant SNVs and indels were identified between six twin pairs 
in our cohort, a significant portion may turn out to be false positives based on independent 
validation. If we are to assume that the variants are real, and indeed deleterious, it would 
add to the literature that postzygotic mutations and somatic mosaicism do play a role in 
MZ twin discordance, and help explain disease onset in six out of the thirteen twin pairs. 
However, no structural differences were detected between all the twin pairs investigated, 
suggesting that CNVs may not be a significant factor in twin discordancy. Regardless, 
our results are in line with published literature, which suggests that the rate of post-
fertilisation mutations is low. Yet we cannot exclude the possibility of having missed 
existing somatic mutations in the twin cohort examined, and the search for an explanation 
may lie beyond mere genetic changes at the level of the DNA sequence. 
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This study presents a theoretical framework for mosaicism detection and indicates 
potential weaknesses of existing variant detection tools. The false positive and false 
negative results identified throughout the literature and within this study emphasises the 
limitations of current NGS technology in identifying true discordant variants. Future 
research directions include systematic whole-genome, methylome, transcriptome and 
proteome analyses on discordant MZ twins, to identify novel disease-causing candidate 
genes and elucidate the role of differential gene expression in complex disorders. 
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Appendix A: Patient information sheet & consent form 
TITLE: Genetic investigation of identical twins by next-generation sequencing. 
 
The focus of our research is to determine the extent of genetic similarity between 
identical twins, and we would like to invite you to take part in our research study. 
Before making a decision, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information carefully and ask us if there is anything that is not clear, or if you would 
like more information. 
 
PURPOSE 
To make this research possible, we are gathering genetic material (DNA) from identical 
twins. Since you appear to meet this criterion, we are contacting you to see if you would 
be willing to contribute a saliva specimen for use in this research. 
There is considerable evidence from medical research to suggest that identical twins can 
differ genetically. Because these are likely to involve complex genetic mechanisms, it 
presents novel challenges to determine the extent to which this occurs. Your 
contribution could therefore be of major importance in the field of medical genetics. 
 
PROCEDURES 
If you agree to participate, we will arrange to collect a small saliva sample (2 mL) 
from you. DNA will be extracted from the saliva samples and used for scientific research. 
DNA and clinical information collected from your GP will be stored at St. George’s, 
University of London. This will include information about your age, sex, and clinical 
status. Your DNA and clinical data will be stored in a coded way to keep your identity 
confidential. 
 
RISKS 
There are no more than minimal medical risks associated with this research. These 
samples would be for research purposes only and will be stored indefinitely; no diagnostic 
genetic testing will be performed without your consent. It should be noted that this is 
research only and for that reason will not have any insurance implications. 
 
CONFIDENTIALITY 
All information which is collected during the course of the research will be kept 
strictly confidential. We will take the following steps to ensure confidentiality. A 
research number will be assigned to you, and your name will not be used. The only people 
who will have access to your individual identity are Dr Jamal Nasir and staff. The results 
from the analysis of your DNA will not be released or shared in any way with your 
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relatives, with insurance companies, or any third party not involved in research. 
When results of this study are published, your name will not be used. We are happy 
to update you with the outcome of the research if you wish to be informed. 
 
PARTICIPATION IS VOLUNTARY 
You do not have to contribute to this study if you don’t want to. You have the right to 
leave the study at any time without giving any reason, and without penalty. If you 
wish to leave the study, please contact Dr. Jamal Nasir or Mr. Nirmal Vadgama. 
 
WHO HAS REVIEWED THE STUDY? 
This study has been reviewed by the Research Degrees Committee and other senior 
medical and academic staff at St. George’s, University of London. It has also been 
reviewed by the Eleanor Peel Trust and St George’s Hospital NHS Trust Charitable 
Foundation Medical Research Committee who are funding the research. 
 
CONTACTS 
If you have any questions about the study please contact: 
Dr. Jamal Nasir 
Senior Lecturer in Functional Genetics 
Division of Biomedical Sciences (BMS) 
Room 2.142C 
Jenner Wing 
St. George’s University of London 
Cranmer Terrace, London 
SW17 0RE 
 
Email: jnasir@sgul.ac.uk 
Tel. 0208 725 1064 
Fax  0208 725 1039 
 
 
Nirmal Vadgama BSc(Hons), MRes 
Division of Biomedical Sciences (BMS) 
Room 2.140F 
Jenner Wing 
St. George’s University of London 
Cranmer Terrace, London 
SW17 0RE 
 
Email: nvadgama@sgul.ac.uk  
Tel. 0207 737 2661 
Mob. 0786 422 0709 
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CONSENT FORM 
Title of Project: Genetic investigation of identical twins by next-generation sequencing 
Please ✓box 
as appropriate 
1) I confirm that I have read and understand the information sheet 
dated _________ for the above study and have had the 
opportunity to ask questions. 
 
2) It may not be possible to identify an alteration in these genes 
using current technology but it may be possible in the future. I 
am therefore happy for the sample to be stored for future 
testing. 
3) I understand that my participation is voluntary and that I am 
free to withdraw at any time, without giving reason, without 
my medical care or legal right being affected. 
4) I understand that sections of my medical notes may be looked 
at by responsible individuals from St. George’s, University of 
London where it is relevant to my taking part in research. I give 
permission for these individuals to have access to my records. 
5) I would like to receive any results relevant to me. 
6) I agree to take part in the above study. 
 
You will get a copy of this consent form to keep once it is returned to us. 
 
Signature of Subject.............................................. Date............................ 
 
Name of Subject....................................................  
 
Signature of Investigator........................................ Date............................ 
 
Name of Investigator..............................................  
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Appendix B: Raw data for proteomic analysis  
Table 1: Differentially expressed proteins identified in serum of the affected (KG) or unaffected (HG) 
twin.  List of proteins identified by proteomic analysis of serum from 2 individuals: KG (affected) run 1 
and run 2 datasets; HG (unaffected) run 1 and run 2 datasets, used in the g:profiler analysis. 
 
HG Run 1 HG Run 2  KG Run 1 KG Run 2 
UniProt ID HGNC symbol UniProt ID HGNC symbol UniProt ID 
HGNC 
symbol 
UniProt ID HGNC symbol 
A0M8Q6 IGLC7 A0M8Q6 IGLC7 O14791 APOL1 A6NJ16 IGHV4OR15-8 
P01597 IGKV1-39 B7U540 KCNJ18 O43866 CD5L O14791 APOL1 
P01611 IGKV1D-12 O15078 CEP290 O75636 FCN3 O43866 CD5L 
P01617 IGKV2D-28 O43929 ORC4 O75882 ATRN O75122 CLASP2 
P01619 IGKV3-20 P00751 CFB P00450 CP O75636 FCN3 
P01700 IGLV1-47 P02787 TF P00734 F2 P00734 F2 
P01717 IGLV3-25 P02790 HPX P00739 HPR P00736 C1R 
P01742 IGHV1-69 P03952 KLKB1 P00747 PLG P00738 HP 
P01762 IGHV3-11 P04004 VTN P00748 F12 P00739 HPR 
P01766 IGHV3-13 P04114 APOB P00915 CA1 P00742 F10 
P01770 IGHV3-30 P04206 IGKV3-20 P01008 SERPINC1 P00747 PLG 
P01771 IGHV3-33 P04217 A1BG P01023 A2M P00915 CA1 
P01773 IGHV3-30 P04264 KRT1 P01024 C3 P00918 CA2 
P01775 IGHV3-23 P04406 GAPDH P01031 C5 P01009 SERPINA1 
P01779 IGHV3-23 P04433 IGKV3-11 P01598 IGKV1-5 P01011 SERPINA3 
P01781 IGHV3-7 P06396 GSN P01599 IGKV1-17 P01019 AGT 
P01814 IGHV2-70 P06733 ENO1 P01602 IGKV1-5 P01023 A2M 
P01861 IGHG4 P07225 PROS1 P01603 IGKV1-33 P01024 C3 
P01876 IGHA1 P08697 SERPINF2 P01604 IGKV1-5 P01031 C5 
P01877 IGHA2 P08779 KRT16 P01613 IGKV1D-33 P01042 KNG1 
P02533 KRT14 P0C0L5 C4B P01620 IGKV3-20 P01591 JCHAIN 
P02538 KRT6A P0C0S5 H2AFZ P01625 IGKV4-1 P01598 IGKV1-5 
P02747 C1QC P11277 SPTB P01714 IGLV3-19 P01600 IGKV1-39 
P02750 LRG1 P12259 F5 P01833 PIGR P01602 IGKV1-5 
P02768 ALB P13645 KRT10 P01834 IGKC P01610 IGKV1-17 
P02790 HPX P13671 C6 P01871 IGHM P02774 GC 
P04004 VTN P13805 TNNT1 P02647 APOA1 P04003 C4BPA 
P04114 APOB P15924 DSP P02649 APOE P04208 IGLV1-47 
P04207 IGKV3-15 P18428 LBP P02671 FGA P04211 IGLV7-43 
P04209 IGLV2-14 P19012 KRT15 P02741 CRP P04220 BOT 
P04259 KRT6B P19013 KRT4 P02743 APCS P04275 VWF 
P04264 KRT1 P19823 ITIH2 P02751 FN1 P05090 APOD 
P04406 GAPDH P19827 ITIH1 P02788 LTF P05109 S100A8 
P04430 IGKV1-16 P22792 CPN2 P04003 C4BPA P05155 SERPING1 
P04433 IGKV3-11 P23246 SFPQ P04196 HRG P05156 CFI 
P05154 SERPINA5 P29622 SERPINA4 P04275 VWF P05452 CLEC3B 
P05787 KRT8 P35443 THBS4 P05109 S100A8 P05543 SERPINA7 
P07358 C8B P35527 KRT9 P05155 SERPING1 P06309 IGKV2D-28 
P08697 SERPINF2 P35858 IGFALS P05160 F13B P06312 IGKV4-1 
P08779 KRT16 P43652 AFM P05164 MPO P06331 IGHV4-34 
P0C0L5 C4B P62736 ACTA2 P06312 IGKV4-1 P06727 APOA4 
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P0CG06 IGLC2 P62805 HIST1H4A P06681 C2 P07360 C8G 
P11277 SPTB Q02413 DSG1 P07996 THBS1 P08185 SERPINA6 
P13645 KRT10 Q04695 KRT17 P08571 CD14 P08571 CD14 
P13647 KRT5 Q06033 ITIH3 P08603 CFH P09871 C1S 
P15169 CPN1 Q16610 ECM1 P09871 C1S P0CG04 IGLC1 
P15924 DSP Q5D862 FLG2 P0CG04 IGLC1 P0CG05 IGLC3 
P23083 IGHV1-2 Q5SW24 DACT2 P10643 C7 P0DJI8 SAA1 
P27918 CFP Q5T749 KPRP P10909 CLU P10643 C7 
P29622 SERPINA4 Q5VTE0 EEF1A1P5 P12035 KRT3 P10909 CLU 
P30740 SERPINB1 Q66K66 TMEM198 P18136 IGKV3-20 P18136 IGKV3-20 
P35527 KRT9 Q6NXT2 H3F3C P20742 PZP P19652 ORM2 
P35542 SAA4 Q6UWP8 SBSN  P23142 FBLN1 P20742 PZP 
P35908 KRT2 Q86TI0 TBC1D1  P51884 LUM P20851 C4BPB 
P62736 ACTA2 Q86YZ3 HRNR  P68871 HBB P21399 ACO1 
Q01546 KRT76 Q8NFH3 NUP43  P69905 HBA1 P23142 FBLN1 
Q02413 DSG1 Q8WXI4 ACOT11  P80108 GPLD1 P25311 AZGP1 
Q04695 KRT17 Q96M42 LINC00479  Q03591 CFHR1 P27169 PON1 
Q7Z794 KRT77 Q96P31 FCRL3  Q14520 HABP2 P36955 SERPINF1 
Q86YZ3 HRNR Q96PD5 PGLYRP2  Q5TH69 ARFGEF3 P43234 CTSO 
Q99856 ARID3A Q9C0H6 KLHL4  Q96KV7 WDR90 P49913 CAMP 
Q9UBP0 SPAST Q9NQL9 DMRT3  Q9UL18 AGO1 P51884 LUM 
Q9Y6D5 ARFGEF Q9NR34 MAN1C1    P53367 ARFIP1 
  Q9NXC5 MIOS    P68871 HBB 
  Q9NZT1 CALML5    P69905 HBA1 
  Q9ULV0 MYO5B    P80108 GPLD1 
       P80188 LCN2 
       P80748 IGLV3-21 
       Q00325 SLC25A3 
       Q02223 TNFRSF17 
       Q03591 CFHR1 
       Q08380 LGALS3BP 
       Q14520 HABP2 
       Q14624 ITIH4 
       Q5T0N5 FNBP1L 
       Q5T4S7 UBR4 
       Q5VYK3 ECM29 
       Q6P9F7 LRRC8B 
       Q6VAB6 KSR2 
       Q6ZT07 TBC1D9 
       Q7Z2Z2 EFL1 
       Q8TD19 NEK9 
       Q8TF72 SHROOM3 
       Q8WZ42 TTN 
       Q92835 INPP5D 
       Q99676 ZNF184 
       Q9BZC7 ABCA2 
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Table 2: Enriched GO terms associated with the proteins at high levels in the serum of the affected (KG) or unaffected (HG) twin. GO terms were identified as 
significantly following g:Profiler analysis. P-values <0.05 are considered as significantly enriched. S = number of protein identifiers (IDs) in both the study dataset and GO term 
group, T = number of human protein IDs associated with the GO term, t = number of protein IDs in study or GO datasets. Rows highlighted in green are terms enriched in both 
KG (affected) datasets but not either of the HG (unaffected) datasets. Rows highlighted in orange are terms enriched in both HG (unaffected) datasets but not either of the KG 
(affected) datasets. 
term ID 
t 
type 
t 
group 
t name 
t 
depth 
T 
KG - Run 1, t=50 
  
KG - Run 2, t=77 
  
HG - Run 1, t=45 
  
HG - Run 2, t=62 
  
p-value t S p-value t S p-value t S p-value t S 
GO:0045104 BP 4 
   intermediate filament cytoskeleton 
organization 1 40 #N/A #N/A #N/A   #N/A #N/A #N/A   1.45E-06 45 6   0.024 62 4   
GO:0045103 BP 4    intermediate filament-based process 1 41 #N/A #N/A #N/A   #N/A #N/A #N/A   1.7E-06 45 6   0.0266 62 4   
GO:0010876 BP 5    lipid localization 1 353 #N/A #N/A #N/A   0.0419 77 9   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0009892 BP 5    negative regulation of metabolic process 1 2477 #N/A #N/A #N/A   0.00265 77 27   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:1903027 BP 5    regulation of opsonization 1 2 #N/A #N/A #N/A   0.0492 77 2   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0010605 BP 5 
    negative regulation of macromolecule 
metabolic process 2 2286 #N/A #N/A #N/A   0.00755 77 25   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0050789 BP 5     regulation of biological process 2 10756 #N/A #N/A #N/A   0.0149 77 63   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0043170 BP 5       macromolecule metabolic process 4 9000 #N/A #N/A #N/A   0.000825 77 59   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0009913 BP 6    epidermal cell differentiation 1 177 #N/A #N/A #N/A   #N/A #N/A #N/A   0.0116 45 6   #N/A #N/A #N/A   
GO:0008544 BP 6    epidermis development 1 297 #N/A #N/A #N/A   #N/A #N/A #N/A   5.01E-06 45 10   0.0155 62 8   
GO:0030216 BP 6     keratinocyte differentiation 2 127 #N/A #N/A #N/A   #N/A #N/A #N/A   0.00167 45 6   #N/A #N/A #N/A   
GO:0031424 BP 6      keratinization 3 50 #N/A #N/A #N/A   #N/A #N/A #N/A   0.0182 45 4   #N/A #N/A #N/A   
GO:0042160 BP 8    lipoprotein modification 1 6 #N/A #N/A #N/A   0.00391 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0008152 BP 8    metabolic process 1 10975 0.0144 50 44   0.000746 77 66   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0034442 BP 8    regulation of lipoprotein oxidation 1 5 #N/A #N/A #N/A   0.00196 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0042161 BP 8     lipoprotein oxidation 2 6 #N/A #N/A #N/A   0.00391 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0050748 BP 8 
     negative regulation of lipoprotein 
metabolic process 3 7 #N/A #N/A #N/A   0.00682 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:1903318 BP 8      negative regulation of protein maturation 3 33 0.00415 50 4   0.0291 77 4   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0010955 BP 8       negative regulation of protein processing 4 33 0.00415 50 4   0.0291 77 4   #N/A #N/A #N/A   #N/A #N/A #N/A   
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GO:0043277 BP 8        apoptotic cell clearance 5 35 0.00529 50 4   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0051179 BP 9    localization 1 5810 3.96E-05 50 35   6.37E-13 77 59   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:1902578 BP 9    single-organism localization 1 3031 4.95E-08 50 29   3.81E-11 77 42   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0051234 BP 9     establishment of localization 2 4738 6.36E-07 50 34   7.3E-14 77 55   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0044765 BP 9     single-organism transport 2 2804 6.83E-09 50 29   2.31E-12 77 42   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0006909 BP 9      phagocytosis 3 264 3.93E-06 50 10   0.0377 77 8   0.00057 45 8   #N/A #N/A #N/A   
GO:0046903 BP 9      secretion 3 1085 2.64E-05 50 16   1.01E-07 77 23   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0006810 BP 9      transport 3 4605 2.78E-07 50 34   1.85E-14 77 55   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0032940 BP 9       secretion by cell 4 952 0.000284 50 14   3.04E-06 77 20   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0016192 BP 9       vesicle-mediated transport 4 1492 7.52E-14 50 27   2.68E-15 77 35   7.31E-05 45 17   0.00251 62 18   
GO:0006897 BP 9        endocytosis 5 655 1.16E-09 50 17   3.76E-08 77 19   8.98E-05 45 12   #N/A #N/A #N/A   
GO:0006887 BP 9        exocytosis 5 405 0.000228 50 10   2.84E-06 77 14   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0006898 BP 9         receptor-mediated endocytosis 6 316 1.33E-06 50 11   7.52E-09 77 15   9.11E-06 45 10   #N/A #N/A #N/A   
GO:0045055 BP 9         regulated exocytosis 6 285 8.21E-06 50 10   4.09E-07 77 13   #N/A #N/A #N/A   0.0115 62 8   
GO:0002576 BP 9          platelet degranulation 7 106 4.47E-10 50 10   1.16E-12 77 13   #N/A #N/A #N/A   5.61E-06 62 8   
GO:0007010 BP 12    cytoskeleton organization 1 1158 #N/A #N/A #N/A   #N/A #N/A #N/A   0.000119 45 15   #N/A #N/A #N/A   
GO:0010035 BP 12    response to inorganic substance 1 469 #N/A #N/A #N/A   0.000164 77 13   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0045109 BP 12     intermediate filament organization 2 20 #N/A #N/A #N/A   #N/A #N/A #N/A   2.84E-06 45 5   #N/A #N/A #N/A   
GO:0001816 BP 16    cytokine production 1 626 0.00146 50 11   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0002431 BP 16 
   Fc receptor mediated stimulatory signaling 
pathway 1 127 #N/A #N/A #N/A   #N/A #N/A #N/A   0.00167 45 6   #N/A #N/A #N/A   
GO:0038094 BP 16    Fc-gamma receptor signaling pathway 1 125 #N/A #N/A #N/A   #N/A #N/A #N/A   0.00152 45 6   #N/A #N/A #N/A   
GO:0050891 BP 16    multicellular organismal water homeostasis 1 60 #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   0.00423 62 5   
GO:0030104 BP 16    water homeostasis 1 71 #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   0.00982 62 5   
GO:0038096 BP 16 
    Fc-gamma receptor signaling pathway 
involved in phagocytosis 2 121 #N/A #N/A #N/A   #N/A #N/A #N/A   0.00126 45 6   #N/A #N/A #N/A   
GO:0002433 BP 16 
    immune response-regulating cell surface 
receptor signaling pathway involved in 
phagocytosis 2 121 #N/A #N/A #N/A   #N/A #N/A #N/A   0.00126 45 6   #N/A #N/A #N/A   
GO:0050820 BP 16     positive regulation of coagulation 2 26 1.67E-05 50 5   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
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GO:1900048 BP 16     positive regulation of hemostasis 2 25 1.35E-05 50 5   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0051240 BP 16 
    positive regulation of multicellular 
organismal process 2 1414 0.00595 50 15   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0001817 BP 16     regulation of cytokine production 2 568 0.00503 50 10   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0033561 BP 16     regulation of water loss via skin 2 20 #N/A #N/A #N/A   #N/A #N/A #N/A   0.0424 45 3   0.00134 62 4   
GO:0061436 BP 16      establishment of skin barrier 3 18 #N/A #N/A #N/A   #N/A #N/A #N/A   0.0304 45 3   0.00085 62 4   
GO:0030194 BP 16      positive regulation of blood coagulation 3 25 1.35E-05 50 5   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0090303 BP 16       positive regulation of wound healing 4 48 0.000415 50 5   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0051918 BP 16        negative regulation of fibrinolysis 5 10 2.23E-05 50 4   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0051649 BP 22    establishment of localization in cell 1 2109 #N/A #N/A #N/A   0.0232 77 23   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0031589 BP 23    cell-substrate adhesion 1 307 0.00337 50 8   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0010810 BP 23    regulation of cell-substrate adhesion 1 177 0.00102 50 7   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0050832 BP 29    defense response to fungus 1 33 0.00415 50 4   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0009620 BP 29    response to fungus 1 47 0.0176 50 4   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0065007 BP 38    biological regulation 1 11372 0.0101 50 45   0.0166 77 65   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0050817 BP 38    coagulation 1 357 7.89E-10 50 14   6.87E-05 77 12   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0002376 BP 38    immune system process 1 2387 6.5E-15 50 33   2.83E-08 77 34   0.0123 45 18   #N/A #N/A #N/A   
GO:0048519 BP 38    negative regulation of biological process 1 4572 0.016 50 27   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0031324 BP 38 
   negative regulation of cellular metabolic 
process 1 2308 0.035 50 18   0.000636 77 27   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0048523 BP 38    negative regulation of cellular process 1 4251 0.0143 50 26   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0001869 BP 38 
   negative regulation of complement 
activation, lectin pathway 1 2 0.0167 50 2   0.0492 77 2   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0048518 BP 38    positive regulation of biological process 1 5194 8.8E-06 50 34   0.000584 77 43   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0019538 BP 38    protein metabolic process 1 5370 4.03E-06 50 35   1.25E-07 77 50   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0032268 BP 38 
   regulation of cellular protein metabolic 
process 1 2326 0.000384 50 21   0.0104 77 25   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0051239 BP 38 
   regulation of multicellular organismal 
process 1 2631 0.00309 50 21   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0048583 BP 38    regulation of response to stimulus 1 3592 1.67E-10 50 34   0.0149 77 32   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0050896 BP 38    response to stimulus 1 8162 1.8E-07 50 44   1.06E-05 77 59   0.0392 45 34   #N/A #N/A #N/A   
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GO:0007596 BP 38     blood coagulation 2 352 6.51E-10 50 14   5.88E-05 77 12   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0002252 BP 38     immune effector process 2 713 3.18E-10 50 18   1.36E-06 77 18   1.97E-06 45 14   #N/A #N/A #N/A   
GO:0006955 BP 38     immune response 2 1530 1.02E-14 50 28   8.09E-08 77 27   0.000106 45 17   #N/A #N/A #N/A   
GO:0043086 BP 38     negative regulation of catalytic activity 2 819 0.00037 50 13   0.003 77 15   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0032269 BP 38 
    negative regulation of cellular protein 
metabolic process 2 980 0.00285 50 13   0.000193 77 18   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0050819 BP 38     negative regulation of coagulation 2 51 2.01E-09 50 8   #N/A #N/A #N/A   #N/A #N/A #N/A   0.00186 62 5   
GO:0002683 BP 38 
    negative regulation of immune system 
process 2 370 0.00122 50 9   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0051241 BP 38 
    negative regulation of multicellular 
organismal process 2 1001 0.00361 50 13   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0048585 BP 38     negative regulation of response to stimulus 2 1348 0.000082 50 17   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0002684 BP 38 
    positive regulation of immune system 
process 2 934 2.04E-10 50 20   3.02E-07 77 21   6.23E-05 45 14   #N/A #N/A #N/A   
GO:0045862 BP 38     positive regulation of proteolysis 2 353 0.00949 50 8   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0048584 BP 38     positive regulation of response to stimulus 2 1994 1.05E-10 50 27   0.000134 77 26   0.0242 45 16   #N/A #N/A #N/A   
GO:0072376 BP 38     protein activation cascade 2 131 1.42E-29 50 21   1.35E-26 77 22   9.38E-15 45 13   3.01E-05 62 8   
GO:0051604 BP 38     protein maturation 2 266 9.52E-09 50 12   1.74E-07 77 13   #N/A #N/A #N/A   0.00688 62 8   
GO:0006508 BP 38     proteolysis 2 1684 6.27E-16 50 30   1.45E-17 77 39   0.00262 45 16   #N/A #N/A #N/A   
GO:0065008 BP 38     regulation of biological quality 2 3506 5.86E-05 50 27   0.000775 77 34   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0050790 BP 38     regulation of catalytic activity 2 2328 0.00918 50 19   0.0105 77 25   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0050818 BP 38     regulation of coagulation 2 90 4.64E-09 50 9   #N/A #N/A #N/A   #N/A #N/A #N/A   0.0316 62 5   
GO:1900046 BP 38     regulation of hemostasis 2 85 2.73E-09 50 9   #N/A #N/A #N/A   #N/A #N/A #N/A   0.0239 62 5   
GO:0050776 BP 38     regulation of immune response 2 879 4.48E-12 50 21   7.56E-07 77 20   2.89E-05 45 14   #N/A #N/A #N/A   
GO:0002682 BP 38     regulation of immune system process 2 1336 1.42E-10 50 23   6.06E-06 77 23   0.00502 45 14   #N/A #N/A #N/A   
GO:0051246 BP 38     regulation of protein metabolic process 2 2489 7.4E-06 50 24   0.000197 77 29   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0032101 BP 38     regulation of response to external stimulus 2 703 9.37E-13 50 20   1.08E-06 77 18   #N/A #N/A #N/A   0.0454 62 11   
GO:0080134 BP 38     regulation of response to stress 2 1272 5.76E-10 50 22   0.000396 77 20   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0009605 BP 38     response to external stimulus 2 2021 1.21E-08 50 25   8.31E-06 77 28   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0006950 BP 38     response to stress 2 3579 1.59E-11 50 35   1.28E-08 77 42   #N/A #N/A #N/A   #N/A #N/A #N/A   
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GO:0002250 BP 38      adaptive immune response 3 390 8.04E-07 50 12   8.62E-10 77 17   2.59E-07 45 12   #N/A #N/A #N/A   
GO:0072378 BP 38      blood coagulation, fibrin clot formation 3 26 5.18E-12 50 8   2.75E-08 77 7   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0007597 BP 38      blood coagulation, intrinsic pathway 3 19 1.68E-08 50 6   3.05E-07 77 6   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0006956 BP 38      complement activation 3 108 4.34E-19 50 15   2.56E-19 77 17   6.9E-16 45 13   0.000175 62 7   
GO:0006952 BP 38      defense response 3 1448 1.47E-16 50 29   8.72E-13 77 32   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0006959 BP 38      humoral immune response 3 223 1.77E-17 50 17   3.04E-15 77 18   2.74E-13 45 14   0.00184 62 8   
GO:0045087 BP 38      innate immune response 3 791 1.85E-09 50 18   1.17E-07 77 20   0.0421 45 10   #N/A #N/A #N/A   
GO:0002443 BP 38      leukocyte mediated immunity 3 332 2.23E-06 50 11   1.53E-08 77 15   8.11E-07 45 11   #N/A #N/A #N/A   
GO:0030195 BP 38      negative regulation of blood coagulation 3 47 9.99E-10 50 8   #N/A #N/A #N/A   #N/A #N/A #N/A   0.00123 62 5   
GO:1900047 BP 38      negative regulation of hemostasis 3 47 9.99E-10 50 8   #N/A #N/A #N/A   #N/A #N/A #N/A   0.00123 62 5   
GO:0051346 BP 38      negative regulation of hydrolase activity 3 396 9.58E-07 50 12   2.12E-06 77 14   #N/A #N/A #N/A   0.0154 62 9   
GO:0044092 BP 38      negative regulation of molecular function 3 1067 0.00734 50 13   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0051248 BP 38 
     negative regulation of protein metabolic 
process 3 1034 0.000781 50 14   1.26E-05 77 20   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0045861 BP 38      negative regulation of proteolysis 3 306 1.62E-05 50 10   1.64E-11 77 17   #N/A #N/A #N/A   0.00186 62 9   
GO:0032102 BP 38 
     negative regulation of response to external 
stimulus 3 259 6.95E-09 50 12   0.00339 77 9   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:1903035 BP 38 
     negative regulation of response to 
wounding 3 68 3.38E-10 50 9   0.0259 77 5   #N/A #N/A #N/A   0.00792 62 5   
GO:0030168 BP 38      platelet activation 3 163 0.011 50 6   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0050778 BP 38      positive regulation of immune response 3 664 5.67E-12 50 19   4.92E-09 77 20   7.78E-07 45 14   #N/A #N/A #N/A   
GO:0032103 BP 38 
     positive regulation of response to external 
stimulus 3 264 0.0146 50 7   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:1903036 BP 38 
     positive regulation of response to 
wounding 3 55 0.000831 50 5   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0016485 BP 38      protein processing 3 239 2.69E-09 50 12   4.56E-08 77 13   #N/A #N/A #N/A   0.0031 62 8   
GO:0030193 BP 38      regulation of blood coagulation 3 85 2.73E-09 50 9   #N/A #N/A #N/A   #N/A #N/A #N/A   0.0239 62 5   
GO:0050878 BP 38      regulation of body fluid levels 3 504 8.12E-08 50 14   0.00282 77 12   #N/A #N/A #N/A   0.00188 62 11   
GO:0031347 BP 38      regulation of defense response 3 658 2.27E-07 50 15   0.000182 77 15   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0002920 BP 38      regulation of humoral immune response 3 51 2.01E-09 50 8   1.63E-09 77 9   0.000407 45 5   4.36E-05 62 6   
GO:0051336 BP 38      regulation of hydrolase activity 3 1348 0.000541 50 16   0.00101 77 20   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0002697 BP 38      regulation of immune effector process 3 313 0.000299 50 9   0.016 77 9   #N/A #N/A #N/A   0.0228 62 8   
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GO:0050727 BP 38      regulation of inflammatory response 3 303 2.01E-09 50 13   6.25E-08 77 14   #N/A #N/A #N/A   0.00171 62 9   
GO:2000257 BP 38      regulation of protein activation cascade 3 33 2.84E-13 50 9   2.19E-11 77 9   0.00334 45 4   0.000197 62 5   
GO:1903317 BP 38      regulation of protein maturation 3 82 3.14E-11 50 10   3.77E-09 77 10   0.00447 45 5   7.05E-07 62 8   
GO:0030162 BP 38      regulation of proteolysis 3 696 7.74E-13 50 20   6.61E-14 77 25   #N/A #N/A #N/A   0.000949 62 13   
GO:1903034 BP 38      regulation of response to wounding 3 146 1.15E-08 50 10   #N/A #N/A #N/A   #N/A #N/A #N/A   0.023 62 6   
GO:0009611 BP 38      response to wounding 3 644 5.59E-11 50 18   0.000138 77 15   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0002253 BP 38       activation of immune response 4 536 2.34E-12 50 18   9.27E-11 77 20   7.03E-07 45 13   #N/A #N/A #N/A   
GO:0002460 BP 38 
      adaptive immune response based on 
somatic recombination of immune receptors 
built from immunoglobulin superfamily 
domains 4 262 1.81E-07 50 11   5E-10 77 15   6.45E-08 45 11   #N/A #N/A #N/A   
GO:0006957 BP 38 
      complement activation, alternative 
pathway 4 14 0.000105 50 4   0.000756 77 4   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0006958 BP 38       complement activation, classical pathway 4 84 5.84E-13 50 11   8.54E-16 77 14   1.58E-11 45 10   #N/A #N/A #N/A   
GO:0001867 BP 38       complement activation, lectin pathway 4 9 0.00355 50 3   0.0163 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0042730 BP 38       fibrinolysis 4 27 1.27E-09 50 7   #N/A #N/A #N/A   #N/A #N/A #N/A   0.00477 62 4   
GO:0007599 BP 38       hemostasis 4 357 7.89E-10 50 14   6.87E-05 77 12   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0006954 BP 38       inflammatory response 4 656 1.24E-14 50 21   2.8E-12 77 23   #N/A #N/A #N/A   0.00356 62 12   
GO:0002449 BP 38       lymphocyte mediated immunity 4 262 1.81E-07 50 11   5E-10 77 15   6.45E-08 45 11   #N/A #N/A #N/A   
GO:0002921 BP 38 
      negative regulation of humoral immune 
response 4 11 0.00695 50 3   0.000252 77 4   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0010466 BP 38       negative regulation of peptidase activity 4 243 0.000576 50 8   3.19E-09 77 14   #N/A #N/A #N/A   0.000266 62 9   
GO:2000258 BP 38 
      negative regulation of protein activation 
cascade 4 8 0.00237 50 3   5.39E-05 77 4   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0061045 BP 38       negative regulation of wound healing 4 60 1.03E-10 50 9   0.0139 77 5   #N/A #N/A #N/A   0.00423 62 5   
GO:0002673 BP 38 
      regulation of acute inflammatory 
response 4 72 8.04E-12 50 10   4.25E-08 77 9   #N/A #N/A #N/A   0.000358 62 6   
GO:0052547 BP 38       regulation of peptidase activity 4 391 1.23E-05 50 11   1.23E-08 77 16   #N/A #N/A #N/A   0.00152 62 10   
GO:0070613 BP 38       regulation of protein processing 4 81 2.77E-11 50 10   3.32E-09 77 10   0.00421 45 5   6.38E-07 62 8   
GO:0061041 BP 38       regulation of wound healing 4 126 2.6E-09 50 10   #N/A #N/A #N/A   #N/A #N/A #N/A   0.00983 62 6   
GO:0042060 BP 38       wound healing 4 540 5.06E-11 50 17   1.32E-05 77 15   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0002526 BP 38        acute inflammatory response 5 136 1.63E-17 50 15   1.57E-17 77 17   0.00251 45 6   4.05E-05 62 8   
280 
 
GO:0019724 BP 38        B cell mediated immunity 5 155 5.93E-10 50 11   1.99E-13 77 15   2.06E-10 45 11   #N/A #N/A #N/A   
GO:0045916 BP 38 
       negative regulation of complement 
activation 5 8 0.00237 50 3   5.39E-05 77 4   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0010951 BP 38 
       negative regulation of endopeptidase 
activity 5 233 0.000418 50 8   1.8E-09 77 14   #N/A #N/A #N/A   0.00256 62 8   
GO:0030449 BP 38        regulation of complement activation 5 32 3.44E-11 50 8   1.6E-11 77 9   0.00294 45 4   0.000168 62 5   
GO:0052548 BP 38        regulation of endopeptidase activity 5 369 0.0012 50 9   6.84E-08 77 15   #N/A #N/A #N/A   0.00869 62 9   
GO:0051917 BP 38        regulation of fibrinolysis 5 14 5.19E-07 50 5   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0006953 BP 38         acute-phase response 6 48 0.0192 50 4   2.86E-06 77 7   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0016064 BP 38 
        immunoglobulin mediated immune 
response 6 153 5.14E-10 50 11   1.63E-13 77 15   1.79E-10 45 11   #N/A #N/A #N/A   
GO:0001868 BP 38 
        regulation of complement activation, 
lectin pathway 6 2 0.0167 50 2   0.0492 77 2   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0002455 BP 38 
         humoral immune response mediated by 
circulating immunoglobulin 7 94 2.13E-12 50 11   4.55E-15 77 14   7.3E-13 45 11   #N/A #N/A #N/A   
GO:2000379 BP 41 
   positive regulation of reactive oxygen 
species metabolic process 1 83 0.00656 50 5   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0072593 BP 41    reactive oxygen species metabolic process 1 228 0.00554 50 7   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0019835 BP 47    cytolysis 1 29 0.00243 50 4   0.000334 77 5   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0043062 BP 63    extracellular structure organization 1 332 0.00603 50 8   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0030198 BP 63     extracellular matrix organization 2 331 0.0059 50 8   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0043534 BP 70    blood vessel endothelial cell migration 1 73 0.00346 50 5   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0043588 BP 73    skin development 1 242 #N/A #N/A #N/A   #N/A #N/A #N/A   1.52E-05 45 9   0.000257 62 9   
GO:0031639 BP 81    plasminogen activation 1 18 0.0339 50 3   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0042744 BP 83    hydrogen peroxide catabolic process 1 22 #N/A #N/A #N/A   0.00539 77 4   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0043691 BP 98    reverse cholesterol transport 1 18 0.0339 50 3   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0034384 BP 106    high-density lipoprotein particle clearance 1 9 0.00355 50 3   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0034443 BP 110    negative regulation of lipoprotein oxidation 1 4 #N/A #N/A #N/A   0.000786 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0097006 BP 119 
   regulation of plasma lipoprotein particle 
levels 1 55 0.0331 50 4   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0044788 BP 129    modulation by host of viral process 1 20 0.0472 50 3   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0043226 CC 18    organelle 1 12783 #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   0.00059 62 59   
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GO:0043227 CC 18     membrane-bounded organelle 2 11980 #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   0.00107 62 57   
GO:0031410 CC 34    cytoplasmic vesicle 1 1733 0.00301 50 17   0.00325 77 22   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0005576 CC 34    extracellular region 1 4494 2.61E-24 50 48   6.78E-21 77 61   1.56E-19 45 42   2.92E-14 62 47   
GO:0044421 CC 34    extracellular region part 1 3800 5.57E-26 50 47   9.16E-23 77 59   1.23E-16 45 38   2.11E-17 62 47   
GO:0005577 CC 34    fibrinogen complex 1 9 1.34E-05 50 4   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0032994 CC 34    protein-lipid complex 1 41 0.000184 50 5   0.000047 77 6   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0030141 CC 34    secretory granule 1 355 2.73E-07 50 12   6.46E-05 77 12   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0031983 CC 34    vesicle lumen 1 106 2.72E-17 50 14   1.05E-17 77 16   0.0159 45 5   4.89E-09 62 10   
GO:0072562 CC 34     blood microparticle 2 136 1.27E-44 50 28   9.35E-44 77 31   4.8E-11 45 11   6.93E-16 62 15   
GO:0060205 CC 34 
    cytoplasmic membrane-bounded vesicle 
lumen 2 105 2.36E-17 50 14   8.93E-18 77 16   0.0152 45 5   4.44E-09 62 10   
GO:0044433 CC 34     cytoplasmic vesicle part 2 912 2.19E-06 50 16   6.45E-05 77 18   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0043230 CC 34     extracellular organelle 2 2764 3.75E-24 50 42   3.13E-22 77 52   6.79E-19 45 36   2.78E-22 62 46   
GO:0005615 CC 34     extracellular space 2 1378 1.5E-38 50 43   2.8E-37 77 52   1.31E-12 45 24   1.2E-11 62 27   
GO:1990777 CC 34     lipoprotein particle 2 39 0.000142 50 5   3.43E-05 77 6   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0031091 CC 34     platelet alpha granule 2 74 7.5E-10 50 9   5.48E-08 77 9   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0031093 CC 34      platelet alpha granule lumen 3 55 4.48E-11 50 9   3.36E-09 77 9   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0034774 CC 34     secretory granule lumen 2 86 5.16E-11 50 10   3.4E-12 77 12   #N/A #N/A #N/A   1.04E-06 62 8   
GO:0031089 CC 22    platelet dense granule lumen 1 14 #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   0.0323 62 3   
GO:0099503 CC 34     secretory vesicle 2 462 5.5E-06 50 12   0.00112 77 12   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0031982 CC 34     vesicle 2 3994 5.69E-19 50 43   1.56E-16 77 54   1.34E-14 45 37   1.83E-16 62 47   
GO:0071682 CC 34      endocytic vesicle lumen 3 17 1.6E-06 50 5   0.00178 77 4   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:1903561 CC 34      extracellular vesicle 3 2763 3.69E-24 50 42   3.07E-22 77 52   6.71E-19 45 36   2.73E-22 62 46   
GO:0097708 CC 34      intracellular vesicle 3 1712 0.00254 50 17   0.00264 77 22   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0034358 CC 34      plasma lipoprotein particle 3 39 0.000142 50 5   3.43E-05 77 6   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0070062 CC 34       extracellular exosome 4 2748 2.95E-24 50 42   2.36E-22 77 52   5.55E-19 45 36   3.46E-21 62 45   
GO:0034364 CC 34       high-density lipoprotein particle 4 26 1.67E-05 50 5   2.53E-06 77 6   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0034385 CC 34       triglyceride-rich lipoprotein particle 4 20 0.0472 50 3   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0034366 CC 34        spherical high-density lipoprotein particle 5 8 0.00237 50 3   0.0109 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
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GO:0034361 CC 34        very-low-density lipoprotein particle 5 20 0.0472 50 3   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0044430 CC 39    cytoskeletal part 1 1525 #N/A #N/A #N/A   #N/A #N/A #N/A   0.000101 45 17   #N/A #N/A #N/A   
GO:0005856 CC 39    cytoskeleton 1 2038 #N/A #N/A #N/A   #N/A #N/A #N/A   3.17E-05 45 20   #N/A #N/A #N/A   
GO:0099080 CC 39    supramolecular complex 1 735 #N/A #N/A #N/A   #N/A #N/A #N/A   1.79E-08 45 16   #N/A #N/A #N/A   
GO:0099513 CC 39     polymeric cytoskeletal fiber 2 698 #N/A #N/A #N/A   #N/A #N/A #N/A   8.23E-09 45 16   #N/A #N/A #N/A   
GO:0099081 CC 39     supramolecular polymer 2 712 #N/A #N/A #N/A   #N/A #N/A #N/A   1.11E-08 45 16   #N/A #N/A #N/A   
GO:0099512 CC 39      supramolecular fiber 3 712 #N/A #N/A #N/A   #N/A #N/A #N/A   1.11E-08 45 16   #N/A #N/A #N/A   
GO:0045095 CC 39       keratin filament 4 97 #N/A #N/A #N/A   #N/A #N/A #N/A   4.14E-09 45 9   #N/A #N/A #N/A   
GO:0031838 CC 73    haptoglobin-hemoglobin complex 1 4 #N/A #N/A #N/A   0.000786 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0045111 CC 83    intermediate filament cytoskeleton 1 247 #N/A #N/A #N/A   #N/A #N/A #N/A   1.15E-12 45 14   0.00396 62 8   
GO:0005882 CC 83     intermediate filament 2 203 #N/A #N/A #N/A   #N/A #N/A #N/A   7.27E-14 45 14   0.000901 62 8   
GO:0005579 CC 88    membrane attack complex 1 7 #N/A #N/A #N/A   0.00682 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0031012 CC 133    extracellular matrix 1 527 0.0222 50 9   #N/A #N/A #N/A   #N/A #N/A #N/A   0.0219 62 10   
GO:0004064 MF 3    arylesterase activity 1 6 #N/A #N/A #N/A   0.00391 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0070051 MF 4    fibrinogen binding 1 3 0.0499 50 2   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0003823 MF 20    antigen binding 1 129 #N/A #N/A #N/A   0.0446 77 6   2.1E-06 45 8   #N/A #N/A #N/A   
GO:0071814 MF 22    protein-lipid complex binding 1 23 0.000916 50 4   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0071813 MF 22     lipoprotein particle binding 2 23 0.000916 50 4   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0008233 MF 29    peptidase activity 1 708 6.77E-05 50 13   0.000471 77 15   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0070011 MF 29 
    peptidase activity, acting on L-amino acid 
peptides 2 688 4.83E-05 50 13   0.000325 77 15   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:1901681 MF 32    sulfur compound binding 1 240 0.000524 50 8   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0098772 MF 37    molecular function regulator 1 1354 0.019 50 14   0.00492 77 19   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0030234 MF 37     enzyme regulator activity 2 957 0.0142 50 12   0.000771 77 17   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0005200 MF 37     structural constituent of cytoskeleton 2 110 #N/A #N/A #N/A   #N/A #N/A #N/A   2.57E-10 45 10   0.00445 62 6   
GO:0004857 MF 37      enzyme inhibitor activity 3 381 0.0166 50 8   1.28E-06 77 14   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0061134 MF 37      peptidase regulator activity 3 214 1.12E-05 50 9   2.54E-11 77 15   #N/A #N/A #N/A   0.0176 62 7   
GO:0061135 MF 37       endopeptidase regulator activity 4 175 0.000941 50 7   3.43E-11 77 14   #N/A #N/A #N/A   0.00466 62 7   
GO:0030414 MF 37       peptidase inhibitor activity 4 177 0.00102 50 7   4.02E-11 77 14   #N/A #N/A #N/A   0.00503 62 7   
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GO:0004866 MF 37        endopeptidase inhibitor activity 5 169 0.000743 50 7   2.1E-11 77 14   #N/A #N/A #N/A   0.00369 62 7   
GO:0004867 MF 37 
        serine-type endopeptidase inhibitor 
activity 6 95 0.0128 50 5   1.71E-08 77 10   #N/A #N/A #N/A   0.0411 62 5   
GO:0004175 MF 41    endopeptidase activity 1 478 5.99E-07 50 13   2.51E-06 77 15   0.0473 45 8   #N/A #N/A #N/A   
GO:0017171 MF 41    serine hydrolase activity 1 275 5.85E-10 50 13   1.7E-08 77 14   4.61E-05 45 9   #N/A #N/A #N/A   
GO:0004252 MF 41     serine-type endopeptidase activity 2 246 1.4E-10 50 13   3.77E-09 77 14   0.000332 45 8   #N/A #N/A #N/A   
GO:0008236 MF 41     serine-type peptidase activity 2 272 5.09E-10 50 13   1.47E-08 77 14   4.19E-05 45 9   #N/A #N/A #N/A   
GO:0008289 MF 58    lipid binding 1 654 #N/A #N/A #N/A   0.00712 77 13   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0031720 MF 59    haptoglobin binding 1 3 0.0499 50 2   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0005539 MF 61    glycosaminoglycan binding 1 204 7.39E-06 50 9   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0008201 MF 61    heparin binding 1 157 1.95E-05 50 8   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0005198 MF 96    structural molecule activity 1 706 #N/A #N/A #N/A   #N/A #N/A #N/A   1.37E-07 45 15   #N/A #N/A #N/A   
GO:0030492 MF 112    hemoglobin binding 1 5 #N/A #N/A #N/A   0.00196 77 3   #N/A #N/A #N/A   #N/A #N/A #N/A   
GO:0005102 MF 122    receptor binding 1 1450 0.0414 50 14   #N/A #N/A #N/A   #N/A #N/A #N/A   #N/A #N/A #N/A   
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Appendix C: Coverage and variant statistics for exome sequencing 
 IP16 IP17 RT1a RT1b PD821 PD161 HG(b) KG(b) HG(s) KG(s) VL FL KIR KEL AFF UNAFF Average 
Total variants 23672 24209 24667 24892 24662 24754 25868 25924 25796 25587 25373 25461 25325 26052 24814 24259 25082.19 
Heterozygous variants 14259 14652 13837 13973 14996 15034 16013 16082 15972 15836 15628 15684 15559 16065 15178 14822 15224.38 
Homozygous variants 9413 9557 10830 10919 9666 9720 9855 9842 9824 9751 9745 9777 9766 9987 9636 9437 9857.81 
Coding variants 21036 21433 21824 21968 21751 21797 22815 22878 22768 22636 22441 22489 22460 22955 21904 21483 22164.88 
Heterozygous coding variants 12705 12985 12271 12352 13245 13245 14149 14219 14131 14037 13869 13892 13829 14167 13462 13185 13483.94 
Homozygous coding variants 8331 8448 9553 9616 8506 8552 8666 8659 8637 8599 8572 8597 8631 8788 8442 8298 8680.94 
Splice variants 2636 2776 2843 2924 2911 2957 3053 3046 3028 2951 2932 2972 2865 3097 2910 2776 2917.31 
Heterozygous splice variants 1554 1667 1566 1621 1751 1789 1864 1863 1841 1799 1759 1792 1730 1898 1716 1637 1740.44 
Homozygous splice variants 1082 1109 1277 1303 1160 1168 1189 1183 1187 1152 1173 1180 1135 1199 1194 1139 1176.88 
Nonsynonymous SNVs 9490 9682 9864 9939 9758 9771 10239 10272 10209 10179 10104 10142 10251 10492 9874 9657 9995.19 
Heterozygous nonsynonymous SNVs 5783 5927 5560 5618 5950 5945 6391 6436 6384 6362 6274 6285 6357 6526 6129 5986 6119.56 
Homozygous nonsynonymous SNVs 3707 3755 4304 4321 3808 3826 3848 3836 3825 3817 3830 3857 3894 3966 3745 3671 3875.63 
Synonymous SNVs 10603 10794 10991 11053 11017 11050 11533 11546 11519 11437 11302 11313 11207 11421 10977 10798 11160.06 
Heterozygous synonymous SNVs 6359 6494 6211 6237 6734 6743 7142 7156 7126 7065 6980 6996 6898 7049 6738 6609 6783.56 
Homozygous synonymous SNVs 4244 4300 4780 4816 4283 4307 4391 4390 4393 4372 4322 4317 4309 4372 4239 4189 4376.50 
Stoploss SNVs 9 11 12 12 11 11 13 13 13 13 17 17 9 8 11 11 11.94 
Heterozygous stoploss SNVs 5 7 7 7 6 6 12 12 12 12 13 13 4 3 8 8 8.44 
Homozygous stoploss SNVs 4 4 5 5 5 5 1 1 1 1 4 4 5 5 3 3 3.50 
Stopgain SNVs 72 75 71 73 59 59 67 67 67 71 79 78 76 81 80 77 72.00 
Heterozygous stopgain SNVs 59 61 48 50 41 38 53 50 53 55 58 57 57 61 66 63 54.38 
Homozygous stopgain SNVs 13 14 23 23 18 21 14 17 14 16 21 21 19 20 14 14 17.63 
Deletions 218 230 228 229 220 221 221 218 219 212 219 216 230 229 235 239 224.00 
Heterozygous deletions 136 138 133 132 130 130 126 125 122 121 133 129 132 131 137 143 131.13 
Homozygous deletions 82 92 95 97 90 91 95 93 97 91 86 87 98 98 98 96 92.88 
Insertions 200 196 196 193 189 192 212 213 207 205 191 195 206 209 218 212 202.13 
Heterozygous insertions 119 112 101 97 94 94 117 116 115 114 99 97 103 106 118 111 107.06 
Homozygous insertions 81 84 95 96 95 98 95 97 92 91 92 98 103 103 100 101 95.06 
Frameshift deletions 63 67 61 61 67 71 64 67 63 61 61 58 80 79 75 74 67.00 
Heterozygous frameshift deletions 33 33 27 28 33 36 30 32 27 28 30 28 38 35 37 38 32.06 
Homozygous frameshift deletions 30 34 34 33 34 35 34 35 36 33 31 30 42 44 38 36 34.94 
Frameshift insertions 62 57 58 57 57 57 64 63 64 64 52 51 58 57 64 62 59.19 
Heterozygous frameshift insertions 30 27 25 23 25 24 28 30 30 31 20 18 23 22 24 22 25.13 
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Homozygous frameshift insertions 32 30 33 34 32 33 36 33 34 33 32 33 35 35 40 40 34.06 
Ts/Tv ratio 3.02 2.98 2.96 2.96 2.97 2.95 2.95 2.94 2.95 2.97 3.01 3.01 2.94 2.92 2.93 2.96 2.96 
Heterozygous Ts/Tv ratio 3.07 3.02 2.96 2.95 3.02 3.01 2.99 2.96 2.98 3.01 3.1 3.11 2.93 2.91 2.97 2.99 3.00 
Homozygous Ts/Tv ratio 2.94 2.91 2.97 2.97 2.89 2.87 2.89 2.91 2.91 2.92 2.88 2.87 2.96 2.93 2.87 2.92 2.91 
Novel Varients 172 177 350 348 117 122 136 134 138 138 150 158 149 167 152 140 171.75 
                  
Total reads 41146376 72641801 78243596 1.08E+08 90927756 99806001 83590179 85463775 85353802 61617739 80054992 97206924 35828951 81825854 1.09E+08 62983273 79627084 
Mapped to target reads 32832986 57069814 57872331 79572806 62838744 69615504 59187597 61176445 60475872 43138989 56827493 69090065 25868488 52187435 79127354 45922530 57050278 
Percentage 79.8 78.56 73.96 73.71 69.11 69.75 70.81 71.58 70.85 70.01 70.99 71.08 72.2 63.78 72.33 72.91 71.96438 
Mapped to target reads plus 150bp 37617148 64933592 64403921 88750871 70582058 78281869 66042281 68086421 66821215 47627118 63630277 77563149 29615038 60055515 89501305 51432982 64059048 
Percentage 91.42 89.39 82.31 82.21 77.62 78.43 79.01 79.67 78.29 77.29 79.48 79.79 82.66 73.39 81.82 81.66 80.9025 
Mean coverage 59.74 104.47 108.06 148.35 117.03 129.66 110.97 114.84 113.83 81.33 106.07 128.78 47.66 96.16 146.62 85.8 106.2106 
Accessible target bases 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 33323618 
Accessible target bases 1x 32443868 32557326 32694429 32759740 32795331 32804574 32990307 32991645 32974977 32949035 32939272 32962488 32906613 33021700 32764297 32649489 32825318 
Percentage 97.36 97.7 98.11 98.31 98.41 98.44 99 99 98.95 98.88 98.85 98.92 98.75 99.09 98.32 97.98 98.50438 
Accessible target bases 5x 31673420 32070797 32237744 32349466 32331876 32365474 32746246 32745348 32710645 32598597 32622333 32676388 32440357 32788860 32296165 31972762 32414155 
Percentage 95.05 96.24 96.74 97.08 97.02 97.12 98.27 98.26 98.16 97.82 97.9 98.06 97.35 98.4 96.92 95.95 97.27125 
Accessible target bases 10x 30419518 31478701 31857004 32078543 32000123 32068292 32489713 32491580 32428826 32134865 32302785 32413443 31477751 32524463 31891409 31109920 31947934 
Percentage 91.29 94.46 95.6 96.26 96.03 96.23 97.5 97.5 97.31 96.43 96.94 97.27 94.46 97.6 95.7 93.36 95.87125 
Target bases 20x 27085420 29917177 30908654 31488836 31222102 31403252 31729446 31757170 31643208 30691993 31426251 31746844 27932594 31650028 30854176 28843995 30643822 
Percentage 81.28 89.78 92.75 94.49 93.69 94.24 95.22 95.3 94.96 92.1 94.31 95.27 83.82 94.98 92.59 86.56 91.95875 
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Appendix D: A detailed clinical case report of an MZ 
twin pair discordant for ischaemic stroke 
KG and HG are 62-year-old, female, MZ twins of Caucasian descent. KG experienced a 
stroke in April 2007, resulting in right-sided weakness affecting her speech, writing, 
memory and balance, requiring her to use a stick. She also complained of sialorrhea and 
dribbling from the right side of her mouth. She has since experienced recurrent accidental 
falls. An MRI scan showed a left ganglion infarct, ischaemic changes in both cerebral 
hemispheres and a small right temporal infarct. There is still some persistent weakness in 
her right leg and none of the complications from stroke have completely resolved. A 
coincidental finding of a right sided intra-cavernous ICA cerebral aneurysm measuring 9 
mm was made in January 2007 following CT and MRI scans to investigate diplopia 
resulting from right sided (lateral rectus) 6th nerve palsy, first diagnosed in May 2006, for 
which she underwent right-sided Jensen’s procedure. This has been managed 
conservatively ever since, measuring 10 mm in 2009. 
HG also has a history of diplopia, first reported in 1969 aged 18, and was recently (2011) 
diagnosed with glaucoma.  She also underwent a CT scan in 2011 as a result of left optic 
disc atrophy after walking into a telephone booth.  This scan was normal with no evidence 
of intracranial pathology. 
KG and HG were born as healthy babies, following a normal delivery with no obstetric 
complications, with approximately similar birth weights. In clinical examinations, the 
twins are described as hirsute. Currently, KG and HG weigh 83 kg and 70 kg respectively, 
with a height of 1.6 and 1.63 metres respectively, and BMIs of 32 and 26 respectively. 
KG’s weight has fluctuated considerably from 65 kg to 84 kg since September 1998. 
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KG’s heart size from a medical report in 2001 is described at the upper limit of normal, 
and she underwent a laproscopic choleocystectomy in 1993. 
KG had meningococcal meningitis in June 1963, aged 12. She was briefly hospitalised as 
a result, with left sided hemiplegia which later resolved. An angiogram (reported 1st 
August 1963) ‘showed no evidence of any space-occupying lesion in the brain, nor any 
sub-dural abcess’. She had several left-sided Jacksonian epileptic attacks whilst in 
hospital, and EEG showed an abnormal record with evidence of acute right parietal 
disturbance. However, after several follow up scans and neurological examinations in 
August and September of 1963 and January 1964, it was concluded that KG had made a 
complete recovery. She appeared to remain seizure-free for several years until the age of 
16 when she was diagnosed with epilepsy, which was reported to be due to the earlier 
meningitis.  Her initial EEG findings were mostly within normal limits, except for high 
amplitude delta activity on closing the eyes during photic stimulation. According to the 
medical notes, KG had an average of 6 seizures per year between the ages of 16-21 years. 
Her last two reported seizures were in October 2002 in July 2003. On each of these 
occasions she was unresponsive for about a minute, but it was noted that no injury had 
occurred. Anecdotally, her medical records noted that the earlier descriptions of her 
seizures were entirely compatible with having experienced both complex partial seizures 
and generalised tonic-clonic seizures.  An EEG was also performed on HG at around the 
time when KG was first diagnosed with epilepsy, and it was reported to be very similar, 
with a marked delta response to photic stimulation. Although HG had never been 
diagnosed with epilepsy, she had a further series of EEGs between 1968 and 1977 (aged 
25) all of which were described as unstable and ‘well outside normal limits’ suggesting 
‘some slight tendency to fits’. 
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The twins were diagnosed with hypertension around 2002 and it appears there is a family 
history of hypertension from the mother’s side of the family. Their brother, who is a 
smoker, also has hypertension. There is also a family history of colon cancer and 
depression (Figure D.1). Their mother died of colon cancer at the age of 77, and a paternal 
aunt is thought to have died from bowel or stomach cancer aged 84. KG had an excision 
of a non-malignant fibroadenoma from her right breast at age 34. Both the father and 
grandfather have suffered from depression. The father had a subdural haemorrage aged 
88 years following a fall. The grandfather committed suicide, aged 55 (neurasthenia).  
Both sisters have suffered from depression and anxiety since their teens, but there is no 
evidence for suicide ideation. HG appears to have suffered from more severe depression, 
having received at least seven courses of electroconvulsive therapy (ECT), and was 
sectioned under Section 25 of the Mental Health Act in 1976 aged 25. HG also appears 
to have had recurrent feelings in her mid-twenties described in various medical reports at 
the time as ‘lesbian thoughts’, ‘lesbian feelings’, ‘latent lesbian tendencies’ and ‘she still 
gets an urge to go out with girls’. 
The sisters grew up believing they were MZ twins, but this has been confirmed by 
molecular analysis on DNA from saliva samples. In addition, cytogenetic analysis 
revealed that the sisters have a pericentric inversion on chromosome 5, with breakpoints 
at 15p13.1 and 15q11.2. 
The sisters carry some of the risk factors associated with stroke. Both started smoking at 
the age of 16, and have been diagnosed with hypertension for 11 years. KG gave up 
smoking following the onset of stroke. Prior to that her smoking was restricted due to 
smoking restrictions at her place of work – she was an NHS receptionist for 37 years prior 
to the stroke. HG did not have restrictions at work and smoked throughout. She still 
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smokes up to 10 cigarettes a day. The sisters consume alcohol only on special occasions, 
but not excessively. KG was diagnosed with a single patch of alopecia areata in 1995 
(aged 44), and more recently with seborrheoic dermatitis capitis in 2012 (aged 60).  HG 
was diagnosed with atopic dermatitis in 2004 (aged 53).  These problems might be linked 
to a family history of psoriasis (in father) and suggest an autoimmune disorder in the 
family (Figure D.1). 
Described herein are MZ twins with a family history of hypertension, depression and 
psoriasis.  However, they are discordant for stroke, and there is no obvious family history 
of stroke. Despite sharing the same risk factors and still smoking, HG has not suffered a 
stroke.  To our knowledge, this is the first documented case of twins discordant for stroke.  
KG also has an intracranial aneurysm. 
Remarkably, the twins share a uniquely similar set of circumstances. Both are right 
handed and enjoy a similar diet. These church-going, celibate spinsters have lived 
together in the same house since the age of 3, within a few miles from their place of birth. 
They have largely been part of the same medical practice for this period, mostly with the 
same doctor for the past 30 years. This is documented in over 300 pages of detailed 
medical notes spanning more than 50 years. This provides a unique opportunity for 
exploring the genetic, epigenetic, environmental, and therapeutic aspects of stroke, by 
searching for genomic, transcriptomic and proteomic differences between the twins. 
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Figure D.1. Family tree of KG and HG. The twins are discordant for stroke and intracranial aneurysm, but 
there is a family history of hypertension and depression. 
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